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SUMMARY
This study initially investigated the effects of extracellular 
calcium on the metabolism of cyclic AMP and cyclic GMP in the 
isolated perfused hearts of rats and rabbits. Calcium produced 
concentration-related changes in cyclic nucleotide levels, although 
the mechanisms of these observations were not elucidated. However, 
the study illustrated the complexities of the metabolic control of 
cyclic nucleotide levels.
The interactions of calcium and cyclic nucleotides on the 
electrical stability of the myocardium were then investigated using 
ventricular fibrillation threshold determinations in isolated rat 
hearts. Fibrillation thresholds were found to be dependent on the 
calcium concentration of the perfusate and changed independently of 
cyclic AMP levels. A number of other interventions, which may relate 
to arrhythmia production or anti-arrhythmic therapy, also produced 
changes in fibrillation thresholds which were not dependent on the 
nyocardial content of cyclic AMP.
The influence of ionic milieu was studied in a model of 
ventricular arrhythmias which involved ligation of the main left 
coronary artery of the isolated rat heart. During ligation, 
arrhythmias occurred in a solution containing a low potassium and a 
high calcium concentration. It was demonstrated that these ischaemia- 
induced ventricular arrhythmias did not appear to be influenced by 
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1.1 Ionic basis of cardiac contractility.
It has been known since the classical studies of Sidney Ringer 
(1883) that extracellular calcium is an absolute requirement for the 
maintenance of cardiac contractility. lYom this simple observation 
further, more elegant, studies have been performed to show that there 
is a highly developed and complex control mechanism mediating the 
effects of extracellular calcium on contractile activity.
The ionic movements which are involved in the excitation of 
cardiac cell membranes are complex and difficult to investigate due 
to inherent technical considerations (Vaughan Williams, I98O). 
However, it is now generally accepted that there is a slow depolari­
sing current during the plateau phase of the cardiac action potential 
the magnitude of vdiich is a function of the extracellular calcium 
concentration and resting membrane potential. This current is red­
uced by divalent cations such as manganese and drugs like verapamil, 
while remaining unaffected in sodium-free medium or by the fast chan­
nel inhibitor tetrodotoxin (Noble, 1979)- Langer (1978) has proposed 
that a carrier-mediated sodium/calcium exchange mechanism represents 
a means of sarcolemmal calcium transfer on a be at-to -beat basis, 
although Fabiato and Fabiato (1979) consider this suggestion to be 
highly speculative.
The quantity of calcium which enters the cell during the action 
potential has been calculated to be insufficient to activate the 
contractile proteins (Solaro et al, 1974). Although the slow inward 
calcium current is small, its presence is critical for myocardial 
contractility, as inhibitors of this current (see Section 1*5) cause 
cessation of contractile activity despite sufficient intracellular 
calcium being present to activate the contractile proteins (Langer,
1974) and action potentials are still generated (Fieckenstein, 1971). 
Therefore, the influx of calcium during the action potential must 
amplify the release of intracellular calcium which then activates the 
contractile proteins. The mechanism of this amplification is not 
fully understood althou^ two theories are currently being investig­
ated.
One theory is that the slow inward calcium current releases more 
calcium from the sarcoplasmic reticulum in a process termed calcium- 
triggered calcium release. This triggered release has been demon­
strated by the elaborate study of Fabiato and Fabiato (1977) on 
cardiac tissue in which the sarcolemma had been mechanically removed. 
In these cardiac skinned fibres a concentration of calcium, which 
was too small to produce contraction directly, produced myofibril 
activation which was attributed to calcium release from the sarco- 
tubular system.
Langer et al (1980) considered that the control of myocardial 
contractility, as demonstrated by Fabiato and Fabiato, could be 
attributed to their experimental design and, as an alternative, 
speculated that the surface-bound calcium of the glycocalyx was the 
important determinant of contractility in intact muscle. A series 
of experiments by Langer showed the sarcolemma to contain a small 
number of hi^ affinity sites for calcium and a higher number of 
lower affinity sites. The curves for contractile force against 
extracellular calcium and for calcium binding to the low affinity 
sites against extracellular calcium were superimposable (Philipson 
and Langer, 1979). A good relationship was also established between 
the ability of lanthanum to dispiLace calcium from the sarcolemma and 
its depression of excitation-contraction coupling in the intact 
muscle (Frank, 1979).
Alternatively, considering a combination of these two theories 
it ma}^ that the bound calcium on the sarcolemma would act as an acti­
vator of calcium-triggered calcium release from the sarcoplasmic 
reticulum, althou^ even in this system Langer (iÇBo) considered the 
sarcolemmal-bound calcium to be the regulatory factor.
On completion of myofibril activation calcium must be removed 
from the contractile proteins and either be sequestered into intra­
cellular stores or extruded from the cell. The sarcotubular network 
of the sarcoplasmic reticulum has been demonstrated to sequester 
calcium at a rate which would be kinetically compatible with muscle 
relaxation. Also, this system has been found to possess the required 
h i^ affinity sites for the removal of calcium from the contractile 
proteins (Katz, 1979). In addition, a calcium/sodium exchange mech­
anism has been implicated in the efflux of calcium from Hie cell as 
well as in calcium influx, as previously mentioned. This dual action 
seems possible as it has been shown that movement of ions via this 
carrier mechanism depends on the relative intra- and extracellular 
concentrations of calcium and sodium (Fozzard, 1977). A calcium- 
dependent ATPase pump in the sarcolemma has also been speculated, 
although experimental evidence of its existence is scant (Vaughan 
Williams, I98O).
The effect of extracellular calcium on myocardial contractility 
shows species variation. In rat papillary muscle, for example, a 
calcium concentration of 2.5 niM produced the maximum contractile 
response, whereas rabbit papillary muscle required a concentration 
in excess of 10 mM for maximal inotropy (Forester and Mainwood, 1974; 
Quinn et al, 1981). The maximum inotropic concentrations of calcium 
in dog and cat myocardium are intermediate to those in rat and rabbit
and this has been attributed to species variation in the calcium- 
triggered calcium release (Sutko and Wilierson, I98O).
1.2 Involvement of cyclic AMP in contractile and chronotropic
responses.
The possible role of cyclic AMP in the control of cardiac cont­
ractility has been extensively and critically reviewed by Tsien
(1977). Therefore, only a comparatively brief survey of the liter­
ature relevant to this thesis will be presented.
To implicate cyclic AMP as a modulator in a biological systan, 
Sutherland et al (1968) established four criteria which must be 
fulfilled.
The first criterion is that cyclic AMP levels should increase 
with an appropriate time course and precede the inotropic response.
An increased inotropic response should also be associated with 
increased tissue levels of cyclic AMP. Several reports observed that 
P-adrenoceptor stimulation produced increases in tissue cyclic AMP 
levels prior to the positive inotropic response and that the increase 
in tissue levels had a similar pattern to the profile of inotropic 
activity (Cheung and Williamson, 1965; Drummond et al, I966; Robison 
et al, 1965). Similar relationships have also been established for 
the inotropic responses to histamine (Verma and McNeill, 1974) and 
dopamine (Osnes et al, 1975). Whether the o^-adrenoceptor mediated 
inotropic effect of phenylephrine is cyclic AMP-dependent is not 
clear. Some authors have observed no increase in cyclic AMP despite 
a positive inotropic response (Benfey et al, 1974)> while others 
report a temporal relationship consistent with a modulatory role for 
cyclic AMP (Osnes et al, 1975; McNeill and Verma, 1972). Dissociat­
ions between cardiac contractility and cyclic AMP levels have been
found with ^ucagon, papaverine (Henry et al, 1975) and taurine 
(Schaffer et al, 1978).
The second criterion of Sutherland is that the relative potencies 
of a series of drugs on elevations of cyclic AMP levels in intact 
muscle should be the same as the relative potency on adenyl cyclase 
activity in broken cell preparations. This relationship has been 
established for isoprenaline, adrenaline and noradrenaline (Suther­
land et al, 1968).
The third criterion states that stimulation or inhibition of 
phosphodiesterase in the intact tissue should lead to changes in 
contractility in accord with the fluctuating levels of cyclic AMP.
It has been shown that phosphodiesterase inhibitors increase cyclic 
AMP levels and produce positive inotropic responses (McNeill et al, 
1973). However, the many conflicting reports are probably due to the 
wide variety of drugs which are classed as phosphodiesterase inhibit­
ors from biochemical studies, but this may not necessarily be their 
mechanism of action in intact cardiac muscle (Tsien, 1977)* Stim­
ulators of phosphodiesterase (e.g. imidazole) have been shown to 
reduce cyclic AMP levels and contractility (Williamson, 1976).
The fourth and final criterion to implicate cyclic AMP in a 
biological response is that application of cyclic AMP should mimic 
the response observed in conditions in which elevated cyclic AMP 
levels have been noted. However, due to the poor lipid solubility 
of cyclic AMP, direct application can produce a negative inotropic 
response due to its direct membrane effects (Meinertz et al, 1973)*
To increase membrane penetrability, many lipid soluble analogues of 
cyclic AMP have been synthesised, of which the most commonly used is 
N^,2 '-o-dibutyryl cyclic AMP. This analogue has been found to mimic
qualitatively the effects of ^ -adrenoceptor stimulation, except for 
the time course of effect, which is appreciably slower (Meinertz et 
al, 1975; Dhalla et al, 1972; Drummond and Hemmings, 1972). While 
dibutyryl cyclic AMP does stimulate cyclic AMP-dependent protein 
kinase (Gk*eengard, 1975), it has also been shown to be a very potent 
inhibitor of phosphodiesterase, which could be the mechanism of its 
inotropic action (Miller, 1977). To avoid permeability problems 
another approach is to apply cyclic AMP microiontophoretically. This 
has been found to mimic the electrophysiological effects of adrenaline 
(Tsien et al, 1972).
Therefore, there is good evidence that these criteria may be 
satisfied and that cyclic AMP may modulate cardiac contractility.
Investigations into the possible role of cyclic AMP in drug- 
induced chronotropy are difficult due to the small size of the sinus 
node. However, Taniguchi et al (1979) have recently used an isolated 
rabbit sinus node preparation and observed increased cyclic AMP levels 
which could be consistent with a modulatory role of cyclic AMP in 
positive chronotropy.
Since Sutherland’s criteria can be satisfied for the involvement 
of cyclic AMP in modulating cardiac contractility, it is desirable to 
define the mechanism of action. Initially it was considered that 
cyclic AMP increased energy production by its well-defined biochem­
ical action on glucose and glycogen metabolism, but the failure to 
observe phosphorylase activation before a positive inotropic response 
makes this mechanism unlikely (Mayer, 1974).
To investigate other mechanisms it is helpful to consider the 
three distinct effects of adrenaline on cardiac inotropy. These are:
(a) increase in peak tension.
(b) decrease in time to peak tension,
(c) decrease in relaxation time.
I.e. a stronger, but abbreviated systole.
Experimental evidence has now been obtained which can explain 
the involvement of cyclic AMP in these three effects. Cyclic AMP 
activates the calcium slow channel (Reuter, 1974) which would pre­
sumably increase the calcium-triggered calcium release from the sar­
coplasmic reticulum resulting in an increase in peak tension. The 
rate of release of calcium from the sarcoplasmic reticulum is accel­
erated in the presence of cyclic AMP and hence the time to peak 
tension is decreased (Katz, 1979)» Increased rate of relaxation may 
be attributable to a more rapid sequestration of calcium into the 
sarcoplasmic reticulum via a cyclic AMP-induced phosphorylation of 
phospholamban (WoUenberger and Will, 1978) and to the phosphoryl­
ation of a component of the contractile proteins, resulting in a 
decreased affinity for calcium (Bailin, 1979).
1.3 Cyclic GMP in contractile and chronotropic responses-
physiological antagonism of cyclic AMP?
Compared to the extensive literature relating to cyclic AMP 
to cardiac contractility, information on the possible modulatory 
role of cyclic GMP in cardiac function is relatively scant. The 
possibility of a regulatory role for cyclic GMP is of interest since 
it has been proposed a.s a physiological antagonist of cyclic AMP in 
many biological systems (Goldberg et al, 1975).
George et al (1973) showed that the action of acetylcholine on 
developed tension and heart rate in isolated perfused rat hearts was 
correlated better with cyclic GMP levels than with cyclic AMP levels. 
Endoh et al (198I) have also shown a relationship between elevated
8cyclic GMP levels and depressed force of contraction in dog atria, 
but they failed to observe a similar effect on ventricular muscle. 
Other data to substantiate Sutherland’s first criterion does little 
to confirm the relationship between contractile force and cyclic GMP 
levels. Brooker (1977) reported that low concentrations of acetyl­
choline decreased contractile force in guinea-pig atria whereas a 
hundred-fold increase in acetylcholine concentration was required to 
produce significant changes in cyclic GMP levels. This observation 
was confirmed by Keely and Lincoln (1978). Watanabe and Besch (1975) 
found that acetylcholine produced elevated levels of cyclic GMP 
without significant changes in contractile force of guinea-pig vent­
ricular muscle. Mirro et al (1979) also found dissociations between 
atrial cyclic GMP levels and the electrophysiological effects of 
acetylcholine on guinea-pig atria. The use of sodium nitroprusside, 
which is a known stimulant of guanyl cyclase (Goldberg and Haddox,
1977), has also produced dissociations by slightly increasing 
contractile force vhilst elevating cyclic GMP levels in isolated rat 
hearts (Diamond et al, 1977). However, it has been suggested that 
the modulatory role of cyclic GMP may only be apparent in the presence 
of |3-adrenoceptor stimulation and not on basal contractile force 
(Watanabe and Besch, 1975).
Little data are available to substantiate the role of cyclic GMP 
in Sutherland’s other three criteria, although the dibutyryl deriv­
ative of cyclic GMP was observed to antagonise the inotropic effects 
of noradrenaline in perfused guinea-pig ventricle (Watanabe and 
Besch, 1975). However, Endoh and Shimizu (1979) failed to confirm 
that the dibutyryl and 8-bromo derivatives of cyclic GMP mimicked 
the cardiac effects of acetylcholine.
As stated in Section 1.2, metabolic investigations into mechan­
isms related to chronotropic responses are methodologically difficult. 
Taniguchi et al (1979) found elevations in cyclic GMP levels in some, 
but not all, interventions and this had a time-dependency which would 
be consistent with a modulatory role for cyclic GMP in the negative 
chronotropic response. Few reports attribute the negative inotropic 
effect of cyclic GMP to a particular mechanism of action. The major 
proposed mechanism results from the finding that analogues of cyclic 
GMP inhibit the calcium slow channel in rabbit atria (Kohlhardt & Haap, 
1978). Another suggestion (Blumenthal et al, 1978) was that cyclic 
GMP phosphorylates a component of the contractile proteins, in a 
manner similar to cyclic AMP, via a protein kinase mechanism.
However, the effect of this phosphorylation in modulating contract­
ility is not readily apparent. Many authors have implicated the 
separate cyclic nucleotides in a biological response but Flitney’s 
group has amassed considerable evidence to show that very good correl­
ations exist between the ratio of cyclic AMP to cyclic GMP and 
contractile state in a variety of experimental situations (Flitney 
and Sin^, 198O; Sin^ and Flitney, I98O). They stress that the 
ratio of cyclic nucleotides is more important than the absolute levels 
of either one. However, all their work was performed on strips of 
frog ventricle and, as they concede (Flitney and Singh, 198O), this 
relationship may not be applicable to mammalian myocardium.
1.4 Calcium on cyclic nucleotide metabolism in intact tissue
and in biochemical studies.
Several authors have reported the effects of calcium on nyocard­
ial cyclic AMP levels in a variety of systems, although a review of 
the literature shows no consensus of opinion.
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Endoh et al (1976), using rabbit papillary muscle, observed that 
increased frequency of stimulation produced changes in developed 
tension which were inversely related to the changes in tissue cyclic 
AMP levels. Using the rationale that contractile changes were 
related to fluctuations in free intracellular calcium, the effects 
of altering extracellular calcium concentration were investigated.
As may be expected, decreasing the calcium concentration from 2.5 to 
0 mM decreased developed tension and, consistent with their paced 
study, tissue levels of cyclic AMP were reciprocally related to 
extracellular calcium concentration. Harary et al (1976) studied 
a range of calcium concentrations on cultured cells derived from 
Langendorff perfused rat hearts. In agreement with Endoh et al (1976) 
they found that elevating extracellular calcium concentration from 
0.1 to 1 mM produced concentration-related decreases in cyclic AMP 
levels. In this preparation calcium also modulated the rate of 
beating of the heart cells.
In opposition to these two studies, Dhalla et al (1977) observed 
no effect of extracellular calcium (between 0 to 5.0 mM) on cyclic 
AMP levels in the Langendorff perfused rat heart.
Namm et al (1968) observed that omission of calcium (normally
3.2 mM) from the perfusate of an isolated rat heart produced a large 
increase in cyclic AMP levels after 30 min. Dobson et al (1976) 
observed that removal of calcium or the presence of a calcium chela­
ting agent in the perfusate of guinea-pig papillary muscle did not 
alter cyclic AMP levels after 30 - 60 min compared to controls in 
the presence of 2.5 mM calcium, Hancock and Hess (1976) measured 
cyclic AMP levels in the Langendorff perfused rat heart after shorter 
periods of calcium omission ( 2 - 4  min). They observed a decrease in 
cyclic AMP compared to levels observed at 2.5 mM calcium.
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Therefore, the three reports which studied calcium omission on 
cyclic AMP levels have produced three sets of conflicting data.
The effects of bolus injections of calcium chloride have been 
investigated by Hartley and McNeill (1976) and by Sen et al (1975) 
and again conflicting results were obtained despite both authors 
using the isolated rat heart for their studies. Hartley and McNeill 
(1976) found that injections of 2 mg of calcium chloride did not 
significantly alter cyclic AMP levels at various times after the 
injections. Although cyclic AMP levels were unaltered, phosphorylase 
was significantly elevated. Sen et al (1975) found that a dose of 
0.3 mg of calcium chloride produced a rapid increase in cyclic AMP 
which reached a maximum after 5 sec.
The use of drugs classified as calcium slow channel antagonists 
(see Section 1.5) has also produced contradictory results. Endoh 
et al (1976) showed that the methosy derivative of verapamil, D600, 
at a concentration of 1 x 10”^M increased cyclic AMP levels of rabbit 
papillary muscle. However, Shanfeld et al (1975) observed that 
verapamil (6 x 10 ^) produced a decrease in contractility which was 
associated with a significant decrease in cyclic AMP levels. This 
report also demonstrated that if perfusion of verapamil was main­
tained, then both contractility and cyclic AMP levels reverted to 
normal after 20 min. In a later report from the same laboratory, 
Hancock and Hess (1976) showed again that verapamil decreased cyclic 
AMP in the rat heart, but that this reduction was not concentration- 
dependent. They also showed that lanthanum decreased cyclic AMP levels,
Very little information regarding the influence of extracellular 
calcium on cyclic GMP levels in cardiac tissue is available.
Hancock and Hess (1975) observed that the omission of calcium from
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the perfusate of isolated rat hearts did not alter cyclic GMP levels. 
In the same report it was shown that a very h i ^  concentration of 
verapamil (l x 10~^) decreased cyclic GMP levels, whereas lanthanum 
did not produce any significant effect.
Endoh et al (1976) explained their results on the premise that 
calcium had been shown to stimulate phophodiesterase activity 
(Teo and Wang, 1973) and therefore it would be expected that increased 
extracellular calcium should decrease cyclic AMP levels. This argu­
ment may be strengthened by the reports of Drummond and Duncan (1970) 
and Tada et al (1975) who showed inhibition of adenyl cyclase by 
calcium, Drummond and Duncan (1970) used a crude membrane prepara­
tion from bovine cardiac muscle for their investigation. Calcium 
inhibited both the basal level of adenyl cyclase activity whereas 
fluoride and magnesium stimulated activity. A relatively h i ^  of 
0.3 mM was established for calcium. It may also be noteworthy that 
their preparation responded poorly to catechol amine stimulation.
Tada et al (1975) used a more purified preparation of guinea-pig 
ventricular sarcolemma. Calcium in the range 10 10 ^ progress­
ively decreased control levels of adenyl cyclase activity. They " 
elaborated on the methodological problems in exploring adenyl 
cyclase activity in sarcolemma preparations. A particularly perti­
nent point is that the decreased adenyl cyclase activity may merely 
be a manifestation of increased phosphodiesterase activity since 
calcium has been shown to stimulate phosphodiesterase (Teo and Wang, 
1973). In recognising this possible interference these authors have 
attempted to minimise its effect by the addition of 0.5 mM cyclic AMP 
to the reaction mixture, presumably to produce substrate inhibition 
of phosphodiesterase (Kakuchi et al, 1975).
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Tada et al (1975) have proposed that the inhibitory effect of 
calcium on adenyl cyclase activity and the previously demonstrated 
effects on phosphodiesterase activity represent a feedback mechanism 
for the regulation of cyclic AMP levels within the myocardium.
However, a more extensive review of the literature on the effects 
of calcium on the enzymes responsible for the synthesis and degrad­
ation of cyclic nucleotides shows that this probably represents an 
oversimplified view of the regulatory process.
Adenyl cyclase is a membrane-bound entity (Perkins, 1973) whose 
activity is demonstrable in sarcolemmal preparations (Tada et al,
1975). However, adenyl cyclase activity has also been shown in 
preparations of sarcoplasmic reticulum from cardiac muscle (Epstein 
et al, 1971; Katz et al, 1974). The question of contamination of 
these sarcoplasmic reticulum preparations with some sarcolemma has 
been raised and resolution of purer preparations is required for a 
definitive characterisation of the localisation of adenyl cyclase 
(Jones et al, 1978). But this does cause speculation as to how an 
effect of calcium on a subcellular biochemical process relates to the 
tissue in an intact situation.
Guanyl cyclase activity has also been shown to be manipulated by 
calcium. In the myocardium guanyl cyclase has been shown to exist in 
soluble and particulate forms (Kimura and Murad, 1974; Suhakle et al,
1976). The particulate form, which was assumed to be sarcolemmal, 
was stimulated by manganese and partially inhibited in the presence 
of calcium. The particulate form in these experiments was solubil­
ised in Triton X-100. The native soluble form was found to be 
stimulated in the presence of calcium. However, the enzyme was 
inhibited in the presence of adenosine triphosphate and it has been
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speculated (SuhakLe et al, 1976) that in normal myocardium soluble 
guanyl cyclase would be inhibited by cellular levels of adenosine 
triphosphate. It was also found that the particulate form contained 
the major part of the total activity.
Teo and Wang (1972) found that calcium stimulated cardiac 
phosphodiesterase activity but this is probably an oversimplific­
ation. Kakuchi et al (1975) isolated two forms of phosphodiesterase 
in rat ngrocardium of vdiich only one form was stimulated by calcium.
This stimulation was also dependent on substrate concentration.
More recently. Gain and Appleman (1978) have characterised three 
phosphodiesterases from rat heart of which only the cyclic GMP 
phosphodiesterase was stimulated by calcium.
1.5 Development and definitions of calcium antagonists.
In 1969f Fleckenstein observed that a newly synthesised derivat­
ive of papaverine mimicked the n^rocardial effect of extracellular 
calcium removal. It reduced contractüe force which was associated 
with a slight reduction in the plateau i^ iase of the action potential 
and reduced both h i^ energy phosphate utilisation and oxygen consump­
tion. These effects of the new organic compound, which is now called 
verapamil, could be overcome by elevation of the extracellular calcium. 
Verapamil was initially found to be a potent vasodilator but it became 
apparent that its mode of action was different from that of the then 
commonly used vasodilators such as nitrates and papaverine itself, 
since verapamil also depressed cardiac contractility.
By 1971 fleckenstein had tested a series of compounds including 
verapamil, D6OO, prenylamine and nifedipine, all of vhich possessed 
the common properly that their pharmacological actions were enhanced 
in low extracellular calcium and abolished in h i ^  extracellular
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calcium. On the basis of these findings, a new class of drugs 
termed * calcium antagonists* was defined. This definition is broad 
and has led to a wide variety of drugs being classed as such (see 
Rahwan and Witiak, 1979 for citation of references). However, only 
those drugs in which the predominant pharmacological characteristic 
is calcium antagonism should be included in this classification.
There is still dispute as to whether the term Tcalcium slow channel 
antagonist* is a better description of these drugs (Nayler, 198O).
In this thesis the term calcium slow channel antagonist will be 
used to define drugs such as verapamil.
There is now available a wide variety of calcium slow channel 
antagonists with notable heterogeneity of structure. Besides organic 
compounds, certain di- and trivalent cations are also termed calcium 
slow channel antagonists, two of the most commonly used being mangan­
ese and lanthanum (Gargouil, I98I). Therefore, a wide variety of 
compounds can produce the overall end response to be classified as 
•calcium antagonists* but it appears that they exert their effects 
by different mechanisms (Henry, 1979)•
The majority of the work to establish a site of action for the 
calcium slow channel antagonists has used verapamil and it seems 
generally agreed that a sarcoleramal site is probable. An intracellular 
site of action for verapamil is doubtful because of its inability to 
modify contractile activity of cardiac cells in which the sarcolemma 
has been removed (Nawrath et al, 198O). Biochemical studies have 
been unable to detect an influence of verapamil con calcium uptake or 
binding in preparations of sarcoplasmic reticulum and mitochondria 
except at very higji concentrations (Nayler and Szeto, 1972;
Watanabe and Besch, 1974). In contrast, Nayler et al (198O) found
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that labelled verapamil did bind to carbohydrate residues in sarco- 
lemmal preparations. The sarcolemmal site of action is indicated in 
a more indirect manner by the comparative study of cardiac and skel­
etal muscle preparations. Cardiac muscle, which is sensitive to 
extracellular calcium, responds rapidly to verapamil vdth a depress­
ion of contractility whilst skeletal muscle, which is not dependent 
on extracellular calcium for contraction, responds very slowly 
(Langer et al, 1975). Although the sarcolemma represents the most 
likely organelle for the effects of verapamil, the electrophysiol- 
ogical study of Payet et al (1980) suggests that verapamil and 
manganese have different sites of action within the sarcolemma.
Despite the relatively good agreement on the site of action 
of calcium slow channel antagonists on the sarcolemma, the mechanism 
or mechanisms of action remain unresolved. According to the present 
paradigm of excitation-contraction coupling in cardiac muscle noted 
earlier (see Section 1.1), the calcium which initiates contraction 
enters via the slow channel and it is well established that these 
drugs are potent inhibitors of this channel. However, no sin^e 
mechanism appears to explain this inhibtion.
Bayer et al (1975) used the optical isomers of verapamil in an 
electrophysiological study and showed that the 1-isomer was the 
specific calcium slow channel inhibitor, vhilst the d-isomer was a 
specific fast channel inhibitor. This observation was confirmed by 
Raschack (1976) but disputed by Nawrath et al (198O), who found that 
the isomers were only quantitatively different in their pharmacol­
ogical actions, with the 1-isomer being approximately 25 times more 
potent than the d-isomer on the slow channel.
Voltage clamp experiments revealed that nifedipine appeared to
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reduce the number of channels without affecting the kinetics and 
hence the drug prevented activation (Henry, 1979). In contrast, 
verapamil reduced the rates of activation, inactivation and recovery 
of the slow channel (Bayer et al, 1975). Verapamil also inhibited 
the outward potassium repolarising current (Kass and Tsien, 1975), 
althou^ this may be due to the indirect effect of reduction in 
intracellular calcium (Siegelbaum and Tsien, I98O).
To illustrate further disparity of mechanisms Bayer et al (1975) 
showed that verapamil converted the positive force-frequency 
relationship of cat papillary muscle into a negative relationship, 
but this effect was not observed in reduced extracellular calcium 
or in the presence of manganese or lanthanum (Rosenberger and Trig^e,
1978).
1.6 Ischaemic heart disease - incidence and consequences.
Cardiovascular diseases are the most common cause of mortality 
in the western world, accounting for approximately 50^ of all deaths 
in people over 20 years of age, of which about 70^ are attributable 
to ischaemic heart disease (Pantridge et al, 1975). The term 
•ischaemic heart disease* is usually taken as encompassing myocardial 
infarction (acute and sub-acute), angina pectoris and variant forms
(WHO, 1967).
The particular type of ischaemic heart disease relevant to this 
investigation is the * sudden death* syndrome, which is almost cert­
ainly due to ventricular fibrillation and occurs in 50^ of cases 
where no previous evidence of heart disease had been established 
(Pantridge et al, 1975; Stamler, 1975). Deaths from ventricular 
fibrillation are generally in the pre-hospital phase and within the 
first hour of the onset of symptoms. This explains the small reduc­
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tion in coronary deaths after the introduction of coronary care units 
in the late iç60s and also illustrates the difficulties in obtaining 
data pertaining to the mechanism of the event.
In the prevention of sudden death, therapy should be directed 
at the primary cause of the event(s) leading to death. Althou^ this 
is presently unknown, possibilities include thrombus formation, coro­
nary spasm and metabolic changes leading to an increased oacygen 
demand in the face of a decreased availability. The evidence that 
coronary spasm is the primary event is;
(a) low incidence of coronary arterial thrombi in patients dying 
suddenly from coronary heart disease;
(b) increased frequency of thrombi as the time interval increases 
between acute coronary attack and death and hence thrombus may be 
a consequence and not a cause of sudden death;
(c) frequent disparity between histological age of thrombus and age 
of related infarct;
(d) incorporation into thrombi of radioactive fibrinogen injected 
after the onset of the coronary attack;
(Oliva and Breckln^ridge, 1977)*
It has also been observed that an acute coronary attack is not 
necessarily associated with a complete occlusion of a coronary artery 
at autopsy, which has been taken as evidence of relaxation of a spasm 
producing reperfusion of the ischaemic myocardium (Bashe et al, 1975). 
The comparative ease with \diich reperfusion produces ventricular 
arrhythmias in animal models gives some support for this phenomenon 
precipitating sudden death.
Unfortunately, the unpredictable nature and pre-hospitcil occur­
rence of the primary event together with the lack of an animal model
19
makes prophylaxis extremely difficult.
Following the primary event the two causes of death are cardio­
genic shock and ventriculeur fibrillation. It is the latter which is 
responsible for the majority of deaths following an acute coronary 
attack (Pantridge et al, 1975) and the possible mechanisms producing 
this fibrillation have been investigated in this thesis.
1,7 Evidence for the role of cyclic AMP as a prime arrhythmogenic
mediator.
The link between cyclic AMP and ventricular arrhythmias was 
initially suggested by Podzuweit et al (1976), vdio observed that 
cyclic AMP levels increased in the ischaemic zone of coronary artery 
ligated baboon hearts prior to the onset of ventricular fibrillation. 
Since this observation, several reports implicating cyclic AMP as a 
prime mediator of ventricular arrhythmias are available, mostly from 
collaborators of the original study. The baboon work was later 
expanded (Podzuweit et al, 1978) showing that the onset of ventric­
ular arrhythmias may be causally related to cyclic AMP levels and 
not to hi^ energy phosphate or lactate levels. Bricknell and Opie
(1978) manipulated cyclic AMP levels by placing various metabolic 
substrates in the perfusate of the ^obally underperfused rat heart 
and found that tissue cyclic AMP content was correlated with the 
onset of reperfusion arrhythmias, Opie et al (1978) considered that 
more direct evidence for the role of cyclic AMP was illustrated by 
the lowering of ventricular fibrillation threshold in the isolated 
perfused rat heart by dibutyryl cyclic AMP in the presence of theo­
phylline, Lubbe et al (1978) later showed that higher concentrations 
of dibutyryl cyclic AMP reduced ventricular fibrillation thresholds 
by themselves. The reduction of ventricular fibrillation threshold
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was unaffected by atenolol but potentiated in the presence of theo­
phylline. Cyclic AMP itself did not influence fibrillation threshold 
except in the presence of theophylline, in which case a reduction 
was noted.
Lubbe et al (1978) also showed that adrenaline infusions in 
rat hearts produced changes in ventricular fibrillation threshold 
which could be related to changes in cyclic AMP levels. The use of 
theophylline and atenolol during adrenaline infusions produced shifts 
in fibrillation threshold which could also be related to changes in 
cyclic AMP levels. Focal infusions of a number of cyclic AMP anal­
ogues and of drugs known to elevate cyclic AMP levels into the 
infarct edge, have been shown to produce ventricular arrhythmias 
in the anaesthetised pig (Podzuweit et al, 1978). Podzuweit (198O) 
later produced similar results by focal infusion into the normal pig 
heart. It may be noteworthy that the arrhythmia produced in Podzu­
weit *s study was ventricular tachycardia and not fibrillation or 
spasmodic ectopic beats. Elevated levels of cyclic AMP were report­
ed in dogs which fibrillated on exposure to theophylline compared to 
dogs which tolerated theophylline infusions (Suguira et al, 1979).
Besides the original baboon study, other reports show a relat­
ionship between incidence of ventricular arrhythmias and increased 
levels of cyclic AMP induced by coronary artery ligation. Coronary 
artery ligation of the isolated perfused rat heart produced a 
gradual decrease of ventricular fibrillation threshold reaching a 
basal level at 15 min, at which time cyclic AMP was elevated (Opie 
and Lubbe, 1979; Lubbe et al, 1980). Propranolol and amiodarone 
increased fibrillation threshold whilst reducing the elevation of 
cyclic AMP in ischaemic tissue (Lubbe et al, 1979, 1980). Sotalol 
and atenolol both failed to attenuate either the increase in cyclic
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AMP levels or the increase in electrical instability.
Corr et al (1978) used the coronary artery occluded anaesthet­
ised cat and measured cyclic AMP levels from simultaneous transmural 
biopsies in normal and ischaemic left ventricle. Unlike the findings 
of Lubbe et al (1980) cyclic AMP levels were increased in both normal 
and ischaemic myocardium, although levels were hipest in the ischaem­
ic zone. Levels of cyclic AMP did have a similar time-related course 
to the occurrence of premature ventricular contractions. It was also 
observed that in cats which developed spontaneous ventricular fibril­
lation, levels of cyclic AMP were hi^er in both ischaemic and normal 
ngrocardium compared to cats which did not fibril!ate. Propranolol 
was usually effective in reducing cyclic AMP levels in ischaemic 
tissue and in reducing the number of premature ventricular contract­
ions, although in three cats large elevations in cyclic AMP levels 
and ventricular arrhythmias occurred despite the presence of |3-adreno­
ceptor antagonism, A time-de pendent relationship between ventricular 
ectopic beats and cyclic AMP levels was also observed in the coronary 
artery ligated heart of the anaesthetised pig (Opie et al, 1979).
Sheridan et al (198O) studied the involvement of cyclic AMP in 
reperfusion arrhythmias in the cat preparation. They found that 
reperfusion produced a high incidence of ventricular arrhythmias but 
cyclic AMP levels decreased in both normal and previously ischaemic 
myocardium. It was therefore concluded that cyclic AMP was not 
involved in these reperfusion arrhythmias. Opie et al (1980) 
performed a simulated reperfusion study in which paced guinea-pig 
papillary muscles were exposed to hypoxic Krebs-Henseleit solution 
containing high potassium and lactate and then reperfused with normal 
solution. Coupled extrasystoles occurred if dibutyryl cyclic AMP was
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present in the perfusate but not in its absence.
The mechanism by which cyclic AMP may produce arrhythmias is 
speculative. Heterogeneous distribution of cyclic AMP, which is 
known to influence action potential duration, may give rise to 
inhomogeneity of repolarisation, which is a condition that may pre­
dispose to ventricular arrhythmias (Han, 1969). Cyclic AMP regulates 
the calcium slow channel (Reuter, 1974). Elevated levels of cyclic 
AMP may initiate the slow response in myocardium which has been 
partially depolarised due to the accumulation of extracellular potass­
ium in the ischaemic tissue. These slow responses have been implic­
ated in predisposing to re-entrant arrhythmias (Wit et al, 1972). 
lontophoretically applied cyclic AMP may also induce a steeper rate 
of rise of phase 4 depolarisation in Purkinje fibres resulting in 
enhanced automaticity (Tsienetal,1972)i Finally,cyclic AMP has been 
shown to produce after potentials which would also contribute to 
automaticity (Lazzara et al, 1978; Opie et al, 1980).
1.8 The release of catecholamines during ischaemia - is it
relevant to early post-ligation arrhythmias?
Clinically there appears to be irrefutable evidence that there
are increased catecholamine levels in blood and urine in the hosp­
ital phase of nyocardial infarction (for references see Ceremuzynski, 
1970). However, the relevance of these increased levels, whidi are 
usually measured hours or days after the initial symptoms of an 
acute coronary attack, to the occurrence of arrhythmias in the early 
phase is unclear.
This section will only consider the experimental evidence for 
the involvement of catecholamine release in arrhythmia production. 
Anoxia and reperfusion will also be considered since the former has
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implied relevance to ischaemia and the latter may be relevant to 
coronary spasm.
WoUenberger and Shahab (1968) first showed the release of 
noradrenaline during 3 min anoxio perfusion of Langendorff perfused 
rabbit and rat hearts, although no release was detectable from anoxic 
guinea-pig hearts (ShaUah et al, 1972). As an implication of enhanced 
release during anoxia, Gaudel et al (1979) found decreased levels of 
n^ocardial catecholamines after 30 min of anoxic perfusion in isolated 
rat hearts. This observed anoxia-induced release of catecholamines 
has been inferred to be relevant to metabolic events occurring in 
ischaemia (Hjalmarson, 198O).
A frequently cited paper for the involvement of catecholamines 
in ventricular arrhythmias following ischaemia induction is that of 
Ceremuzynski et al (1969) who occluded the left anterior descending 
coronary artery of anaesthetised dogs amd measured plasma catechol­
amines by bioassay whilst assessing ventricular arrhythmias. It was 
concluded that the severity of ventricular arrhythmias was a function 
of the circulating catecholamines. Unfortunately, there were no 
direct time comparisons between release of catecholamines and vent­
ricular arrhythmias. Also, increases in circulating adrenaline, and 
not noradrenaline, were the most frequent occurrences, which suggests 
that the source of the catecholamines was the adrenal medulla and not 
the ischaemic myocardium. The arrhythmo genic role of this released 
adrenaline is difficult to reconcile with the observation that ligat­
ion of the adrenal vein did not modify the pattern of the arrhythmias 
during ischaemia in the dog (Kelliher et al, 1974). Also, the detri­
mental role of any catecholamines released from the adrenals during 
ischaemia may also be in doubt as Marshall et al (198I) observed 
antiarrhythmic effects of injected adrenaline and noradrenaline in
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the coronary artery ligated anaesthetised rat.
Shahab et al (1972) showed that a 2 min occlusion of the left 
anterior descending coronary artery of the anaesthetised dog produced 
an increase of noradrenaline in the coronary vein with a concomitant 
increase in lactate. Following 15 min (Lammerant et al, 1966) and 
1 hour (Dutta and Booker, 1970) of coronary occlusion in anaesthet­
ised dogs, increased levels of catecholamines (of unstated type) were 
detected in the coronary sinus. Althou^ the study of Richardson et 
al (i960) in the dog has been cited as evidence of early release of 
catecholamines, the increased plasma levels were measured 24 hours 
after coronary artery occlusion and no change in levels was detect­
able in the first 6 hours. Hirche et al (198O) found increases in 
noradrenaline in the first 3 min of occlusion in the coronary vein 
of the coronary artery occluded pig heart, which returned to normal 
levels after 10 min of occlusion.
To overcome the methodological problems of measuring released 
noradrenaline in ischaemia, some authors have measured the myocardial 
tissue levels of this catecholamine. Both Russel et al (196I) and 
Mathes and Gudbjarnason (1971) observed catecholamine depletion in 
the ischaemic myocardium of coronary artery occluded dogs, althougji 
the first measurements were taken as late as 24 hours after occlusion. 
In a more relevant study,Abraham^n et ai(l98| ) observed decreased 
noradrenaline levels in the ischaemic muscle of coronary artery 
ligated rat hearts after 20 min.
Indirect measures of catecholamine release have also been used 
in ischaemic tissue. Hough and Gevers (1975) considered that 
catecholamine release occurred in ^obally underperfused rat hearts 
as indicated by increased levels of phosphorylase a and tri^yceride
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lipase activities. These increases were reduced 'by reserpine pre­
treatment. By far the most extensively measured metabolite to be 
taken as an index of local release of noradrenaline is cyclic AMP 
(Corr et al, 1978). Cyclic AMP has been shown to increase in a 
variety of models in which ischaemia has been induced (for review see 
Krause and WoUenberger, 198O). Whether this increase in cyclic AMP 
necessarily reflects catecholamine release is considered in this 
thesis.
Despite the above evidence, more recent reports have failed to 
detect noradrenaline release from ischaemic myocardium. In anaesth­
etised dogs subjected to left anterior descending coronary artery 
occlusion, no enhanced noradrenaline release could be observed in the 
coronary vein during a 10 min occlusion (McGrath et al, 198I) or a 
2 hour occlusion (Rogg and Bucher, 1979), despite the appearance of 
the profound changes associated with ischaemia in both reports. 
Riemersma and Forfar (198I) were also unable to detect noradrenaline 
release from ischaemic dog myocardium despite the presence of vivi- 
loxene to inhibit the uptake 1 process. In isolated rat hearts in 
which neuronal stores were pre-labelled with (3H)-noradrenaline, no 
increase in overflow could be observed during ligation (Rochette et 
al, 198O; Didier et al, 198O).
The most pertinent question is not just whether noradrenaline is 
released in ischaemia, but vdiether this release initiates or sustains 
ventricular arrhythmias. Only two reports have attempted to resolve 
this problem and conflicting data have been obtained. Hirche et al, 
(1980) noted an increase in noradrenaline levels in coronary vein 
coincident with the first phase of arrhythmias in coronary artery 
ligated pigs. However, Marshall and Parratt (198O) found no such
26
relationship in coronary artery ligated dogs.
The first suggestion that catecholamines were released in 
reperfusion appears to be the finding of WoUenberger and Shahab 
(1968) who found that reperfused rabbit hearts, previously made 
total1y ischaemic, released approximately a quarter of their total 
catecholamine content. Increased levels of noradrenaline in the 
coronary vein were also shown on release of a coronary artery occlus­
ion in the dog (Shahab et al, 1972). The possibUity that released 
noradrenaline was responsible for reperfusion arrhythmias was invest­
igated by Rochette et al (198O). They concluded that either nor­
adrenaline was not implicated in the genesis of reperfusion arrhyth­
mias or that the arrhythmogenic properties of released noradrenaline 
were influenced by the different substrates used in the perfusate of 
the rat heart. A later study by the same group (Didier et al, 198O) 
suggested that noradrenaline was involved in reperfusion arrhythmias. 
Support for this hypothesis comes from the protective effects of 
reserpine (Sommer, I966) and 6-hydroxydopamine (Sheridan et al, I98O) 
pretreatment on reperfusion arrhythmias in the dog and cat, respect­
ively.
1.9 Effectiveness of |3-adrenoceptor antagonism and catecholamine
depletion on early post-ligation arrhythmias.
Drugs classified as ^ -adrenoceptor antagonists have been shown 
to be effective in preventing ventricular arrhythmias occurring in 
the early stages of ischaemia, althougjh whether this is due to 
|3-adrenoceptor antagonism or a secondary property has not yet been 
fuUy defined. Possible beneficial secondary effects which mig)it 
cloud interpretation of results are local anaesthesia, calcium antag­
onism, prolongation of action potential duration and phospholipase A2
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inhibition, althou^ |3-adrenoceptor partial agonist properties and 
|3i-adrenoceptor selectivity may also be desirable properties. The 
arrhythmias relevant to this study of (3-adrenoceptor antagonism are 
those occurring in the early phase immediately after the induction 
of ischaemia.
Propranolol has been shown to exert antiarrhythmic effects 
after coronary artery ligation in anaesthetised dogs (Pentecost and 
Austen, I966; Fear son, 1967; Reynold et al, 1978) and pigs (Morris 
et al, 1969), although no antifibrillatory activity on ischaemia- 
induced arrhythmias was observed in dogs (Pearle et al, 1978), 
cats (Corr et al, 1978) or pigs (Muller and Opie, 1979).
Particularly difficult to interpret is the study of Khan et al (1972) 
who observed that a low dose of propranolol exerted significant anti­
arrhythmic effects in conscious coronary artery ligated dogs, vdiereas 
a higher dose did not. With regard to studies which find an anti­
arrhythmic effect, two studies in which the contribution of the local 
anaesthetic properties of propranolol have been investigated, made 
use of the d-isomer of this drug. The d-isomer has equivalent local 
cinaesthetic potency to the 1-isomer but is a far less potent ^ adreno­
ceptor antagonist (Barrett and Cullum, 1968). The d-isomer was not 
found to possess comparable antiarrhythmic properties to a hi^er 
dose of the racemate in conscious dogs (Khan et al, 1972). However, 
in coronary artery ligated isolated perfused rat hearts, both isomers 
prevented the decrease in ventricular fibrillation threshold during 
ischaemia (Lubbe et al, I98O). These studies have produced a rather 
confusing view as the efficacy and possible mechanisms of the anti­
arrhythmic properties of propranolol.
A more comprehensive sin^e study which investigated secondary
28
properties of oxprenolol concluded that the antiarrhythmic effect 
in anaesthetised coronary artery ligated rat hearts was determined 
by the degree of ^ -adrenoceptor antagonism (Campbell and Parratt, 198I). 
It was also shown that para-oxprenolol and practolol were more potent 
antiarrhythmics than oxprenolol, suggesting that selective -adreno­
ceptor antagonism was beneficial. This is supported by the observ­
ation that practolol is a more potent antifibrillatory drug in dogs 
(Pearle et al, I978). The beneficial effect of selective -adreno­
ceptor antagonism has been attributed to an effect on potassium efflux 
from the ischaemic nyocardium (Corr and Gillis, 1978).
There are relatively few studies on the effects of other 
p-adrenoceptor antagonists on early post-ligation arrhythmias.
Sotalol has antiarrhythmic activity in conscious dogs (Khan et al,
1972) and in anaesthetised rats (Parratt, 198O) and dogs (Kaumann 
and Aramendia, I968). However, sotalol was ineffective in coronary 
artery ligated pigs (Muller and Opie, 198O) and isolated coronary 
artery ligated rat hearts (Lubbe et al, I98O). INPEA has been found 
to possess antiarrhythmic properties in dogs, although the potency of 
both optical isomers was similar (Angelakos and Torchiana, 1973). 
Finally, the ^^-adrenoceptor antagonist, metoprolol, reduced the 
incidence of ventricular fibrillation in pigs (Muller and Opie, 198O).
The development of atenolol, which is a selective P^-adrenoceptor 
antagonist with no local anaesthetic properties, may aid the resol­
ution of the controversy over the effectiveness of p-adrenoceptor 
antagonism. Unfortunately, initial reports with this drug are con­
flicting, Parratt (198O) observed a protective effect with atenolol 
on the incidence of ventricular fibrillation in coronary artery ligated 
anaesthetised rats. A similar protection was reported in dogs (Aben^- 
roth et al, 1977). In contrast, Lubbe et al (1980) did not observe
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any increase in the reduced ventricular fibrillation threshold 
during coronary artery ligation in the isolated rat heart despite a 
h i ^  perfusate concentration of atenolol.
Althou^ the effects of chronic dosing with p-adrenoceptor 
antagonists have hitherto not been discussed in this thesis, it is
interesting to note that Menken et al (1979) found a reduced incid­
ence of ventricular fibrillation in coronary artery ligated dogs 
after 5 days oral dosage with atenolol. However, Hirche et al (1979) 
did not observe any decrease in fibrillation due to ischaemia after
2 weeks oral dosage in the pig.
The majority of investigations on the effects of catecholamine 
depletion on early post-ligation arrhythmias have used reserpine 
pretreatment in dogs. No significant reduction in ventricular 
fibrillation has been observed in most of these studies (Maling et 
al, 1959; Ebert et al, 1970; Kaumann and Aramendia, I968) and 
catecholamine depletion may, in fact, exacerbate arrhythmias 
(Melville and Verma, I962). A protective effect of reserpine pre­
treatment has been observed in a model of arrhythmias in the dog 
(Angelakos and Torchiana, 1973). This general lack of antiarrhythmic 
activity has been attributed to lack of depletion of adrenal catechol­
amines and postsynaptic supersensitivity (Corr and Gillis, 1978), 
althougih the former is not in agreement with the findings of Maling 
et al (1959), while the latter has not been investigated.
Catecholamine depletion by chemical sympathectongr with 6-hydroxy­
dopamine reduced the incidence of ventricular fibrillation in cats 
(Sheridan et al, 1980). Sethi et al (1973) selectively depleted the 
heart by intracoronary artery injection of 6-hydroxydopamine, which 
prevented ischaemia-induced fibrillation in dogs.
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1.10 Ionic basis of arrhythmias.
The involvement of ionic changes in the production of ventric­
ular arrhythmias vrill be considered firstly in the context of ionic 
milieu which have been shown to precipitate ventricular arrhythmias, 
and then briefly reviewing the ionic changes that occur in ischaemia 
and how these changes may relate to arrhythmia production.
The two ions which have been most intensively investigated for 
their effects on ventricular arrhythmias are potassium and calcium. 
Several authors have observed the production of ventricular fibri­
llation upon reduction of the extracellular potassium concentration 
(Ch'umbach et al, 1954; Dir ken et al, 1955; Armitage et al, 1957).
This may be the result of enhanced automaticity of Purkinje fibres 
and conversion of previously non-pacemaker fibres to pacemakers, 
or conduction irregularities which permit re-entry (Surawicz, 1971). 
Very high extracellular potassium has been shown to produce fibri­
llation in isolated rabbit hearts, presumably due to re-entry since 
automaticity is suppressed by potassium (Surawicz, 1967).
Excess calcium precipitated ventricular fibrillation when large 
quantities were infused into rabbit Langendorff preparations 
(a^umbach et al, 1954; Beaulnes and Lavales, I964). In vivo experi­
ments have also shown that calcium infusions increase vulnerability 
to fibrillation in rabbits (Cuparencu et al, 1980) and produce vent­
ricular arrhythmias in rats (Barzu et al, 1978) and dogs (Cuparencu 
et al, 1978). There is some evidence, albeit less convincing, that 
low calcium may increase vulnerability to fibrillation in isolated 
rabbit hearts (Surawicz et al, 1964).
A relationship appears to exist between the potassium:calcium 
ratio , independent of the effects of the absolute levels of the
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individual ions. Grumbach et al (1954) observed that the fibrillation 
produced by lowered extracellular potassium could be prevented by a 
concomitant reduction in calcium concentration in the perfusate of 
rabbit hearts. This relationship of the potassium:calcium ratio in 
ventricular instability has also been observed by Karki (1958) and 
Gettes et al (1966).
Reductions in extracellular sodium have also been shown to 
increase vulnerability to fibrillation in the isolated rabbit heart 
(Karki, 1958), which could be overcome by elevation of the extracell­
ular potassium concentration. In isolated rat hearts, reductions in 
extracellular sodium have also been shown to produce ventricular 
fibrillation, an effect vdiich was dependent on the extracellular 
calcium concentration (Woodward, I98I).
All the above manipulations of the extracellular calcium, sodium 
and potassium would have increased intracellular calcium. Reduction 
of extracellular potassium would have inhibited the potassium/sodium 
ATPase resulting in a greater intracellular concentration of sodium 
to exchange across the sarcolemma for calcium via the sodium/calcium 
exchange mechanism. Similarly, reduction in extracellular sodium 
would alter the sodium/calcium exchange system in favour of an influx 
of calcium. In support of the concept that increased intracellular 
calcium may produce instability, de Mello (1975) found that an abrupt 
increase in intracellular calcium caused electrical uncoupling in 
canine Purkinje fibres. This adverse effect seems to be due to the 
increased intracellular calcium inhibiting the cell-to-cell communi­
cation by an action on the nexus (Tsien and Seigelbaum, 1978) and 
disrupting the functional syncytium.
However, these concepts of ions producing arrhythmias have
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seldom been cited in the context of the clinical phenomenon of acute 
myocardial infarction. This could be related to the severity of the 
concentration changes of ions which are needed to produce fibrill­
ation and also the difficulty with which these results from non-isch- 
aemic tissue may be translated to ventricular arrhythmias due to 
ischaemia.
The most extensive studies of ion movements in ischaemia have 
been on potassium. It was shown as early as 1938 (Dennis and Moore) 
that potassium accumulated in coronary venous blood in the first few 
minutes of ischaemia in the cat. The released potassium was implic­
ated in the production of arrhythmias by the observation of a temp­
oral relationship between potassium release and the onset of ventric­
ular arrhythmia (Harris et al, 1954; Cherbakoff et al, 1957).
This possible role of potassium in arrhythmia production was further 
substantiated by Regan et al (1967) who mimicked the effects of 
potassium egress by infusing a potassium solution into the coronary 
artery of the anaesthetised dog to produce arrhythmias. In contrast, 
Thomas et al (1970) measured potassium release in ischaemia from the 
local coronary vein of the coronary artery occluded dog heart and 
showed a marked increase in potassium concentration which preceded 
the appearance of ventricular instability. They also showed a 
disparity between potassium release and incidence of ventricular 
arrhythmias vdien the instability was induced by varying sites of 
occlusion, A similar disparity between coronary sinus potassium and 
arrhythmias was observed in dogs and pigs (Cherry and îfyers, 1971). 
Further evidence that potassium may not be involved in the occurrence 
of ventricular arrhythmias is that blood from ischaemic areas produced 
electrophysiological properties which differed qualitatively from 
those observed by an equivalent concentration of potassium (Downar
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et al, 1977). The electrophysiological changes occurring in ischaemia 
are reductions in action potential duration, maximum diastolic poten­
tial, peak dV/dt and overshoot of phase 0 (Corr and Sobel, 1977).
However, all these studies were measuring coronary arteriovenous 
differences and they may not represent a good quantitative assessment 
of potassium egress if accumulated potassium is not washed out due to 
decreased coronary blood flow. This has recently been overcome with 
the development of ion selective electrodes which may be placed on 
the epicardium of the ischaemic area. Using these methods Hirche et 
al (1980) found a relationship between potassium egress from the 
ischaemic myocardium and the occurrence of ventricular arrhythmias 
in the coronary artery ligated pig heart, although a relationship 
between extracellular potassium and fibrillation was not shown. 
Extracellular potassium accumulation has also been observed by 
Wiegand et al (198O) using ion selective electrodes. They suggested 
that the rate of accumulation of potassium was compatible to ascribing 
a role for potassium in producing the phase 1 arrhythmias of the 
Harris dog model (Harris, 1950). A similar conclusion was drawn by 
Weiss and Shine (198I) from their experiments on rabbit septum.
Far less information is available on the effects of ischaemia 
on the extracellular concentrations of other ions. No changes were 
observed in concentrations of calcium and magnesium in blood from 
ischaemic porcine heart (Downar et al, 1977) which has been taken as 
evidence that these ions do not contribute to arrhythmias induced by 
ischaemia (Corr & Sobel 1977). Sodium concentration has also been 
found to be unaltered in blood from ischaemic areas (Cherry and îtyers,
1971).
Acidosis, due to the accumulation of hydrogen ions, occurs in
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ischaemic tissue concomitantly with the onset of anaerobic metabolism. 
However, Hirche et al (198O) failed to observe a relationship between 
epicardial hydrogen ion concentrations and the onset of fibrillation 
in coronary artery ligated pigs. In addition, changes in pH in 
electrophysiological studies did not mimic changes brou^t about by 
blood from ischaemic myocardium (Downar et al, 1977).
Changes in intracellular ionic composition during ischaemia have 
not been extensively investigated, althou^ with the recent develop­
ment of small ion selective electrodes this is likely to be an area 
which will soon be expanded.
There have been several attempts to measure tissue calcium levels 
in ischaemia but no concensus of opinion has been reached. Some 
authors have been unable to detect a change in tissue calcium levels 
during ischaemia (Shen and Jennings, 1972; Sugiyama et al, 1979),
\diilst increased calcium levels have been reported by other workers 
(Vogel et al, 198O; Nayler et al, 198O).
1.11 Calcium slow channel antagonists and their effects on
ventricular arrhythmias.
Melville et al (1964) first found that verapamil possessed anti­
arrhythmic properties in dog models involving aconitine and adrenaline 
infusions in the chloroform sensitised heart. Since these observations 
the majority of investigations on the effects of calcium slow channel 
antagonists on cardiac arrhythmias have used verapamil as the pharma­
cological tool. Several reports showed that verapamil in bolus 
injections (Huang et al, 1977) and infusions (Brooks et al, I98O) 
did not change the ventricular fibrillation threshold in the normal 
myocardium of anaesthetised dogs. However, in isolated perfused rat 
hearts Thandroyen et al (198O) demonstrated an increase in fibrill-
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ation threshold in normally perfused hearts using relatively hi^ 
concentrations of verapamil.
Verapamil also exerted protective effects on the reduction in 
ventricular fibrillation threshold in dogs (Brooks et al, I98O;
Fondacaro et al, 1978; Verrier et al, I980) and isolated perfused rat 
hearts (Thandroyen et al, 198O) which were subjected to coronary 
artery ligation. Spontaneously occurring arrhythmias during ischaemia 
were also decreased by verapamil in anaesthetised dogs (Elharrer et 
al, I98O; Kaumann and Aramendia, 1968) and cats (Schwartz et al, I98O), 
although not in rats (Kane et al, 198I). Verapamil was effective in 
preventing the decrease in ventricular fibrillation threshold on 
release of an occlusion in anaesthetised dogs (Brooks et al, 198O). 
Verapamil has also been found to be effective against reperfusion 
arrhythmias in the dog (Sugiyama et al, 198O).
Several authors have investigated the effect of verapamil on 
conduction time as a possible mechanism for its anti-arrhythmic effects 
and found that in contrast to what might be expected, verapamil para­
doxically 'increased conduction time in the ischaemic myocardium while 
(A@creasing it in non-ischaemic myocardium, hence reducing the disparity 
between the conduction times in the normal and ischaemic areas 
(Fondacaro et al, 1978; Elharrar et al, 198O; Szekeres, 1979).
The investigation of Huang et al (1979) concluded that the anti­
arrhythmic action of verapamil was due to non-specific inhibition of 
the sodium fast channel. In agreement with this, Bayer et al (1976) 
observed that the d-isomer of verapamil was almost exclusively a 
fast channel inhibitor, while the 1-isomer was a relatively selective 
slow channel inhibitor (see Section 1.5). The suggestion that the 
anti-arrhythmic action of verapamil was due to fast channel inhibition 
was supported by the study of Raschack (1976) who used optical isomers.
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Despite the implication of these studies, the only study in 
which the anti-arrhythmic activity of the isomers was investigated 
in models using coronary artery ligation was that of Kaumann and 
Serur (1975), who found a similar anti-arrhythmic potenqjr for both 
isomers of verapamil. Therefore, there appears to be general agree­
ment that verapamil possesses anti-arrhythmic properties, althougih 
whether this is attributable to calcium slow channel inhibition is 
questionable (Henry, 1979; Sin^, 1979).
The anti-arrhythmic action of nifedipine is even less well 
defined. Nifedipine has been shown to be effective against experi­
mentally induced atrial arrhythmias (Refsum et al, 1975, 1979) but 
reports of effects on ventricular arrhythmias have been conflicting. 
Kane et al (198I) reported that a low dose of nifedipine was anti­
arrhythmic in coronary artery ligated anaesthetised rats. A later 
report found that other dihydropyridine derivatives were similarly 
effective (Fagbemi and Parratt, 198I»). An anti-arrhythmic action 
has also been shown in the isolated perfused coronary artery ligated 
rat heart (Thandroyen et al, I980). However, in a direct comparison 
between the properties of verapamil and nifedipine. Verrier et al (198O) 
failed to observe any effect of nifedipine on ventricular fibrillation 
thresholds during occlusion and reperfusion in the anaesthetised dog, 
althou^ verapamil was shown to be protective. This disparity of 
effects on arrhythmias has also been observed by Ribeiro et al (198O) 
on reperfusion arrhythmias in the dog.
Reports on the effects of other drugs classed as calcium slow 
channel antagonists on ventricular arrhythmias are sparse. Schoen- 
berger et al (1979) found that prenylamine elevated ventricular 
fibrillation thresholds under basal conditions and during occlusion 
in the anaesthetised dog. Parratt (1980) observed that lidoflazine
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prevented arrhythmias in coronary artery ligated anaesthetised rats.
In contrast, Thandroyen et al (I980) found that even very hi^ 
concentrations of diltiazem failed to elevate the reduction in 
fibrination threshold in the isolated perfused coronary artery 
ligated rat heart.
1.12 Biochemical events in the ischaemic heart relevant to arrhythmia
production and possible protective biochemical interventions.
Changes in carbohydrate metabolism as a consequence of ischaemia 
have been extensively characterised, but only a few reports have 
related these changes to the production of the electrophysiological 
characteristics underlying the onset of arrhythmias. McDonald et al 
(1971) speculated that adenosine triphosphate produced by glycolytic 
metabolism (and not oxidative metabolism) has a particular role in 
the maintenance of the action potential. It has now been shown that 
inhibitors of glycolysis, such as iodoacetate, lactate and pyruvate, 
produce a shortening of the action potential duration vdiich is thou^t 
to be arrhythmogenic (Opie et al, 1979).
More direct evidence for the role of glycolytic flux in main­
taining normal electrical activity in the heart is the study of 
Bricknell and Opie (1978). Using reperfusion arrhythmias in the 
isolated rat heart as a model, they found that the presence of 
pyruvate increased the incidence of arrhythmias compared to those 
found in the presence of ^ucose.
Although glycolysis is considered to be inhibited in ischaemic 
tissue, glucose infusion has been shown to reduce vulnerability to 
electrically induced ventricular arrhythmias in the coronary artery 
ligated anaesthetised dog (Russell and Oliver, 1979). This protective 
effect of glucose has been related to a reduction in potassium egress
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from the ischaemic myocardium (Regan et al, I967). These workers 
also showed insulin to have similar effects on potassium efflux.
Oliver et al (I968) were the first to speculate that free fatty 
acids were involved in arrhythmia production in man. They also found 
that elevated free fatty acid levels, induced by Intralipid-heparin, 
preceded the onset of premature ventricular contractions in coronary 
artery ligated mongrel dogs (Kurien et al, 1971), although Opie et al 
(1971) failed to repeat these findings in greyhounds. A possible 
explanation of this disparity is that arrhythmia production may 
depend on the ratio of free fatty acids bound to albumin rather than 
absolute levels of free fatty acids. Hence, the poor nutritional 
state of the mongrel dogs used in the study of Kurien may explain 
this difference. In support of this concept, Willebrands et al (1973) 
reported that a high free fatty acid:albumin ratio could evoke 
arrhythmias even in the absence of ischaemia. This effect of free 
fatty acids has been confirmed by several other authors (see Opie,
1975, for citation of references).
The intracellular accumulation of free fatty acids during 
ischaemia and their relevance to arrhythmia production have not been 
examined so closely. Kurien et al (1971) speculated that intra­
cellular free fatty acid accumulation would have a detergent effect 
on cell membranes producing enhanced potassium egress. However, the 
experimental evidence to support this hypothesis requires consolidation.
Sobel et al (1978) have recently speculated that the lysophospho- 
lipids may be the prime arrhythmogenic mediator in ischaemic hearts.
Ly sopho sphotidylcholine and lysopho sphoethanolamine accumulated in the 
ischaemic area of coronary artery ligated rabbit hearts and these two 
metabolites were shown to produce electrophysiological changes in
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Purkinje fibres which were consistent with the changes observed 
during ischaemia (Corr et al, 1979)»
Prostaglandins have also been implicated in the production of 
early post-ligation arrhythmias. In the early phase of ischaemia 
there is no enhanced release of prosta^andins E and (Coker et 
al, 1981»; Sugiyama et al, 1979). However, prostacyclin and throm­
boxane are released into the coronary vein during coronary artery 
occlusion in the anaesthetised dog (Coker et £il, 1981k). From work 
using a low dose of aspirin (to inhibit preferentially synthesis of 
thromboxane B^) it has been suggested that thromboxane B^ is 
arrhythmic, \diile prostacyclin may be anti-arrhythmic (Coker et al, 
1981<). However, the effects of exogenous prostacyclin have produced 
conflicting reports on arrhythmias produced by coronary artery 
ligation in the anaesthetised rat (Coker et al, 19814) and conscious 




2.1 Rat hearts perfused by the Langendorff technique.
Throughout this study male and female Wistar rats (University of 
Bath strain) l?0-400g were used.
Animals were stunned and their hearts rapidly removed and perf­
used using a modified Langendorff technique. The apparatus used is 
represented diagrammaticaUy in Figure 1.
Hearts were initially perfused at a constant flow of 10 ml.min  ^
by means of Watson-Marlow flow inducers (HRIOO and HR200), The perf­
usate during the initial period was a modified Krebs-Henseleit solu­
tion of the following composition: CaClg 1.23mM; KCl 4*7niM; NaCl 
llS.QmM; KHgRO^  ^l.lSmM; MgSO^ 1.2mM; NaHCO^ 24.9mM; glucose ll.SmM, 
which was previously gassed with 95% 0^^ 5% 00^. The pH of the perf­
usate was 7.4. The perfusion system contained a Whatman filter in a 
Millipore holder to eradicate the possibility of small particles 
entering the coronary circulation.
Temperature was maintained at 37°C by means of a Grant SU5 
circulating pump. Temperature was monitored by insertion of a therm­
istor probe just above the aortic cannula and was displayed on a 
Light L aboratories meter,
A fine nickel pin was inserted into the apex of the heart and 
attached to a Devices UFl force displacement transducer via a thread 
passed over a pulley. The UFl force displacement transducer was 
coupled to a Devices 3559 pre-amplifier.
Developed tension was assessed at a diastolic tension of 2g,
Heart rate was derived from the signal from the 3559 pre-amplifier 
by passing it into a Devices 4521 instantaneous rate conditioning
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unit. Heart rate was displayed on a Devices 3411 display meter. 
Perfusion pressure was monitored with a Bell & Howell physiological 
pressure transducer (type 4-442) which was coupled to a Devices 3552 
pressure pre-ampLifier. All recordings were displayed on a Devices 
M19 8 channel recorder. When required, epicardial electrocardiograms 
were recorded by placing fine wire electrodes soldered into metal 
needles on the right atrium and apex of the left ventricle (i.e. 
analogous to lead II of electrocardiology). The earth electrode was 
placed into the perfusion fluid prior to it entering the aortic 
cannula. Electrocardiographic electrodes were coupled to a Devices 
3442 EGG pre-amplifier. The signal from the 3442 pre-amplifier was 
monitored on a Narco TM storage oscilloscope. Permanent electro­
cardiogram recordings could be obtained by storing the required dis­
play and transferring this display to a Devices MX2 chart recorder. 
During the early stages of this study electrocardiogram recordings 
were displayed on a Tektronix (type 502A) oscilloscope and permanent 
recordings were obtained on an SE Laboratories U-V recorder (type 
SE 2005).
In some experiments left ventricular pressure development was 
measured by inserting a polyethylene cannula into the ventricle 
through the mitral valve, and connecting this to a Bell & Howell 
physiological pressure transducer (type 4-442) via thick-walled 
silastic tubing. The transducer was coupled to a Devices 3552 press­
ure pre-amplifier.
2.2 Tissue preparation for rat myocardium.
Hearts were freeze-clamped after the appropriate experimental 
intervention using a pair of WoUenberger tongs vdiich had been 
previously cooled to the temperature of liquid nitrogen (-196 0^).
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The flattened disc of tissue which was produced facilitated rapid 
cooling of the tissue. For example, Ig of tissue has been shown to 
cool to 0°C in less than 100msec (Denton and Pogson, 1976). In 
contrast, a 1cm thick piece of tissue (which is approximately the 
width of a rat heart) would need about 20 seconds to freeze complete­
ly due to poor thermal conduction.
The samples were stored in liquid nitrogen until the tissue 
extraction procedures were carried out.
Pieces of ventricle were isolated vdiich were free of excess 
frozen Krebs-Henseleit solution. Ventricular muscle was then pulver­
ised to a fine powder in a stainless steel pestle and mortar which 
had previously been cooled to the temperature of liquid nitrogen. 
Approximately 100-200 mg of the powdered tissue were placed in a pre- 
wei^ed Eppendorff tube which contained 1ml of perchloric acid (6^ 
v/v). The tube was then reweighed. The tissue was allowed to extract 
for at least 30 minutes (timed from the last sample preparation) 
before being centrifuged for 2 minutes in a Beckman Microfuge.
A 70^ |Ul aliquot of the supernatant was removed and placed in 
another Eppendorff tube containing Ikiiversai indicator solution 
(BKl). The supernatant was neutralised with a known volume of 2M 
KH^COy'O. IM Tris solution.
Samples of neutralised extract were stored at -20°C until used.
2.3 Pacing of Langendorff perfused rat hearts.
In a series of 17 experiments hearts were perfused and instru­
mented as described in Section 2.1. Following a stabilisation period 
of 10 minutes, the right atrium was removed as completely as possible,
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Bipolar stimulating electrodes were placed on the metal aortic cannula 
and on the atrioventricular groove. After complete removal of the 
right atrium hearts continued to beat at approximately 150 beats.min"^ 
presumably due to their idioventricular rhythm. Therefore, the lowest 
pacing frequency that was routinely obtainable was 200 beats.min"^.
Hearts were stimulated at rates between 200 and 500 beats.min”  ^
with square wave pulses of 1 msec duration and 6V amplitude, delivered 
by a Grass S44 stimulator. Five minutes after commencement of stimu­
lation, hearts were freeze-clamped with WoUenburger tongs as descr­
ibed previously (Section 2.2).
Developed tension was assessed throughout the experiment with 
the exception of the period immediately prior to freeze-clamping, 
during the nickel pin attached to the apex was removed.
2.4 Production of ischaemia in Langendorff perfused rat hearts.
(a) Global ischaemia
Global ischaemia was produced by reduction of the flow rate 
from the normal value of 10 ml.min  ^to 2 ml.min
(b) Coronary artery ligation.
Following removal from the animals, the hearts were immersed 
in cold Krebs-Henseleit solution until arrested. A ligature was placed 
loosely around the main left coronary artery, which was clearly visi­
ble due to the presence of residual blood. The heart was then trans­
ferred to the Langendorff apparatus and the procedures carried out as 
described in Section 2.1. Coronary artery ligation was produced by 
tightening the ligature at the appmpriate point in the procedure 
(see Results).
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2.5 Determination of (3H)-noradrenaline overflow and tissue (3H)
levels during coronary artery ligation.
Hearts were perfused as described previously (Section 2.1).
After a stabilisation of ten minutes (3H)-noradrenaline was infused 
via a needle placed immediately above the aortic cannula. (3H)-nor­
adrenaline was infused for 10 min at a rate of 0.175 ml.min 
Total activity infused over the 10 min period was 17.5/(Ci (1- 7,8- 
3H -noradrenaline, 15.9 Ci.mmol diluted in physiological saline),
A 20 min washout period was allowed with 1 min samples collected 
every 5 min. After 20 min washout, the ionic milieu of the perfusion 
fluid was adjusted to that under investigation and the perfusate was 
collected continuously at 1 min intervals. The coronary artery lig­
ature was tightened at 25 min and perfusate collection continued for 
a further 30 min.
At the end of the 30 min ligation period 0.05 nil of Evans Blue 
dye (O.5^ w/v) was injected at a site immediately prior to the aortic 
cannula. Hearts were rapidly freeze-clamped with WoUenberger tongs 
cooled in liquid nitrogen, with care being taken to the orientation 
of the clamping process; i.e. ’folding* the ischaemic area into the 
ischaemic area. The dyeing process aided identification of the is­
chaemic and non-ischaemic areas. Differentiation was further aided 
by the location of the coronary artery ligature.
Small pieces of ventricle from the ischaemic and non-ischaemic 
areas were isolated and placed in separate pre-weighed vials and the 
weight of the tissues was determined. Tissues were solubilised over­
night by the addition of 0.5 nil Luma-solve (quaternary ammonium 
hydroxide, LKB). Scintillation fluid (4 nü Aqualuma, LKB) was added 
to the vials. Vials were stored for 24 hours at 4 C to reduce the
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chemiluminescence produced by the highly alkaline solubilising solu­
tion.
To show that this method would detect enhanced ( ) -noradrenaline 
overflow, the effects of the indirectly acting sympathomimetic, tyra- 
mine, were examined. Figure 2 shows the response to a 10 yug bolus 
injection of tyramine vdiich produced a large increase in (gH)-nor­
adrenaline overflow, with a concomitant increase in developed tension 
and heart rate,
2.6 Evaluation of ventricular fibrillation thresholds and vulnerable
period duration.
Apparatus
Two methods of evaluating ventricular fibrillation thresholds 
were used in this study:
1) Ventricular fibrillation produced by a single stimulus of 
2 msec duration (similar to that described by Lubbe et al, 
1975).
2) Ventricular fibrillation produced by a train of stimuli.
The apparatus for producing ventricular fibrillation by the single 
stimulus method is represented diagrammaticaUy in Figure 3.
Langendorff perfused rat hearts were instrumented for the measurement 
of developed tension, left ventricular pressure, heart rate, perfusion 
pressure and epicardial electrocardiogram. Hearts were paced at 300 
beats.min  ^with bipolar stimulating electrodes placed on the metal 
aortic cannula and the atrio-ventricular groove. Stimulation para­
meters were square-wave pulses of 2 msec duration, 6V amplitude deli­
vered by one channel of a Grass S88 two channel physiological stimu­
lator via a Gk'ass SIU 5A stimulus isolation unit. The second channel 
of the stiumlator was connected to bipolar stimulating electrodes
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placed across the ventricular wall, via a Grass CCU lA constant curr­
ent unit and a Grass SIU 5A stimulus isolation unit. The positioning 
of the electrodes and the use of stimulus isolation units reduced 
stimulus artifacts to a level \diich rarely affected electrocardio­
graphic recordings adversely. Electrocardiographic recording was via 
a Devices 3442 pre-amplifier which contained a mute overload circuit 
which operated in the event of a voltage surge to the recording elec­
trodes. Due to the extra-pulses activating this , the mute overload 
circuit was disconnected at pin PLX III.
The second channel of the Grass S88 stimulator was synchronised 
with the first channel so that a sin^e extra-pulse could be deliver­
ed at a controlled delay after the pacing stimulus. With the use of 
the constant current unit the extra-pulse may also have a preset 
current (or energy). The extra-pulse also triggered a sin^e sweep 
of the Narco TM storage oscilloscope.
Assessment of ventricular fibrillation thresholds by the stimulus 
train method required the use of a Grass S48 as a second stimulator. 
The Grass S48 was synchronised with the second channel of the Grass 
S88 which was itself synchronised with the first channel (i.e. the 
pacing channel). The use of the second channel of the Grass S88 
permitted the delivery of a train of pulses from the S48 with a con­
trolled delay after the pacing stimulus (with the use of the arrhyth­
mic pulse facility of the S88). Train parameters were either pulses 
of 2 msec duration every 10 msec for 100 msec, delivered 10 msec after 
the R wave, or 2 msec duration pulses every 5 msec for 60 msec deli­
vered 10 msec after the R wave. Trains were delivered via a Grass 
CCU lA constant current unit and a Grass SIU 5A stimulus isolation 




Assessment of ventricular fibrillation thresholds was initiated 
after a 15 min stabilisation period when all measured parameters were 
stable.
a) Sin^e stimulus method.
Stimulation was commenced with a stimulus delivered 10 msec 
after the peak of the R wave at an initial current dependent on pre­
vious experience of the experimental situation (5 mA for 2.46 mM 
calcium, 10 mA for 1.23 mM calcium). The delay between the peak of 
the R wave and the extra-pulse was increased initially at intervals 
of 5 msec, with pulses being delivered every 5 seconds. When extra­
pulses produced electrocardiographic abnormalities the delay was 
increased at 2.5 msec intervals. Ventricular fibrillation threshold 
was obtained to the nearest 1 mA, which was considered as accurate as 
experimental apparatus and conditions allowed. On induction of vent­
ricular fibrillation no further extra-pulses were delivered before 
the measured parameters reattained a steady state.
b) Stimulus train method.
Stimuli were initiated at 5 mA and increased in 1 mA incre­
ments until ventricular fibrillation was obtained. Trains of stimuli 
were delivered at 20 sec intervals unless an abnormality had been 
produced by a previous train of stimuli, in which case measured para­
meters were allowed to stabilise before recommencement of stimulation.
Criteria for ventricular fibrillation threshold.
Isolated rat hearts rarely fibrHlated persistently, so a time 
factor was introduced to quantify the fibrillation produced. Fibri­
llation was diagnosed as the appearance of chaotic electrical activity 
with associated collapse of left ventricular pressure which persisted 
for 800 msec (a convenient measure on the oscilloscope graticule).
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Ventricular fibrillation threshold was taken as the current vdiich 
produced fibrillation on two successive occasions.
2 .7 Rabbit hearts perfused by the Langendorff technique.
New Zealand rabbits were killed by cervical dislocation. Hearts 
were rapidly removed and placed in ice-cold physiological saline.
The aorta was located and attached to a cannula which permitted retro­
grade perfusion of the aorta at a constant pressure head of 70 cm H^O.
Initially, all hearts in one series of experiments were perfused 
with a Ringer-Locke solution of the following composition (mM):
CaCl^, 1.2; KCl, 5.6; NaCl, 157.4; NaHCO^ 1.8; ^ucose, 5.5, which 
had previously been gassed with pure oxygen. Temperature was main­
tained at 37°C by means of a Grant SU5 circulating pump.
During a 15 min stabilisation period a ligature was placed 
around the major left coronary artery. Following the 15 min stabili­
sation period the perfusate was changed for one containing the calcium 
concentration under investigation; i.e. 0.6 mM (n=5), 2.4 mM (n=4),
3.6 mM (n=5). In 8 experiments the calcium concentration was unalt­
ered (1.2 mM). In 4 experiments the perfusate was changed to one
—7
containing 2,4 mM calcium and verapamil (l.l x 10 M).
A further 15 min stabilisation period was allowed before the 
ligature around the main left coronary artery was tightened. Ligation 
persisted for 5 min before tissue quenching was performed (see Section 
2.8). In 2 experiments hearts were perfused with 1.2 mM calcium and 
10 min of ligation elapsed before quenching was performed. In a 
second series of 4 experiments, rabbit hearts were perfused by the 
Langendorff technique at a constant flow of 20 ml.min  ^by means of a 
Watson-Marlow 501 flow inducer, with Tyrode solution of the following 
composition (mM): CaCl^, 1.2; NaCl, 136.9; KCl, 2.7; MgCl^, 1.1;
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NaHCO^, 11.9; NàH^PO^, 0.42; glucose, 5.6, previously gassed with 
95% 0^, 5% CO^.
Contractility was assessed by attaching a thread to the middle 
posterior surface of the left ventricle and a Devices UFl force dis­
placement transducer, whilst the heart was held in position by two 
ties placed in the superior and inferior regions of the heart. Con­
tractile measurements, at a diastolic tension of 4g, were displayed 
on a Devices MX216 recorder. Heart rate was obtained by feeding the 
transducer signal into a Devices 4521 instantaneous rate conditioning 
unit which was housed in a Devices PX2.
Contractile parameters and heart rate were assessed after 5 min 
of perfusion with Tyrode solutions containing 0.6, 1.2, 2.4 or 3.6 mM 
calcium.
2. 8 Quenching of rabbit nyocardium.
The aim of this series of experiments was to investigate the 
heterogeneous distribution of cyclic nucleotides following coronary 
artery ligation, and therefore freeze-clamping techniques would not 
have been appropriate to separate normal and ischaemic areas.
An alternative method of quenching was adopted. This utilised 
the rapid protein dénaturation properties of microwaves. At the re­
quired time the heart was removed from the perfusion apparatus, the 
ventricles pierced (to prevent the heart exploding due to residual 
fluid) and quickly placed in a Phillips microwave oven (HW 1104) for 
10 seconds. On cooling, the heart could be easily dissected, with 
9 samples being taken from the left ventricle and one from the right 
ventricle. The relative position of each sample was noted diagramm- 
atically, as was the approximate position of the occlusion and the 
visible coronary veins (see Section 3.20). Samples were stored at
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-20°C until extraction.
2.9 Tissue preparation of rabbit myocardium.
A known weigjit of tissue was placed in a cooled pestle contain­
ing 1 ml trichloroacetic acid (10^ w/v). The tissue was vigorously 
ground and left for extraction on ice for at least 30 min. After 
extraction the suspension was poured into an Eppendorf tube (1.5 ml) 
and centrifuged for 2 min in an Eppendorf 5412 centrifuge. SOOyutl of 
the supernatant was transferred into a glass-stoppered test tube.
The samples were then extracted by shaking for 15 min with 5 ml petr­
oleum: ether mixture (40:60) using a mechanical shaker. The test 
tubes were then placed in liquid nitrogen to freeze the lower aqueous 
layer and thus enabling the upper organic phase to be decanted. This 
extraction procedure was repeated twice for each tissue sample. 
Following extraction the aqueous phase was placed in a Virtis Unitrap 
II freeze-drier overni^t to lyophilise the sample.
Samples were resuspended in SOOyul of 0.05 M sodium acetate 
buffer (pH 6.2) and stored at -20°C until analysis of cyclic AMP, 
cyclic ®1P and lactate was performed,
2.10 Adenosine triphosphate and creatine phosphate determinations. 
Principle of the enzymatic assay used.
The enzymatic analysis of adenosine triphosphate used the follo­
wing reaction sequence:
(1) ATP + GLUCOSE ----— ---► ADP + G-6-P
(2) G-6-P + NADP"*" ■». 6-PHOSPHORGLUCONATE + NADPH +
HK = Hexokinase (EC. 2.7.1*1)
G-6-PDH = Glucose-6-phosphate dehydrogenase (EC. 1.1.1.49)
The composition of the reaction mixture was such that adenosine tri­
phosphate was the limiting factor. Creatine phosphate was then
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determined by the generation of adenosine triphosphate in the follo­
wing reaction:
(3) CP + ADP ^  CREATINE + ATP
CK = Creatine kinase (EC. 2.7.3.21).
Hence, more adenosine triphosphate was available in the reaction mix­
ture to begin the reaction sequence at (l).
The measurement of these reactions was dependent on the absorp­
tion spectra differences of NADP^ and NADPH, in which NADPH has an 
absorbance peak at 340 nm, whilst at this wavelength NADP*^  shows no 
absorbance. Therefore the increase in absorbance at 340 nm during 
the reaction is due to the reduction of NADP^ and is stoichiometri- 
cally related to the concentration of adenosine triphosphate and 
creatine phosphate in the reaction mixture.
Enzymes used.
a) Glucose-6-phosphate dehydrogenase from yeast (Boehringer cat. no.
127663).
b) Hexokinase from yeast (Boehringer cat. no. 127809).
c) Creatine kinase from rabbit muscle (dissolved in 0.5% w/v NaHCO^) 
(Boehringer cat. no. 127566).
Assay procedure.
Each reaction mixture of 1 ml per sample contained the following;
Tris buffer 0.2 M, pH 7.5 350 ywl
NADP"*" 1% w/v 35/41
Glucose 100 mM 20/il
MgCl2 1 M 35/il
Distilled water 550/il
G-6-Pffl 1.4 u 2 /il
ADP 35 mM 8/tl
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One ml of the reaction mixture was placed into quartz semi-micro 
cuvettes with 40/il of neutralised extract. Cuvettes were placed in 
a Cecil CE 595 dual beam spectrophotometer to record absorbance at 
340 nm. The cuvette holder was maintained at 37°0 by means of a 
Circon circulating pump. Earlier work in this study used a Hilger- 
Güford Uhispek photometric spectrophotometer (MK 4 H700) in which 
experimental conditions were identical.
The initial absorbance of the solution was determined before the 
addition of 5/il hexokinase (2.8 U) to the reaction mixture. The 
reaction was found to have gone to completion after 5 min, at Wiich 
time the absorbance was redetermined. Five/il (2,5 U) of creatine 
kinase was then added to the reaction mixture and after a further 10 
min the absorbance was again determined.
Calculation of results assumed an extinction coefficient of
6.22 X 10 Although calculation of results used this extinc­
tion coefficient, standard measurements on 40/tl of adenosine triphos­




The reaction sequence in this enzymatic assay was:
LACTATE + NAD"^  + HYDRAZINE PYRUVATE HYDRAZONE + N AM + H^O
LDH = Lactate dehydrogenase (EC. 1.1.1.27).
Therefore, the reaction was measured using the spectrophotometric 
characteristics of NAIfti (discussed in Section 2.10).
Elnzymes used.




Lactate was determined using a method similar to that described 
by Hohorst (1965), using an autoanalyser constructed at ICI Alderley 
Park. For diagrammatic representation see Figure 4.
Reagents used by the autoanalyser were:
a) Hydrazine (1.25 M) - glycine (2 M) buffer (containing 20 mM EDTA 
with adjusted to 9*5 with 2 M sodium hydroxide.
b) Nicotinamide adenine dinucleotide (oxidised) 0.05 M.
c) Lactate dehydrogenase solution diluted with distilled water to 
give 0.5 ng.ml"^.
d) Sodium acetate buffer (0.05 M, 6.2) was used as a wash reagent.
Reagents were placed on the autoanalyser and samples were placed 
on an automatic sampler. A calibration curve was obtained at the 
beginning of each series of determinations using 0.4, 0.3, 0.2, 0.1, 
and 0.05 //moles lactate/ml solutions diluted from 1 M L-lactate 
(Boehringer cat. no. 125440).
Samples were mixed with reagents in mixing coils before entering 
a delay heating coil which was maintained at 37°0. From the heating 
coil samples were passed through a Technicon Autoanalyser II (Fluoro- 
nephelometer) which detected absorbance changes at 340 nm. Absorb­
ance changes were recorded on a JJ CR552 chart recorder.
2.12 Glycogen determination.
Glycogen was determined by hydrolysis to ^ucose (Pfleiderer,
1965) and subsequent colorimetric determination of glucose using a 
Boehringer-Mannheim Combination glucose test kit (cat. no. 124036).
Heart tissue was freeze-clamped and powdered as described prev­
iously (Section 2.2). The finely powdered tissue was digested by
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placing into a pre-weighed test tube containing 2 ml KOH (30% w/v) 
and 2. 8 ml absolute ethanol. The test tube was then reweighed to 
determine tissue weight. Tubes were placed in boiling water for 30 
mins before being placed in a refrigerator for storage at 4°C over­
night.
Tubes were centrifuged in a MSE bench centrifuge for 20 min at 
12 50 g. The resultant supernatant was discarded and the pellet 
washed in 5 ml ethanol (70% v/v). Tubes were recentrifuged as prev­
iously described. The resultant supernatant was discarded and the 
pellets were dried at 100°C. One ml of 2 M sulphuric acid was added
to the dried pellets and the tubes were then stoppered and placed in
boiling water for 2 hrs.
The acidic solution was neutralised with 2 M sodium hydroxide. 
Five ml of sodium acetate buffer (jH 5.0) was placed in each tube 
(final pH 6.5). An aliquot of 0.1 ml of this buffered solution was 
used for glucose determination.
Principle of glucose assay.
The colorimetric assay used was dependent on the following 
reaction sequence:
GLUCOSE + 0^ + H^O ----— — ► GLUCONATE + H^O^
HgOg + ABTS --- — — ► COLOURED COMPLEX + H^O
GOD = Glucose oxidase
POD = Peroxidase
ABTS = Di-ammonium-2,2' -azino-bis(3-ethyl benzo-thiazoline-6-
sulphonate).
The assay kit contained two reagents, one being a ^ucose stand­
ard and the other a composition of buffer, enzymes and chromogen.
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0,1 ml of standard, or unknown, was placed in 5 ml of the composite 
mixture and the reaction was allowed to go to completion. The opti­
cal density was determined after 25-30 min. Samples were measured in 
1 cm pathlength cuvettes at 6lO nm in a Cecil CE, 595 dual beam spec­
trophotometer.
Concentration of glucose in the sample was determined by:
concentration = 5.55 x —  (mmol.l
standard
2.13 Cyclic AMP assays.
Samples were assayed for cyclic AMP using one of three sets of 
reagents :
a) Amersham Radiochemical Centre cyclic AMP assay kit (TRK 432).
b) A cyclic AMP binding protein isolated from dog heart and supplied 
by Dr.D.M.Yellon (Rayne Institute, St,Thomas’ Hospital, London).
c) A cyclic AMP binding protein isolated from rabbit skeletal muscle.
Using all three sets of reagents, the protocol for the assay 
was identical.
Reagents were placed in labelled Eppendorf tubes using the 
following format :
TUBE NO. 20mM TRIS/4mM STANDARDS/ (3H)-cAMP BINDING SAMPLE








3, 4 50 50 100 zero
5, 6 50 50 100 1 pmol
7, 8 50 50 100 2 pmol
9,10 50 50 100 4 pmol
11,12 50 50 100 8 pmol
13,14 50 50 100 16 pmol
15,16
etc,.
50 50 100 unknown
The binding protein was always the last reagent to be added to the
\ o 1
mixture. Samples were then thoroughly minced and left at 4 C to '
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reach equilibrium. Incubation times were at least 2 hr and not long­
er than 20 hr.
During the incubation period a charcoal suspension was freshly 
prepared. It consisted of Ig Norit GSX charcoal in 20 ml of 20 mM 
TRIS / 4 mM EDTA buffer (pH 7.2) which contained 2% w/v bovine serum 
albumin. The suspension was prepared at least 30 min before use and 
was maintained at 4°C.
At the end of the incubation period, 100//I of the charcoal susp­
ension was placed in as many Eppendorf tubes as could be centrifuged 
at one time. Tubes were rapidly sealed, mixed thoroughly and centri­
fuged for 1.5 min in a Beckman Microfuge.
Within 10 min of centrifuging, a 200yul aliquot of supernatant 
was transferred to mini-vial which contained scintillation fluid.
During the early part of this study the radioactivity of the sample 
was counted on a Phillips PW4510/01 liquid scintillation counter. 
However, the majority of scintillation counting was performed on a 
LKB 1215 Rack-Beta scintillation counter (see Section 2.19).
A standard curve was constructed for each cyclic AMP assay.
Notes on cyclic AMP assay.
a) The purpose of the charcoal suspension was to adsorb any un­
bound nucleotide in the reaction mixture, hence leaving a solution in 
which cyclic AMP and (3H)-cyclic AMP is bound to the protein in 
amounts proportional to their concentration in the solution. However, 
this adsorption process is not 100% efficient and hence the require­
ment for a blank value which effectively reflects the efficiency of 
the adsorption process.
b) Two scintillation fluids were used in the course of this
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study. Either, a cocktail consisting of 7.5 1 xylene (BDH), 2.5 1 
Triton X-II4 (Sigma), 2g POPOP (BDH) and 30g PPO (BIffl), or Aqualuma 
(LKB). Both fluids had similar efficiencies although differences in 
their water handling characteristics were noted, the Aqualuma solu­
tion being able to handle more water before gel formation occurred.
c) In assays in which the cyclic AMP binding protein from rabbit 
skeletal muscle was used, the quantity of charcoal in a 20 ml susp­
ension was 520 mg,
2.14 Cyclic GMP assay.
The cyclic GMP content of the samples was assayed using the 
Amershcim Radiochemical Centre cyclic CMP radio-immunoassay kit (TRK
500).
Reagents were placed in labelled Eppendorf tubes using the foll­
owing format:
TUBE 20mM TRIS/ STANDARDS/ BLANK ANTI­ (3H)-cOT> SAMPLE
NO. 4mM EDTA UNKNOWNS REAŒNT SERUM
BUE'E’ER
^ 1 ) (//I) ^ 1 ) ^ 1) (//I)
1. 2 100 50 50 0
3, 4 100 50 50 0 .5
5, 6 100 50 50 1.0
7, 8 100 50 50 2.0
9,10 100 50 50 4.0
11,12 100 50 50 8.0
13,14 100 50 50 blank
15,16 100 50 50 unknown
etc,.
The anti serum was always the last reagent to be added to the mixture. 
Samples were then thoroughly mixed and maintained at 4°C to reach 
equilibrium. Incubation times were at least 2 hr and not longer than 
20 hr.
At the end of the incubation period 1 ml of ice-cold ammonium 
sulphate solution (60% w/v) was placed into as many tubes as could be
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centrifuged at one time. Five min after the addition of the ammonium 
sulphate to the last tube, samples were centrifuged for 1.5 min in a 
Beckman Microfuge. The supernatant was discarded and the tubes allow­
ed to drain. Any excess fluid left after the draining period was re­
moved with a cotton swab.
Distilled water (0.5 ml) was placed in each tube, which was then 
capped and shaken vigorously to re suspend the pellet. A 0.3 ml ali­
quot of the re suspended solution was then transferred to a mini-vial 
containing 4 ml of scintillation fluid (see Section 2.13(b)). All 
samples were counted on a LKB 1215 Rack-Beta liquid scintillation 
counter (see Section 2.19).
2.15 Calculation of results from cyclic nucleotide assays.
Calculations were always performed on the counts per minute (cpm) 
of a sample, although quenching was noted in case of a spurious quen­
ching phenomenon.
All samples were assayed in duplicate for standards and unknowns 
and the mean of the duplicates was derived. The mean background count 
was subtracted from the mean count of all samples.
Simply plotting results of the standards as cpm against the 
concentration of cyclic nucleotide present would produce a curvilinear 
plot which would be of limited value for extrapolation of unknowns. 
Therefore, a mathematical manipulation was performed to convert the 
data to a more useful rectilinear form.
The mean cpm for the standard in which no ’cold* cyclic nucleo­
tide was present was designated C^ . All mean cpms for other samples
were designated C and the value of C /C was determined for each X o x
sample. This manipulation yielded calibration lines which were linear 
over the range 0-l6 pmol/50yul for cyclic AMP and 0-8 pmol/50 //I for
59
cyclic (Figures 5a & 5b).
All calibration lines were fitted by linear regression and the 
cyclic nucleotide concentration for unknowns was derived from the 
appropriate function key of a Texas Instruments TI51 or TI59 progr­
ammable calculator.
2.16 Preparation of cyclic AMP binding protein from rabbit muscle.
Cyclic AMP binding protein was prepared as described by Tovey et 
al (1974) with the omission of the step requiring adsorption and 
elution from a DEAE cellulose column.
Skeletal muscle from a recently killed rabbit was diced and 
homogenised with an Ultra-Turrax homogeniser (type TP I8-IO) in 50 mM 
Tris/4 mM EDTA buffer (approximately lOOg tissue to 125 ml buffer).
The homogenate was centrifuged at 27 000 g for 30 min at 4°C in a 
MSE 65 superspeed centrifuge. The resultant pellet was discarded and 
the supernatant placed in a beaker on ice. Acetic acid (l M) was 
slowly added to the supernatant with constant stirring until pH 4«8 
was attained, as measured on a Phillips PW 9418 pH meter. The solu­
tion was left to stand for 15 min before recentrifuging at 27 000 g 
for 30 min. The pellet was again discarded and the pH of the super­
natant adjusted to 6.5 by the slow addition of potassium phosphate 
(1 M, pH 7.2). On reaching the required pH the total volume of the 
solution was noted.
The solution was again placed on ice with constant stirring 
whilst solid ammonium sulphate was very slowly added (32.5g per 100 
ml of solution). The solution was constantly stirred for 30 min 
following completion of the ammonium sulphate addition. The solution 
was then centrifuged as before. The supernatant was discarded and 
the pellet dissolved in 5 mM potassium phosphate ./2 mM EDTA buffer
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(pH 7.0) to a volume which was 6% of the volume noted before ammonium 
sulphate fractionation.
Following dissolution, the binding protein was dialysed over­
night against 5 1 of 5 niM potassium phosphate / 2 mM EDTA solution 
(pH 7.0). The binding protein was then centrifuged for 10 min at 
2 000 rpm in a Heraeus-Christ bench centrifuge. The concentration of 
the supernatant was adjusted so that 100yul of the final solution 
bound approximately 20-30% of the activity Wien incubated with (3H)- 
cyclic AMP (12.5 nCi/50/tl; (8-3H)-cyclic AMP, 2.6 Ci/ramol).
An example of the resultant dilution curve is shown in Figure 6.
This method of producing cyclic AMP binding protein has been 
demonstrated by other authors (Tovey et al, 1974) and its characteri­
sation is such that the need for cross-reactivity studies was not 
justified (cf. Section 2.17).
2.17 Preparation of cyclic AMP binding protein from dog myocardium.
The preparation of the cyclic AMP binding protein was carried 
out by Dr.D.M.Yellon (Rayne Institute, St.Thomas’ Hospital, London). 
However, a brief description of the preparation is apt for the purp­
oses of this thesis.
Dog nyocardium was homogenised in Littlefield medium (sucrose, 
250 mM; KCl, 25 mM; MgCl^, 5 mM; Tris, 50 mM) in the proportion of 
2 volumes of tissue to 3 volumes of medium. The homogenate was cent­
rifuged at 10 000 g for 30 min. The supernatant was decanted and the 
concentration adjusted so that 100 /il bound approximately 20-30% of 
the activity when incubated with the (3H)-cyclic AMP solution used in 
the assay (12.5 nCi/50/il).
a) Characterisation of cyclic AMP binding protein with respect to 
cross-reactivity with related compounds.
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To assess the specificity of the binding protein an experiment 
was designed to quantify the ability of ATP, ADP, AMP, adenosine, 
cyclic CM’ and cyclic AMP to displace (3H)-cyclic AMP from the bind- 
protein.
The composition of the reaction mixture was 100/(I of binding 
protein, 50/Ul (3H)-cyclic AMP (12.5 nCi) and 50//I of the substance 
under investigation in the concentrations represented in Figure 7. 
Separation and counting parameters are described elsewhere (see Sect­
ion 2.13).
Activity of the mixture in which the volume was made up to 
200 y/1 with 50 y/1 of 50 mM Tris/4 mM EDTA was denoted All other 
values were denoted B^ . Good specificity for cyclic AMP was found 
(Figure 7).
b) Time-course of binding of (3H)-cyclic AMP to cyclic AMP 
binding protein.
The reaction mixture had the following composition: 100//I 
cyclic AMP binding protein, 50 //I 50 mM Tris/4 mM EDTA buffer and 
50/(I (3H)-cyclic AMP (12.5 nCi). Samples were timed from the addit­
ion of the binding protein. After separation (see Section 2.13), 
activity of bound (3H)-cyclic AMP was recorded at 15, 30, 45, 60 and 
90 min. Equilibrium was achieved within 60 min (Figure 8).
2.18 Preparation of cyclic GMP antiserum in rabbits and goats.
Preparation of antiserum was attempted using the method of 
Brooker et al (1979).
Production of cyclic GMP antibody required the conjugation of 
succinyl cyclic GMP with human serum albumin by means of a carbodi- 
imide coupling procedure. Succinyl cyclic OiP (10 mg) was dissolved 
in 5 ml of 50 mM potassium phosphate buffer (pH 5.5) with 100 mg of
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human serum albumin and 50 mg of l-( 3-dimethylaminopropyl)-3-ethyl 
carbiimide. The reaction mixture was shaken gently overnight in the 
dark at room temperature in a Grant SS30 water bath; the mixture was 
then dialysed for 24 hours against 5 1 of 0.9% w/v sodium chloride 
containing 5 ml sodium phosphate buffer (pH 7.2). Five ml aliquots 
of this solution were lyophilised in an Edwards Modulyo freeze drier 
and stored at 4°C until used.
When required, the protein conjugate was reconstituted with 5 ml 
distilled water and emulsified with 5 ml Freund * s adjuvant minced in 
an ultrasonicator. The emulsion was injected as follows: 
rabbits - 1 ml s.c.; goats - 1 ml s.c. + 1 ml i.m, approximately 
every month.
After 3 months, and at intervals subsequent to this, serum was 
obtained and diluted 1:100 and 1:1000 with 50 mM Tris/4 mM EDTA buff­
er (pH 7*4). Reaction mixtures of 100//I (both dilutions), 50//I 
(3H)-cyclic GMP (8 nCi) and 50 y/1 buffer were placed in Eppendorf 
tubes and incubated at 4°C for at least 2 hours. Serum containing 
bound (3H)-cyclic ®1P was separated by placing 150yUl of the reaction 
mixture on a moistened 0,45/*m Millipore filter inserted in a Milli­
pore manifold and the filter was washed with 10 ml of 50 mM Tris/4 mM 
EDTA buffer. Filters were removed from the manifold and placed in a 
mini-vial containing 4 ml scintillation fluid. Radioactivity of the 
samples was counted in a LKB 1215 Rack-Beta liquid scintillation 
counter (see Section 2.19). However, of the six rabbits injected no 
evidence of cyclic CMP antiserum was found and of the two goats used 
only one showed a favourable response over the one year of the experi­
ment. Unfortunately, the concentration of antiserum found in the goat 
showing a response was not high enough to be used for routine assay 
of cyclic GMP. The idiosyncratic response of animals to the product­
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ion of cyclic GMP antiserum has been experienced by other workers in 
the field (K.D.Bhoola, personal communication).
2.19 Biological measurements by liquid scintillation counting.
Liquid scintillation counting enables the quantification of dis­
crete biological metabolites without the necessity of extensive sam­
ple preparation. Therefore, since its introduction for biological 
measurements by Hayes and Gould (1952) it has rapidly become an 
extensively used method. Briefly, liquid scintillation counting in­
volves placing the radioactive sample in an appropriate medium which 
converts radioactive energy into a pulse of light energy. This pulse 
of light energy is detected by means of a synchronised photocathode 
and is converted to an electrical pulse by a photomultiplier •
During liquid scintillation counting the following energy steps 
occur between the radioactive sample (R^ ) and the constituents of the 
scintillation cocktail:
R ------   SOLVENT --— ► SOLUTE ---- -^--► PHOTOCATHODEs
At each of the three energy transfer steps there is the probability 
that an incomplete energy transfer will occur due to the nature of 
the scintillation cocktail. Interference may arise from (l) photon 
quenching, (2) chemical quenching and (3) colour quenching. There­
fore, the quantification of a sample will depend on the extent of 
this interference (termed quenching), and the ability of the photo­
cathode to detect the light pulses. The resultant quantification is 
expressed in counts per minute (cpm) which is a characteristic of a 
particular liquid scintillation counter and scintillation cocktail. 
Identical quantities of radioactive material may produce different 
cpms in the same liquid scintillation counter and scintillation cock­
tail due to the presence of quenching agents. To convert cpm to an
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absolute quantity of radioactivity, a quench curve must be construct­
ed so that the efficiency of the counting process may be estimated 
(hence taking into account interferences in energy transfer ), From 
the efficiency measurement the absolute value of disintegrations per 
minute (dpm) may be determined:
dpm = cpm X efficiency




d) external standard channels ratio.
For the purpose of this study the external standard channels 
ratio method was used due to the ease with which it may be construc­
ted on the LKB 1215 liquid scintillation counter. Quench curves were 
constructed using the external standard channels ratio as follows:
Four ml of scintillation cocktail was added to the mini-vials which 
contained a capsule of known radioactivity (LKB cat. no. 1210-120, 
dpm = 101100 (0.09yUCi), corrected for decay). To each sample 200yul 
of distilled water was added to simulate the emulsion system found in 
the experimental conditions. Tube 1 was capped. To tubes 2, 3> 4,
5 and 6 were added 5, 10, 15, 20 and 40 yxl of CCl^, respectively.
The samples were then loaded into the LKB 1215 liquid scintillation 
counter which had been programmed to count the samples and to constr­
uct automatically a quench curve (Figure 9)* This curve was stored 
in the counter's memory so that dpms for all subsequent samples were 
calculated automatically. Despite the ease with which an external 
standard channels ratio quench curve may be constructed, two import­
ant shortcomings of this method were borne in mind.
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Firstly, the determination of the external standard channels 
ratio is critically dependent on the geometry of the vial, particu­
larly its thickness. In this study polyethylene vials were used 
which tended to absorb the xylene in the scintillant. Therefore, 
over the course of time the effective volume of scintillant increases 
so producing a continuous drift in the external standard ratio.
Secondly, the external standard channels ratio only takes into 
account interference at steps (2) and (3). Therefore, in emulsions 
which were used in this study determinations of scintillation fluid 
efficiency, rather than sample efficiency, were made.
All samples were counted for either 10 000 counts or 10 min, 
depending on which was reached first.
2.20 Injection schedules for catecholamine depletion.
Reserpine (5 mg.kg ^, i.p.), suspended in polyethylene glycol 
400 (BDH), was administered to animals for 2-3 days prior to experi­
mentation.
6-Hydroxydopamine (50 mg.kg ^, i.v.) was administered through a 
tail vein of ether anaesthetised animals. Hearts were used 17-24 hr 
after administration. This dose of 6-hydroxydopamine has previously 
been shown to produce marked catecholamine depletion in the rat 
ventricle (for review of literature see Kostrzema and Jacobowitz,
1974).
2.21 Determination of dry :wet weight ratio.
Ventricular tissue was separated from other heart tissue and 
thawed. The tissue was then blotted and placed in a beaker of known 
weight and the total weight determined.
Samples were then placed in an oven at 100°C for 3 days, after
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which the samples were removed and placed in a desiccator to cool. 
After cooling to room temperature the dried tissue and the beaker 
were weighed.
2.22 Statistical analysis of data.
Results are expressed as the mean i  standard error of the mean.
The majority of the data satisfied the F-test when sample vari­
ances were compared and hence a Student's t-test was used for stat­
istical comparison of samples. Paired and unpaired t-tests were used 
as appropriate to the experimental design. Two-tailed tables of P 
values were used to assess statistical significance. Significant 
differences between samples were assumed when P<0.05.
Assessment of the data relating to premature ventricular contr­
actions during occlusion was by non-parametric statistics using 
Wilcoxon's rank sum test for unpaired data. Statistical differences 
between incidences of ventricular tachycardia and ventricular fibri­
llation were assessed by Chi-squared analysis. For both these tests 
differences greater than the S% level were denoted as statistically 
different.
Regression lines were fitted by least squares analysis and a 
significant correlation between two variables was assumed when P C 0.05.
Statistical calculations were performed on a Texas Instruments 
TI 51 or TI 59 programmable calculator.
2.23 Drugs used.
Abbott - verapamil hydrochloride
Astra - lignocaine hydrochloride
Bayer - nifedipine
BDH - adrenaline hydrogen tartrate
— histamine acid phosphate
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ICI - d,1-propranolol hydrochloride
- d-propranolol hydrochloride
- atenolol
Radiochemical Centre - (8-3H)-adenosine 3*,5'-cyclic
phosphate, ammonium salt (TRK 304)
- (8-3H)-guanosine 3 -cyclic 
phosphate, ammonium salt (TRK 392)
Sigma - 6-hydroxydopamine hydrobromide
- reserpine
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FIGURE 2 Effects of a lOyUg bolus injection of tyramine 
on perfusion pressure (mmHg), developed tension 


















FIGURE 3 Diagrammatic representation of instrumentation 
of the Langendorff perfused rat heart for the 
assessment of ventricular fibrillation tiiresh- 




















FIGURE 4 Diagrammatic representation of the automated 
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FIGURE 5 Typical calibration curves for:
(a) cyclic AMP
(b) cyclic GMP
Calculations are explained in Section 2«15‘
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FIGURE 6 Graph of the quantity of (gH)-cyclic AMP 
bound to different dilutions of binding 
protein from rabbit skeletal muscle.
■ represents the total activity of 
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FIGURE 7 The ability of cyclic AMP, cyclic GMP, adenosine, AMP, 
ATP and ADP to displace (3H)-cyclic AMP from binding 
protein isolated from dog nyocardium.














FIGURE 8 The influence of incubation time 
on the amount of (gH)-cyclic AMP 
bound to binding protein isolated 
from dog myocardium.
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FIGURE 9 Quench curve for tritium determined by the LKB 1215 
liquid scintillation counter.





In this section the effects of calcium on parameters of cardiac 
function in the rat and rabbit were investigated. The effects on 
cyclic nucleotide metabolism were also investigated and experiments 
were designed to elucidate the mechanisms of the observed effects.
Experiments were performed on rat hearts unless stated otherwise
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3.1 Calcium on developed tension, heart rate and perfusion pressure.
Perfusion with the control calcium concentration of 1.23 mM 
produced a developed tension of 9»1 i  0.1 g. Reduction of the calcium 
concentration to 0.6l, 0.3 and 0 mM produced concentration-related 
decreases in developed tension, with calcium omission producing rapid 
asystole (Figures 10a, 11a and 12a). Elevating the calcium concen­
tration to 2.46 mM and 4*96 mM produced a pronounced positive ino­
tropic response which decreased after 2 min and a new steady state of 
contractile activity was established (Figures 13a and 14a). The time 
lag in the response to alteration of the calcium concentration was 
due to the dead-space of the perfusion system.
The effect of calcium concentration on steady state developed 
tension measured after 5 min is shown in Figure 15. Developed ten­
sion increased when the calcium concentration was increased from 0 to 
2.46 mM. A further increase in the calcium concentration to 4-96 mM 
did not produce a further increase in developed tension.
In most calcium concentrations no significant effects on resting 
tension were observed. However, elevating calcium to 4.96 mM prod­
uced an increase in resting tension which was significant (P<0.05) 
after 5 min. Omission of calcium from the perfusate also produced an 
increase in resting tension which was also significant (P<0.05) 
after 5 min.
The different calcium concentrations did not produce statistic­
ally significant differences in heart rate except in the absence of 
calcium, which produced asystole within 2 min (Figure 10a).
The reduction of the calcium concentration from 1.23 mM to O.6I, 
0,3 and 0 mM produced initial decreases in perfusion pressure, which 
were followed by gradual increases towards control values (Figures
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10c, 11c and 12c), Elevation of the calcium concentration to 2.46 
and 4.96 mM produced an initial transient increase in perfusion pres­
sure. Perfusion pressure returned to control values in the presence 
of 4*96 mM calcium, but a more sustained increase was observed in the 
presence of 2.46 mM (Figures 13c and 14c).
3.2 Calcium on cyclic AMP and cyclic GMP levels.
The calcium concentration of the perfusate was found to have 
effects on the myocardial levels of cyclic AMP and cyclic GMP 
(Figure I6).
Over the range of calcium concentrations which increased devel­
oped tension (O - 2.46 mM) there was a progressive increase in cyclic 
AMP levels from 233 i. 14 to 620 ±. 43 pmoles/g wet wt.. Positive corr­
elations were found between cyclic AMP levels and calcium concentra­
tion (r = 0.80, n = 37, P<0.001; Figure 17) and between cyclic AMP 
and developed tension (r = 0.93, n = 5, P C 0.02; Figure I8) in data 
derived from experiments using the calcium concentration range of 
0 - 2.46 mM. Increasing the calcium concentration to 4.96 mM signif­
icantly decreased cyclic AMP levels (46I ±, 55 pmoles/g wet wt.,
P C 0.05) compared to those found at 2.46 mM. This value was similar 
to those observed in the control calcium concentration of 1.23 mM.
Due to the discrepancies noted in other authors’ reports in the 
effects of calcium omission on cardiac cyclic AMP levels, the effect 
of time after calcium omission on cyclic AMP levels was studied, 
since this was the most obvious source of variance in the experimental 
protocols of the conflicting reports (see Section I.4). Cyclic AMP 
levels measured after 5 and 30 min of calcium exclusion showed the 
changes to be time-de pendent (Figure I9). The reduction in cyclic 
AMP levels observed at 5 min (233 ±  14 pmoles/g wet wt. ) returned to
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control levels at 30 min (433 i  13 pmoles/g wet wt.).
A theoretical mechanism by which tissue cyclic AMP levels could 
be altered is by an effect on efflux (Amer, 1979). Therefore, samples 
of perfusate were collected prior to freeze-clamping and assayed for 
cyclic AMP content. In none of the calcium concentrations could cyc­
lic AMP be detected using the techniques of this investigation.
Since this may have been due to limitations of the sensitivity of the 
assay procedure, the effects of calcium on cyclic AMP efflux could 
not be elucidated.
The effects of changing calcium concentration on tissue cyclic 
GMP levels were less consistent than the effects on cyclic AMP (Fig­
ure l6b). Elevating the calcium concentration to 4.96 nM produced 
a significant increase in cyclic CMP levels (51.1 ±6.4 pmoles/g wet 
wt., Pco.Ol) compared to control levels in the presence of 1.23 mM 
calcium (19-6 ±2.5 pmoles/g wet wt.). Between the range of calcium 
concentrations 0 - 2.46 mM, no significant changes were observed in 
cyclic GMP levels, except during perfusion with 0.6l mM, which prod­
uced a significant increase (33.1 ±2.1 pmoles/g wet wt., P<0.02).
In contrast to cyclic AMP, no correlations were found between cyclic 
GMP and calcium concentration and between cyclic GMP and developed 
tension (Figure 20).
As discussed in Section 1.2, Flitney’s group has emphasised in 
their studies on frog myocardium that the absolute levels of the 
individual cyclic nucleotides are relatively unimportant and that 
the ratio of the two cyclic nucleotides should be considered instead. 
However, in the mammalian myocardium used in this study, no relation­
ship was established between the ratio of cyclic AMP:cyclic GMP and 
developed tension (Figure 21).
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3. 3 Pacing frequency on developed tension and cyclic AMP levels.
Pacing frequency is known to influence the contractile state of 
the myocardium. The effect on the contractile activity is presumably 
a manifestation of the manipulation of intracellular calcium concen­
tration. Therefore, different pacing frequencies were used to in­
vestigate whether the changes in cyclic AMP levels (as stated in 
Section 3.2) were a reflection of an altered contractile state and 
also to establish the relative importance of intra- and extracellular 
calcium in cyclic AMP metabolism.
Increasing the. pacing frequency to give heart rates of 200 - 500 
beats.min  ^produced a progressive decrease in developed tension 
(Figure 22a). However, this decrease in developed tension was not 
associated with a significant alteration in cyclic AMP levels (Figure 
22b), although it was noticed that the cyclic AMP levels in the pac­
ing experiments were higher than those in unpaced preparations.
3.4 Atenolol on developed tension, heart rate and cyclic nucleotide
levels.
To discount the effects of calcium on contractile parameters and 
cyclic nucleotide levels being due to noradrenaline release and sub­
sequent |3-adrenoceptor activation, the actions of atenolol were in­
vestigated.
Atenolol (l x 10 M) did not significantly change developed 
tension, heart rate or cyclic nucleotide levels (Figure 23).
3.5 Calcium slow channel antagonists on developed tension, heart
rate and perfusion pressure.
All measurements were recorded after a contact time of 5 min 
with the calcium slow channel antagonists. The drugs used in this 
study were verapamil, nifedipine and manganese, all of which have
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been classed as calcium slow channel antagonists (Gargouil, 198I).
Verapamil produced a concentration-related depression of devel­
oped tension. Depression of developed tension was significant 
(P<0.01) even at the lowest concentration examined (3 x 10 Fig­
ure 27c). Elxamination of the time course of the effects of verapamil 
on developed tension showed that the drug did not simply produce a 
lower contractile state. The decrease in contractility was preceded 
by a significant (P<0.02) transient increase in developed tension 
(Figure 24a). Verapamil (l x 10 ^M) did not produce changes in heart 
rate or any pronounced effects on perfusion pressure (Figure 24b and 
24c). However, it became apparent during the course of this study 
that the effects of verapamil on perfusion pressure were determined 
by the initial value. Verapamil reduced perfusion pressure if the 
initial value was high. No significant decrease in heart rate was 
observed with verapamil except at the highest concentration used 
(1 X 10”^ M), which produced asystole.
Nifedipine also produced concentration-related decreases in dev­
eloped tension (Figure 27c), although in contrast to verapamil the 
decrease was not preceded by an initial increase (Figure 25a). It was 
also apparent from the experiments using nifedipine that in the pres­
ence of a high control perfusion pressure nifedipine reduced perfusion 
pressure, but had no effect when control values were low.
Only one concentration of manganese was used (l x lO”^). Man­
ganese produced a significant (P<0.01) decrease in developed tension 
(Figure 26a). Heart rate was slightly reduced but this did not 
achieve significance. In marked contrast to verapamil and nifedipine 
manganese produced a marked increase in perfusion pressure which 
followed a small transient reduction (Figure 26c).
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3.6 Calcium slow channel antagonists on cyclic nucleotide levels.
After 5 min perfusion with verapamil, all concentrations used 
decreased cyclic AMP levels. However, the decreases in cyclic AMP 
levels were similar at all concentrations used, although a trend was 
observed for lower cyclic AMP levels in the presence of higher conc­
entrations of verapamil; these levels were not significantly differ­
ent (Figure 27a). All concentrations of verapamil produced slight 
increases in cyclic CMP levels, but the increases were not statist­
ically significant (Figure 27b).
Nifedipine did not significantly affect either cyclic AMP or 
cyclic CMP at both concentrations used (Figure 27a and 27b).
Manganese also did not produce any significant change in cyclic 
AMP or cyclic CMP (Figure 27a and 27b).
Cyclic AMP could not be detected in the perfusate prior to 
freeze-clamping in any experiment in which calcium slow channel an­
tagonists were used.
3.7 Magnesium on developed tension and cyclic nucleotide levels.
Magnesium is an antagonist of calcium in many physiological sit­
uations. In the present study it was used to investigate whether the 
effects observed with calcium in Section 3.2 were related to any di­
valent ion rather than calcium in particular.
Two magnesium concentrations were used (O.6 and 2.4 mM; cf. nor­
mal of 1.2 mM). Developed tension and cyclic nucleotide levels were 
measured after 5 min in the presence of the concentration under in­
vestigation. Neither concentration of magnesium produced significant 
changes in any measured parameter, although the higher concentration 
(2.4 mM) tended to decrease developed tension and cyclic AMP levels 
(Figure 28).
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3.8 Calcium on developed tension and heart rate in the rabbit heart.
The effects of calcium were investigated in rabbit hearts, which 
are known to respond differently from rat hearts.
Increasing calcium produced a concentration-related increase in 
developed tension over the range used (0.6 - 3.6 mM). This is in 
contrast to the rat hearts which did not exhibit any further increase 
in developed tension in calcium concentrations above 2.46 mM (Figure 
29a).
As with rat hearts, calcium did not significantly alter heart 
rate over the concentration range used (Figure 29b).
3.9 Calcium on cyclic nucleotide levels in right and left ventricle
of rabbit heart.
The calcium concentration of the perfusate produced a similar 
trend in cyclic AMP and cyclic GMP levels in both right and left vent­
ricle (Figure 30). Increasing the calcium concentration from 0.6 to
1.2 mM produced an increase in cyclic AMP and cyclic GMP although 
further increasing calcium to 2.4 mM did not produce any further in­
crease in the levels of either cyclic nucleotide. The highest conc­
entration of calcium used (3.6 mM) decreased cyclic nucleotide levels 





























FIGURE 10 Time course of effects of perfusion withO mM calcium on;
(a) Developed and resting tension (g),
(b) Heart rate (beats.min
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F IG U R E  11 Time course of the effects of reducing the calcium 
concentration of the perfusate to 0.3 mM on:
(a) Developed and resting tension (g),
(b) Heart rate (beats.min





















FIGURE 12 Time course of effects of reducing the calcium conc­
entration of the perfusate to O.6I mM on:
(a) Developed and resting tension (g),
(b) Heart rate (beats.min"^),





































Time course of effects of elevating the calcium conc­
entration of the perfusate to 2.46 mM on:
(a) Developed and resting tension (g),
-1
(b) Heart rate (beats.min ),
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FIGURE 14
Time (mins)
Time course of effects of elevating the calcium conc­
entration of the perfusate to 4-96 mM on:
(a) Developed and resting tension (g),
-1(b) Heart rate (beats.min ),
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FIGURE 15 Effect of calcium concentration on developed tension 















FIGURE l6 Effect of calcium concentration on:
(a) Cyclic AMP levels (pmoles/g wet wt.),
(b) Cyclic GMP levels (pmoles/g wet wt.). 
Significant differences from control (1.23 mM) are 










FIGURE 17 Relationship between cyclic AMP levels and calcium
concentration over the range which directly influenced 
steady state contractility (O - 2.46 mM). A signifi­
cant positive correlation was observed (r = 0.8, n = 37, 








Developed Tension Ig )
FIGURE 18 Relationship between cyclic AMP (pmoles/g wet wt. ) and 
developed tension (g) when both variables were manipu­
lated by the calcium concentration over the range which 
directly influenced steady state contractility (O - 2.46 
mM). A significant positive correlation was observed 
(r = 0.93, n = 5, P<0.02).
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FIGURE 19 Time course of changes in cyclic AMP levels (pmoles/g 
wet wt.) after removal of calcium from the perfusate. 
Significant difference from control value at 0 minute 
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Developed Tension ( g )
FIGURE 20 Relationship between cyclic GMP levels (pmoles/g wet
wt.) and developed tension (g) when both variables were 
manipulated by the calcium concentration over the range 
which directly influenced steady state contractility 
(O - 2.46 mM). No significant correlation was observed 















Developed Tension ( g )
FIGURE 21 Relationship between the ratio of cyclic AMP:cyclic GMP 
and developed tension (g) when both variables were man­
ipulated by the calcium concentration over the range 
which directly influenced steady state contractility 
(O - 2.46 mM). No significant correlation was observed 








































FIGURE 22 Effect of pacing frequency on:
(a) Developed tension (g)>
(b) Cyclic AMP (pmoles/g wet wt.).



























Control Atenolol  
1 k10‘^ M
FIGURE 23 Effect of atenolol (l x 10”^M) in the presence of 
1,23 mM calcium on:
(a) Developed tension (g).
(b) Heart rate (beats.min
(c) Cyclic AMP levels (pmoles/g wet wt.),


















FIGURE 24- Time course of the effects of verapamil (l x 10 M) on:
(a) Developed and resting tension (g),
(b) Heart rate (beats.min )^>
(c) Perfusion pressure (mmHg).
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FIGURE 25 Time course of the effects of nifedipine (l xlo”^M) on
(a) Developed and resting tension (g),
(b) Heart rate (beats.min


































FIGURE 26 Time course of the effects of manganese chloride 
(l X 10~^) on:
(a) Developed and resting tension (g),
(b) Heart rate (beats.min )^,
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FIGURE 27 Effects of the calcium slow channel antagonists 
verapamil, nifedipine and manganese on:
(a) Cyclic AMP levels (pmoles/g wet wt.),
(b) Cyclic GMP levels (pmoles/g wet wt.),
(c) Developed tension (g).
Significant differences are denoted (* PcO.OS^and 
** P<0.01).
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Control 0.6 mM 2.6mM
(Mg 2 + )
FIGURE 28 Effect of magnesium on:
(a) Developed tension (g),
(b) Cyclic AMP levels (pmoles/g wet wt.)^
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FIGURE 29 Effect of calcium concentration in Langendorff 
perfused rabbit hearts on;
(a) Developed tension (g),
(b) Heart rate (beats.min )^.

























FI (JURE 30 Effect of calcium concentration on:
(a) Cyclic AMP levels (pmoles/mg wet wt.)j
(b) Cyclic GMP levels (pmoles/g wet wt. )
in the left (■— ■) and right (O— O) vegtricles of 
Langendorff perfused rabbit hearts.
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Section B
This section investigates the effects of calcium concentration 
on functional parameters and cyclic nucleotide levels during ^obal 
underperfusion in the rat heart. The effects of calcium concentration 
on cyclic nucleotide levels during ischaemia produced by coronary 
artery ligation in isolated rabbit hearts were also investigated.
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3.10 Calcium concentration on developed tension and heart rate
during underperfusion.
Hearts were underperfused (2 ml.min  ^compared to 10 ml.min  ^
for ’normal* perfusion) for 30 min in the presence of 0.6l, 1.23 or
2.46 mM calcium.
The initial developed tension at a perfusion rate of 10 ml.min"^ 
was dependent on the calcium concentration (see Section 3.1). With 
calcium concentrations of 2,46 and 1.23 inM, underperfusion signific­
antly (P<0.001) reduced developed tension after 5 min. Thereafter, 
developed tension remained relatively constant for the remaining per­
iod of underperfusion, although developed tension in hearts perfused 
with 2.46 mM calcium was significantly greater (P<0.05) at each time 
point measured than those perfused with 1.23 mM calcium, with the ex­
ception of that at 30 min. Reduction of flow rate to 2 ml.min  ^did 
not significantly affect developed tension in hearts perfused with 
0.61 mM calcium (Figure 3I).
Heart rates were not significantly different in hearts perfused 
with the three calcium concentrations during perfusion at 10 ml.min”  ^
(see Section 3.1). After 5 min of underperfusion heart rates were 
reduced to a similar extent in the different calcium concentrations.
A constant heart rate was attained after 15 min of underperfusion in 
the different calcium concentrations, and this was maintained for the 
remainder of the 30 min period. Heart rates after 15 min of under­
perfusion were significantly lower (P<0.05) in hearts perfused with 
0.61 mM compared to the other two calcium concentrations. Heart rates 
during underperfusion with 1.23 and 2.46 mM calcium were comparable 
(Figure 32).
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3.11 Calcium concentration on cyclic nucleotide levels during
underperfusion.
Increases in cyclic AMP during underperfusion were observed in 
the presence of the three calcium concentrations, although differences 
in the profiles of these increases were apparent (Figure 33).
Underperfusion in the presence of 2.46 mM calcium produced a 
large increase in cyclic AMP levels after 5 min (P<0.001) which 
decreased at 10 min to levels significantly below controls (P<0.05). 
At the subsequent time points measured up to 30 min cyclic AMP levels 
were not significantly different from levels during normal perfusion. 
Underperfusion in the presence of 1.23 mM calcium produced a slower 
in crease in cyclic AMP levels compared to that in the presence of
2.46 mM calcium, although the maximum level reached was of a similar 
magnitude. A peak in cyclic AMP levels was observed after 10 min of 
underperfusion, which returned to levels similar to those measured in 
normally perfused hearts by 15 min. Cyclic AMP levels were also simi­
lar to control values after 20 and 30 min of underperfusion. Under- 
perfusion in the presence of O.6I mM calcium produced no significant 
change in cyclic AMP levels for the first 10 min. Thereafter, cyclic 
AMP increased progressively at each time interval measured.
The effects of underperfusion on cyclic GMP levels were less 
consistent and tended to be more variable than the changes in cyclic 
AMP. There was a trend toward increased cyclic Œ P  levels during 
underperfusion with 2.46 mM calcium, which was attenuated as the cal­
cium concentration was reduced. During underperfusion with O.6I mM 
calcium no increases in cyclic GMP were noted, although the initial 
control level was higher than that observed at higher calcium concen­
trations (Figure 34),
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3.12 Calcium concentration on hi^ energy phosphate levels 
during underperfusion.
To assess the metabolic status of the myocardium during under­
perfusion, the levels of adenosine triphosphate and creatine phos­
phate were determined.
Underperfusion of hearts in the presence of 2.46 and 1.23 mM 
calcium produced depletion of both higjh energy phosphates. In both 
these calcium concentrations a significant (PCO.Ol) decrease in 
creatine phosphate was observed after 5 min of underperfusion.
Creatine phosphate then remained at a constant low level (Figures 35 
and 36). Adenosine triphosphate depletion was slower than that of 
creatine phosphate in both calcium concentrations and was signific­
antly (P<0.05) decreased after 20 min underperfusion in the presence 
of 1.23 mM calcium and after 30 min in the presence of 2.46 mM calcium. 
Profiles of changes in high energy phosphate levels were similar dur­
ing underperfusion in both 1.23 and 2.46 mM calcium.
In the presence of O.6I mM calcium a significantly (P<0.01) 
lower concentration of creatine phosphate was observed \fhen compared 
to adenosine triphosphate during normal perfusion in the presence of
1.23 mM calcium. During underperfusion the levels of the high energy 
phosphates were maintained. In fact, a trend toward increased levels 
of adenosine triphosphate and creatine phosphate was observed during 
underperfusion (Figure 37).
3.13 Calcium concentration on dry:wet weight ratio during under- 
perfusion.
Apstein et al (1977) reported that on perfusion with Krebs-Hen- 
seleit solution an anticipated oedema was produced due to the perfus­
ate being colloid free. They reported a dry:wet weight ratio of 0.247
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for freshly excised rat ventricular muscle which was reduced to 
0.214 after 30 min of o^grgenated perfusion.
The value of dry:wet weight ratio determined in the present 
study was slightly lower than that observed by Apstein et al (1977), 
but was not significantly altered by changes in calcium concentration. 
Thirty min of under per fusion produced a significant (P<0.05) decrease 
in dryrwet wei^t ratio in the presence of 1.23 and 2.46 mM calcium, 
(thus indicating progressive oedema), but no differences at each time 
point were observed between the groups (Figure 38).
3.14 Nifedipine and verapamil on developed tension and heart rate
during underperfusion.
Calcium slow channel antagonists were used to investigate whether 
they mimicked the effects of low calcium perfusion.
The concentrations of nifedipine and verapamil used (l x 10 ^M 
—8and 3 X 10 M, respectively) depressed developed tension during normal 
perfusion to values similar to those observed in the presence of 
0.61 mM calcium. The calcium concentration of the perfusate contain­
ing the calcium slow channel antagonist was 1.23 mM, and a 5 min 
equilibration period was allowed before underperfusion commenced.
During underperfusion in the presence of both verapamil and 
nifedipine, developed tension did not change significantly from con­
trols, in a manner similar to that observed during perfusion with 
0.61 mM calcium (Figure 39%). Heart rate was reduced after 5 min of 
underperfusion in the presence of both drugs, after which time a 
steady heart rate was maintained for the remainder of the 30 min. 
Nifedipine produced heart rates which were significantly (P<0.05) 
lower at each time point compared to verapamil (Figure 39h).
I l l
3.15 Nifedipine and verapamil on cyclic nucleotide levels 
during underperfusion.
In contrast to the effects of underperfusion in the presence of
1,23 mM calcium (Figure 33), both nifedipine and verapamil attenuated 
the increases in cyclic AMP. Nifedipine significantly (P<0.05) de­
creased cyclic AMP levels after 5 min of underperfusion and at all 
subsequent time points did not vary significanÆy from the 5 min 
point. All values of cyclic AMP during underperfusion with verapamil 
were not statistically different from each other (Figure 40a),
Underperfusion in the presence of nifedipine produced signifi­
cant (P<:0.05) elevations in cyclic GMP levels throughout the 30 min. 
Perfusion with verapamil also significantly (P<10.05) elevated cyclic 
GMP levels during underperfusion except at 15 min (Figure 40b).
3.16 Nifedipine and verapamil on hi^ energy phosphate 
levels during underperfusion.
During underperfusion in the presence of nifedipine (l x 10"^M) 
and verapamil (3 x 10 ^) no significant changes in either adenosine 
triphosphate or creatine phosphate levels were observed (Figure 41a 
and 4ib).
3.17 Reserpine pretreatment on developed tension and heart 
rate during underperfusion.
To assess the possible contribution of catecholamine release 
to the changes occurring during underperfusion, hearts were taken 
from animals pretreated with reserpine. Pretreatment with reserpine 
produced hearts whose tension development was significantly (PCO.Ol) 
greater than that of controls (ll.l ±0.5 g). During underperfusion 
developed tension decreased more slowly in reserpinised hearts than 
in controls and reached the lowest value after 15 min (cf. 5 min in
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controls; Figure 31). Developed tension remained constant during 
the 1 5 - 3 0  min of underperfusion (Figure 42a).
Heart was slightly lower in reserpinised hearts than in controls 
althou^ this difference was not significant. After 5 min of under­
perfusion heart rate decreased and then remained constant during the 
rest of the experiment. Heart rates in hearts from reserpinised 
animals were significantly (PCO.OS) higher after 15 mir> of under­
perfusion compared to controls in 1.23 mM calcium (Figure 42a).
3.18 Reserpine pretreatment on cyclic nucleotide levels
during underperfusion.
Levels of cyclic AMP in reserpinised animals were not signifi­
cantly different from controls at normal perfusion rates. During 
underperfusion no significant changes in cyclic AMP levels were 
observed at each time of sampling, unlike control hearts (Figures 
42b and 33).
Cyclic Q4P levels in hearts from reserpinised animals were also 
similar to those of controls at normal perfusion rates. Cyclic GMP 
levels during underperfusion were significantly (P-<0.05) increased 
after 10 and 15 min of underperfusion but not at 5 and 30 min (Fig­
ure 42b). The profile of cyclic GMP levels during under per fusion 
was similar to controls (Figure 34).
High energy phosphates were not determined in this series of 
experiments.
3.19 Incidence of arrhythmias occurring spontaneously
during underperfusion.
Ventricular fibrillation and persistent premature ventricular 
contractions were not observed during underperfusion in any experi­
mental situation (Table l).
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Varying degrees of atrioventricular node block and disturb­
ances of sinus rhythm were observed, although the incidences were 
not significantly different between the groups.
3.20 Coronary artery ligation on lactate, cyclic AMP and cyclic GMP
in the rabbit heart.
The effects of ligation of the main left coronary artery of the 
Langendorff perfused rabbit heart were difficult to quantify due to 
the rather inconsistent changes in levels of lactate, cyclic AMP and 
cyclic C^.
An example of data derived from an experiment is shown in Figure 
43. Five min occlusion of the coronary artery did not produce a well 
defined area of ischaemia, with the highest tissue levels of lactate 
not being near the area of ligation. In this preparation no rela­
tionship was apparent between the levels of lactate and the levels of 
either cyclic AMP or cyclic ŒP. Representing the data from the 6 
hearts perfused with 1.23 mM calcium in the form of scatter graphs of 
cyclic AMP levels against lactate levels (Figure 44)  ^and cyclic GMP 
levels against lactate levels (Figure 45) failed to show any correla­
tion between these variables (r = 0.236, n = 59 and r = 0.169, n = 59, 
respectively).
In two preparations the time of ligation was extended to 10 min 
before tissue quenching, but again there was a lack of consistency in 
the increase in lactate around the area of ligation.
In only one preparation in this series was a well-defined area 
of ischaemia noted, as indexed by tissue lactate levels (Figure 46). 
Lactate levels in this preparation were approximately 4 to 5 times 
higher in the area of ligation compared to the levels in the uninvol­
ved left ventricle and the right ventricle. It may be noted that in
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the areas of h i ^  lactate levels there were also very high cyclic 
AMP levels.
Therefore, it was concluded that the disparity in the metabolite 
levels could have been due to the nyocardial flow characteristics of 
the rabbit heart after ligation and/or the non-working nature of the 
preparation \diich did not generally produce a marked ischaemic area 
in the ventricle.
No controls were performed in the absence of ligation to assess 
uniformity of metabolite levels throughout the myocardium using the 
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FIGURE 31 Time course of effect of underperfusion on developed 
tension (g) in the presence of different calcium con­
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FIGURE 32 Time course of effect of underperfusion on heart rate 
(beats.min in the presence of different calcium 
concentrations. Flow rate was reduced at 0 min. For 
reasons of clarity standard errors have been omitted.
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FIGURE 33 Calcium concentration on the myocardial levels of cyc­
lic AMP (jMoles/g wet wt.) during under per fusion. Flow 
rate was reduced at 0 min. Each point represents the 
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FIGURE 34 Calcium concentration on myocardial levels of cyclic 
GMP (pmoles/g wet wt. ) during underperfusion. Flow 
rate was reduced at 0 min. Each point represents the 
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FIGURE 35 Effect of underperfusion in the presence of 2.46 mM
calcium on nQ^ocardial levels of adenosine triphosphate 
(pmoles/g wet wt.,B— ■) and creatine phosphate 
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FIGURE 36 Effect of underperfusion in the presence of 1.23 mM
calcium on myocardial levels of adenosine triphosphate 
^xmoles/g wet wt, ,■— ■) and creatine phosphate 
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FIGURE 37 Effect of underperfusion in the presence of 0.6l mM
calcium on myocardial levels of adenosine triphosphate 
(pmoles/g wet wt. — ■) and creatine phosphate 
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FIGURE 38 Effect of calcium concentration on the dryrwet weight 
ratio during underperfusion. Each point represents 
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FIGURE 39 Nifedipine (l x 10”^M) and verapamil (3 x 10 on;
(a) Developed tension (g),
(b) Heart rate (beats.min
during underperfusion in the presence of 1,23 mM 
calcium. Points represent the meais of between 
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FIGURE 40 Nifedipine (l x 10”^M) and verapamil (3 x 10 M^) on:
(a) Cyclic AMP levels (pmoles/g wet wt.)^
(b) Cyclic GMP levels (pmoles/g wet wt.)
during underperfusion in the presence of 1.23 mM. 
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FIGURE 41 Levels of adenosine triphosphate and creatine phosphate 
(pmoles/g wet wt.) during underperfusion in the 
presence of:
(a) Nifedipine (l x 10 ^M), 1.23 mM calcium,




































FIGURE 42 Effects of reserpine pretreatment (5 mg.kg”  ^i.p.) on;
(a) Developed tension (g,B— ■) and heart rate 
(beats.min — □),
(b) Cyclic AMP levels (pmoles/g wet wt.,o— o) and 
cyclic GMP levels (pmoles/g wet wt. ,#-— #)
in the presence of 1.23 mM calcium. Points represent 
the means of between 5 and 24 observations.
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FIGURE 43 An example of the effects observed during 5 min of 
coronary artery ligation on;
(a) Lactate levels (jmoles/g wet wt, , 0-- O ),
(b) Cyclic AMP levels (pmoles/mg wet wt.
(c) Cyclic GMP levels (pmoles/g wet wt.,^— A). 
Diagrammatic representations of sampled areas and point 
of ligation (x) are shown. Samples are in rank order 
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y -  108  ♦ 0.18x 
r = 0.236 
n s 59
FIGURE 44 Scatter diagram of cyclic AMP levels (pmoles/mg wet wt. ) 
against lactate levels pmoles/g wet wt.) after 5 min of 
coronary artery occlusion in 6 rabbit hearts perfused 
with 1,2 mM calcium. Each symbol represents samples 
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[Ca2+] 1.2mM y =118.8 ♦ 19.3X 
r = 0.169 
n s 59
FIGURE 45 Scatter diagram of cyclic GMP levels (pmoles/g wet wt. ) 
against lactate levels (yjmoles/g wet wt. ) after 5 min 
of coronary artery occlusion in 6 rabbit hearts perf­
used with 1.2 mM calcium. Each symbol represents samp­
les from a sin^e heart. No correlation was observed.
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FIGURE 46 The only experiment in the series in which a well-def­
ined and marked increase in lactate levels was observed 
in the myocardium after 5 min of coronary artery occlu­
sion. Gferaph shows :
(a) Lactate levels (pmoles/g wet wt.,0— O),
(b) Cyclic AMP levels (pmoles/mg wet wt. ,□— □) ,
(c) Cyclic GMP levels (pmoles/g wet wt. — A)- 
Diagrammatic representations of sampled areas and point 
of ligation (x) are shown. Samples are in rank order 











C a ^  2.43mM 9 5 1 0 0
1.23mM 14 3 4 0 0
0.6lmM 9 2 4 0 0
Verapamil 0 
^  3x10 
C a ^  1.23mM 6 0 3 0 0
Nifedi- __ 
pine 1x10 M 
Ca2+ 1.23mM 5 1 1 0 0
Re serpin- 
ised
Ca2+ 1.23mM 5 2 1 0 0
TABLE 1 Occurrence of arrhythmias during 
30 minutes of underperfusion.
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Section C
In this section the use of ventricular fibrillation thresholds, 
obtained by two methods, as an index of electrical instability was 
investigated. Using these methods the effects of calcium and calcium 
slow channel antagonists were studied, as well as concomitant changes 
in cyclic AMP and developed tension. Finally, various interventions 
which may relate to arrhythmia production or prevention were studied 
for their effects on ventricular stability and cyclic nucleotide 
levels.
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3.21 Ventricular fibrillation thresholds by the single 
stimulus method.
Use of the isolated rat heart for the investigation of ventric­
ular fibrillation thresholds had the advantage that once fibrillation 
was initiated it was self-limiting and hearts invariably reverted to 
pacing rhythm. Therefore, many determinations of fibrillation thres­
hold could be made on one heart. An example of the short time course 
of ventricular fibrillation is shown in Figure 47, in which it may be 
noted that developed tension increased during the course of fibrilla­
tion. Such a finding was considered to be in conflict with the defi­
nition of fibrillation as stated by Lubbe et al (1975) that ’ventric­
ular fibrillation waveforms were invariably accompanied by a fall in 
left ventricular pressure*. However, using instrumentation for the 
simultaneous measurement of left ventricular pressure and developed 
tension it was shown that during ventricular fibrillation left vent­
ricular pressure indeed collapsed despite large increases in resting 
tension (Figure 48). This pattern of activity could be explained by 
the cannula in the left ventricle being obstructed during the increase 
in resting tension, although this was considered unlikely since the 
heart was firmly positioned by an isometric transducer.
An example of an experiment is represented in Figure 49 and 
illustrates that using this method the vulnerable period duration 
and the interval between the peak of the R wave and the nadir of the 
vulnerable period may be determined, as well as the ventricular 
fibrillation threshold.
3.22 Ventricular fibrillation thresholds - comparison of the single 
stimulus and train methods.
The single stimulus method required approximately 15 min for the
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determination of ventricular fibrillation threshold and as a consequ­
ence, a train method was devised which enabled more rapid determin­
ations. Therefore, a series of experiments was completed to compare 
the values of ventricular fibrillation threshold obtained by the 
single stimulus and train methods. Two train parameters were used -
(a) 100 msec duration, 100 Hz frequency, 2 msec pulse width and
(b) 60 msec duration, 200 Hz frequency, 2 msec pulse width. Both 
trains were delivered 10 msec after the peak of the R wave of the 
electrocardiogram.
In a series of 12 experiments a ventricular fibrillation thresh­
old of 9-5 i  0.8 mA was obtained using the single stimulus method, 
whilst the values obtained from the train method were 11,4+0.8 mA 
and 11.5 + 1.0 mA for train parameters (a) and (b), respectively.
The ventricular fibrillation thresholds obtained by the train method 
were significantly (P<0.02) higher than the value obtained by the 
single stimulus method. Ventricular fibrillation thresholds deter­
mined by the two parameter train method were not significantly differ­
ent from each other (Figure 50).
All subsequent determinations of fibrillation thresholds by the 
train method used parameter (b).
3.23 Calcium concentration on ventricular fibrillation thresholds - 
relation to cyclic AMP and developed tension.
The effects of perfusion with 1.23, 2.46 and 4*96 mM calcium 
concentration on ventricular fibrillation thresholds were assessed.
The fibrillation threshold of 21.1+1.5 mA in the presence of 1,23 
mM calcium was significantly (PcO.OOl) lowered in the presence of
2.46 mM calcium (8.3zb 0.5 mA). Following elevation of calcium 
concentration to 4.96 mM a further significant (P<0,01) decrease
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in ventricular fibrillation threshold (3.4 ±  0.9 mA) was obtained 
(Figure 51a). In one series of experiments ventricular fibrillation 
thresholds were assessed whilst the calcium concentration was pro­
gressively increased from 1.23 to 2.46 and finally to 4*96 mM, Some 
hearts were reperfused at the end of the experiment with 1,23 mM 
calcium to determine whether the decreased fibrillation threshold was 
merely an artifact of increasing cellular damage brou^t about by the 
high energy extra-pulses and/or prolonged perfusion time. However, 
threshold values on reperfusion with 1.23 mM calcium were similar to 
those obtained at the onset of the fibrillation threshold determina­
tions.
The interval between the peak of the R wave and the nadir of the 
vulnerable period was also found to be a calcium-dependent phenomenon. 
Increasing the extracellular calcium produced a concentration-related 
decrease in this interval, with each point being significantly differ­
ent (at least P<0.01) from all other points (Figure 51b).
Taking account of the effects of calcium on cyclic AMP levels 
(Section 3.2) it can be seen that although there was a relationship 
between calcium concentration and fibrillation threshold, there was 
was a disparity between cyclic AMP levels and fibrillation threshold 
(Figures 16 and 51a). The effects of calcium on developed tension 
are shown in Section 3.1. Calcium did not show the same pattern of 
activity on developed tension as it did on fibrillation threshold 
(Figures 15 and 51a).
3.24 Calcium slow channel antagonists on ventricular fibrillation
thresholds - relation to cyclic AMP and developed tension.
For assessment of the effects of the calcium slow channel antag­
onists on ventricular fibrillation threshold the following protocol
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was used. Ventricular fibrillation thresholds were assessed in the 
presence of 1.23 mM calcium and then reassessed in the presence of
2.46 mM calcium. The calcium concentration was then maintained at
2.46 mM whilst the ventricular fibrillation thresholds were again
-8 -7determined in the presence of 1 x 10 and 1 x 10 M of either verap­
amil or nifedipine.
The effects of verapamil are shown in Figure 52. As expected,
elevation of the calcium concentration to 2.46 mM produced a decreased
ventricular fibrillation threshold which was not significantly altered
—8in the presence of 1 x 10 M verapamil. A higher concentration of 
—7
verapamil (l x 10 M) elevated the fibrillation threshold signific­
antly (P<0.05) compared to that observed in the presence of 2.46 mM 
calcium, but was significantly lower (P<0.01) than that observed in 
the presence of 1.23 mM calcium.
This comparative lack of effect of verapamil may have, been due 
to the calcium concentration being elevated prior to the administra­
tion of verapamil. Therefore, an experiment was designed in which 
verapamil (l x 10 ^M) was allowed a contact time of 10 min before 
elevation of the calcium concentration from 1.23 to 2.46 mM. 
Vulnerability to fibrillation was assessed during perfusion with
1.23 mM calcium and determined 5 min after the calcium concentration 
had been elevated to 2.46 mM in the presence of verapamil (l x 10 ^M). 
However, even using this protocol, verapamil exerted a statistically 
similar effect on ventricular fibrillation threshold to that observed 
vdien verapamil was administered after the calcium concentration had 
been elevated (Figure 53).
The elevation of the calcium concentration reduced the interval 
between the peak of the R wave and the nadir of the vulnerable period 
as expected. This interveil was not significantly altered with either
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concentration of verapamil (Figure 54).
Despite the relative lack of effect of verapamil on electrical 
instability, the concentrations used produced profound decreases in 
developed tension. The highest concentration of verapamil (l x 10 ^M) 
produced a marked decrease in developed tension and it may be observed 
that the depression of developed tension was far greater than that 
seen in the presence of 1.23 niM calcium (Figure 55a),
The effects of verapamil on cyclic AMP levels under the condi­
tions in which ventricular fibrillation thresholds were determined 
were similar to those described in Section 3.4 (Figures 27a and 55b). 
These changes in cyclic AMP levels could not be related to changes in 
fibrillation thresholds.
Nifedipine produced very similar results to verapamil on vent­
ricular fibrillation threshold (Figure 56), interval between the peak 
of the R wave and nadir of the vulnerable period (Figure 57) and 
developed tension (Figure 58a). The effects of nifedipine on cyclic 
AMP levels were similar to the trends observed in Section 3.4 and 
could not be related to changes in ventricular fibrillation thresh­
olds (Figure 58b).
3.25 Glucose-insulin-potassium on ventricular fibrillation threshold.
The influence of the separate constituents of the glucose- 
insulin-potassium mixture on vulnerability to fibrillation was stud­
ied. Functional parameters and cyclic nucleotide levels were also 
investigated. All values were recorded after 5 min contact with the 
intervention.
Elevation of the potassium concentration from 5.9 mM (normal 
Kf^bs-Henseleit solution) to 7.5 mM (by the addition of potassium 
chloride) did not significantly affect developed tension, heart rate
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or cyclic nucleotide levels (Figure 59). Despite the lack of effect 
on these parameters, the elevated potassium concentration produced a 
significant (PCO. 02) elevation of ventricular fibrillation threshold 
from 10.0 ±  1.8 mA to 15.6 ±  2.8 mA (Figure 60).
As with elevated potassium concentration, a high concentration 
of insulin (500 mU.ml )^ did not significantly affect developed ten­
sion, heart rate or cyclic nucleotide levels (Figure 6l), However, 
The fibrillation threshold was significantly (P<0.05) elevated in 
the presence of insulin from 10.7+ 1.4 mA to 14*3db 2.0 mA (Figure 
62).
The removal of glucose from the perfusate (normally present at 
a concentration of 11.5 mM) produced significant decreases in devel­
oped tension (P<0.05) and cyclic AMP levels (PcO. 05), whilst heart 
rate and cyclic Off* levels were not significantly changed (Figure 63). 
Removal of glucose from the perfusate did not significantly affect 
fibrillation thresholds (Figure 64).
Therefore, by investigation of the separate components of the 
glucose-insulin-potassium mixture in this non-ischaemic model, pro­
tective effects were observed with elevated potassium and insulin, 
with the former being more potent at elevating ventricular fibrill­
ation thresholds. Changes in fibrillation thresholds could not be 
related to changes in cyclic nucleotide levels.
3.26 Adrenaline on ventricular fibrillation threshold.
To investigate whether the findings of Lubbe et al (1979) could 
be reproduced, the effects of adrenaline were investigated.
—7
As expected, adrenaline (l x 10 M) increased developed tension, 
heart rate and cyclic AMP levels when measured after 5 min of perf­
usion. Cyclic GMP levels were not significantly changed (Figure 65).
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This concentration of adrenaline produced a significant (P<0.05) 
reduction in ventricular fibrillation threshold from 11.1 ±  1.3 mA 
to 6.2 ±  1.0 mA (Figure 66). These results are in agreement with 
those of Lubbe et al (1979) suggested a role for cyclic AMP in 
arrhythmogene si s.
3.27 Histamine on ventricular fibrillation threshold.
The naturally occurring autocoid, histamine, was investigated 
because of suggestions that it may be implicated in ventricular 
arrhythmias (Trzeciakowski and Levi, I98I).
However, rats are known to be insensitive to the effects of 
histamine and even a high concentration of 1 x 10”^M did not signif­
icantly affect developed tension, heart rate or cyclic nucleotide 
levels (Figure 67). Histamine also failed to affect significantly 
ventricular fibrillation threshold (Figure 68).
3.28 Sodium nitroprusside on ventricular fibrillation threshold.
Sodium nitroprusside is a stimulant of guanyl cyclase and was 
used as a pharmacological tool to investigate the effect of cyclic 
GMP levels on ventricular fibrillation threshold.
After 5 min exposure to sodium nitroprusside (l x 10 ^ )  there 
was a significant (P<0.01) reduction in developed tension and an 
elevation of cyclic levels (P<^0.01), vdiilst cyclic AMP levels 
and heart rate were not affected (Figure 69). Sodium nitroprusside 
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FIGURE 47 An example of ventricular fibrillation produced by the 
single stimulus method in the isolated rat heart, foll­
owed by spontaneous reversion to sinus rhythm. Upper 
trace is the epicardial electrogram and lower trace 


















FIGURE 48 An example of the effect of ventricular fibrillation 
induced by the single stimulus method on:
(a) Left ventricular pressure (nnnHg),
(b) Perfusion pressure (inmHg),
(c) Developed tension (g).
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FIGURE 49 An example of the determination of ventricular fibrill­
ation thresholds using the single stimulus method during 
perfusion with 3 different calcium concentrations.
• Represents extra-stimuli which produced 
ventricular fibrillation





















FIGURE 50 Ventricular fibrillation thresholds by the single 
stimulus method and the train method using train 
parameters of either 100 msec duration, 100 Hz frequ­
ency and 2 msec pulse width or 60 msec duration, 200 Hz 
frequency and 2 msec pulse width. Both trains were de­
livered 10 msec after the peak of the R wave.
Significant differences from the single stimulus method 
























FIGURE 51 Effect of calcium concentration on:
(a) Ventricular fibrillation threshold (mA) ^
(b) Interval between the peak of the R wave and the 



















FIGURE 52 Effect of verapamil (10 M and 10 M) on ventricular 
fibrillation thresholds (mA) showing:
(a) Individual values, (b) Pooled data.
Significant differences compared to values obtained in 
the presence of 1.23mM calcium are denoted:












Verapamil 1*10 M 
2.46mM Co2*
FIGURE S3 Effects of verapamil (l x 10 ^M) on ventricular
fibrillation thresholds (mA) in the presence of 2.46mM 
calcium, vhen the drug was administered prior to the 
elevation of the calcium concentration from 1.23mM.
This protocol did not prevent the significant reduction 













FIGURE 54 Effect of verapamil (1 x 10 IW and 1 x 10 ^M) on the 
interval between the peak of the R wave and the nadir 
of the vulnerable period (msec). Significant differ­
ences compared to values obtained in the presence of































FIGURE 55 Effect of verapamil on:
(a) Developed tension (g),
(b) Cyclic AMP levels (pmoles/g wet wt.),

























FIGURE 56 Effect of nifedipine (10-8 and 1Q-7m ) on ventricular 
fibrillation thresholds (mA) showing:
(a) Individual values, (b) Pooled data.
Significant differences compared to values obtained 
in the presence of 1.23mM calcium are denoted:





















FIGURE 57 Effects of nifedipine (l x lO” M and 1 x 10”'M) on the 
interval between the peak of the R wave and the nadir 
of the vulnerable period (msec). Significant differ­
ences compared to values obtained in the presence of




























FIGURE 58 Effect of nifedipine on:
(a) Developed tension (g),
(b) Cyclic AMP levels (pmoles/g wet wt.),































Control IK^ I 75 mM
FIGURE 59 Effect of 7*5 mM potassium on:
(a) Developed tension (g).
(b) Heart rate (beats.min ^ ,
(c) Cyclic AMP levels (pmoles/g wet wt.),










P < 0 .0 2
Control K+ 7.5mM
FIGURE 60 Effects of 7.5 mM potassium on ventricular fibrillation 
thresholds (mA) determined by the train method.






































FIGURE 6l Effect of insulin (500 mU.ml on:
(a) Developed tension (g),
(b) Heart rate (beats.min
(c) Cyclic AMP levels (pmoles/g wet wt.),
(d) Cyclic GMP levels (pmoles/g wet wt.).
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FIGURE 62 Effect of insulin (500 mU.ml on ventricular fibrill­
ation thresholds (mÀ) determined by the train method. 






































FIGURE 63 Effects of glucose-free perfusion on:
(a) Developed tension (g),
(b) Heart rate (beats.min ^),
(c) Cyclic AMP levels (pmoles/g wet wt.),
(d) Cyclic GMP levels (pmoles/g wet wt.). 










Control Glucose -  Free
FIGURE 64 Effects of glucose-free perfusion on ventricular 






























** p o c r
Adrenaline 
1 x10-^ M
FIGURE 65 Effects of adrenaline (l x 10 M^) on:
(a) Developed tension (g),
(b) Heart rate (beats.min )^,
(c) Cyclic AMP levels (pmoles/g wet wt.),
(d) Cyclic GMP levels (pmoles/g wet wt.).
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Control Adrenaline  
1 x10“ 7 m
FIGURE 66 Effect of adrenaline (l x IO^^m ) on ventricular
fibrillation thresholds (mA) determined by the train 




































FIGURE 67 Effect of histamine (l x 10”^M) on:
(a) Developed tension (g),
(b) Heart rate (beats.min"^),
(c) Cyclic AMP levels (pmoles/g wet wt.),










Control Histamine  
1 x10"®M
FIGURE 68 Effect of histamine (l x 10 M) on ventricular 
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FIGURE 69 Effects of sodium nitroprusside (l x 10 on;
(a) Developed tension (g),
(b) Heart rate (beats.min ),
(c) Cyclic AMP levels (pmoles/g wet wt.),
(d) Cyclic GMP levels (pmoles/g wet wt.). 















FIGURE 70 Effect of sodium nitroprusside (l x 10 on 
ventricular fibrillation thresholds determined 
by the train method.
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Section D
In the previous section the effects of calcium in non-ischaemic 
tissue were examined. This section extends these studies into vent­
ricular arrhythmias induced by ischaemia. Changes in intracellular 
calcium were effected by manipulation of the concentration of potass­
ium, as well as the calcium concentration of the perfusate. Having 
established a model of arrhythmias, this was then used to study the 
effects of adrenergic influences on the occurrence of ventricular 
arrhythmias.
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3.29 Potassium:calcium ratio on ventricular arrhythmias during
coronary artery ligation.
All hearts were initially stabilised in modified Krebs-Henseleit 
solution containing 1.23 mM calcium and 5.9 mM potassium for 15 min 
(see Section 2.1). Five min prior to ligation the ionic milieu was 
adjusted according to the required experimental conditions. (Calcium 
and potassium concentrations were manipulated by alterations in the 
content of calcium chloride and potassium chloride, respectively).
The criteria for a successful ligation were an increase in per­
fusion pressure and a decrease in developed tension which was assoc­
iated with a discoloured area on the left ventricle. A typical 
example is given in Figure 71.
Ligation of the coronary artery during perfusion with Krebs- 
Henseleit solution (2.46 mM calcium, 5.9 mM potassium) produced a 
very low number of premature ventricular contractions (7 J: 5 / 30 min) 
and a low incidence of ventricular tachycardia (8^ ). Ventricular 
fibrillation was never observed (Figure 72).
Reduction of the potassium concentration to 2.5 mM in the pres­
ence of 2.46 mM calcium produced a h i ^  incidence of ventricular 
arrhythmias during ligation (premature ventricular contractions,
797 -± 101 / 30 min; ventricular tachycardia, 47%; ventricular 
fibrillation, 27%; n = 15). The number of premature ventricular 
contractions following ligation had a distinctive time course.
During the first 3 min of ligation there was a very low number of 
ventricular arrhythmias. Premature ventricular contractions grad­
ually increased in frequency and reached a peak of instability approx­
imately 10 min after ligation. Thereafter, hearts reverted to a more 
stable state for the remainder of the 30 min of recorded activity.
l6 6
The pooled data are shown in Figure 73 «uid a typical example is shown 
in Figure 74»
Concomitant reduction of the calcium concentration to 1.2 mM, in 
the presence of 2.5 mM potassium, greatly attenuated the incidence of 
arrhythmias after ligation (premature ventricular contractions, 21 ±  
8 / 3 0  min; ventricular tachycardia, 13%; ventricular fibrillation, 
0%; n = 12 - Figure 72).
3.30 Potassium:calcium ratio on developed tension, heart rate and
perfusion pressure.
Developed tension was influenced by the manipulations in potass­
ium and calcium used in the coronary artery ligation studies. Devel­
oped tension was significantly (P<0.05) greater in the presence of
2.46 mM calcium, 2.5 mM potassium than in 2.46 mM calcium, 5.9 mM 
potassium, which itself was significantly (P<0.05) greater than the 
developed tension observed during perfusion with 1.23 mM calcium,
2.5 mM potassium (Figure 75b). It is interesting to note that . 
although developed tension was greater in the presence of 2.5 mM pot­
assium (compared to 5.9 mM potassium in the presence of 2.46 mM cal­
cium), the reduction of potassium to 2.5 mM produced a negative ino­
tropic response in the presence of 1.2 mM calcium. These data are 
expressed as changes in developed tension (Figure 76). Heart rates 
were not significantly different between the groups perfused with the 
three ionic milieu (Figure 75).
All three ionic manipulations produced increases in perfusion 
pressure over those observed in the stabilisation period. The biggest 
increase was observed during perfusion with 2.46 mM calcium, 2.5 mM 
potassium and this was significantly higher (P<10.01) than the 
increased perfusion pressure in the other two groups. Increases in
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perfusion pressure were similar when the ionic environment was 
changed to 2.46 mM calcium, 5.9 mM potassium or 1.23 mM calcium,
2.5  mM potassium (Figure 75c).
3. 31 Lignocaine on ventricular arrhythmias during coronary 
artery ligation.
The effects of the classical class I antiarrhythmic drug, ligno­
caine, were investigated on arrhythmias produced by coronary artery 
ligation in the presence of 2.46 mM calcium, 2,5 mM potassium.
For this and subsequent investigations using this model of 
arrhythmias, the drug was infused for 10 min following a stabilisa­
tion period of 15 min. In the presence of the drugs, the calcium 
and potassium concentrations were changed to 2.46 mM and 2.5 mM, 
respectively, 5 min prior to ligation.
Lignocaine (2 x 10 M) significantly reduced the number of pre­
mature ventricular contractions observed (29 ± 1 5 / 3 0  min; PcO.OOl) 
and the incidence of ventricular tachycardia (P<0.05) during coro­
nary artery ligation. Ventricular fibrillation was not observed in 
any of the 7 experiments (Figure 77).
3.32 Lignocaine on developed tension, heart rate and perfusion 
pressure.
Lignocaine (2 x 10 M) did not significantly change developed 
tension, heart rate or the change in perfusion pressure when hearts 
were perfused with 2.46 mM calcium, 2.5 mM potassium (Figure 78).
3. 33 Calcium slow channel antagonists on ventricular arrhythmias 
during coronary artery ligation.
It was previously shown that lowering the calcium concentration 
to 1.2 mM reduced ventricular arrhythmias during coronary artery
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ligation in the presence of 2.5 mM potassium. Therefore, the effects 
of two calcium slow channel antagonists were investigated in the cor­
onary artery ligated hearts in the presence of 2.46 mM calcium,
2.5 mM potassium to study whether they mimicked low calcium perfu­
sion.
Nifedipine (l x 10 ^M) did not affect any parameter of ventri­
cular instability. Similarly, the vehicle for nifedipine (ethanol, 
.0007% v/v) did not significantly alter the incidence of arrhythmias 
(Figure 79).
—8Verapamil (l x 10 M) did not significantly reduce ventricular 
arrhythmias. However, the higher concentration of verapamil used 
(1 X  10 ^M) significantly reduced (P<O.Ol) the number of premature 
ventricular contractions following ligation. The incidence of vent­
ricular tachycardia was reduced and ventricular fibrillation was not 
observed in any of the 5 experiments (Figure 80).
3.34 Calcium slow channel antagonists on developed tension, heart 
rate and perfusion pressure.
Despite the lack of effect of nifedipine (l x 10 ^M) on ventric­
ular arrhythmias, it did significantly (P<CO.05) reduce developed
tension prior to coronary artery ligation, whereas both concentra-
—8 —7
tions (1 X  10 M and 1 x lO” M) of verapamil had no significant
effect on developed tension (Figure 8lb).
Similarly, nifedipine greatly attenuated (P<0.01) the increase 
in perfusion pressure produced by perfusion with 2.46 mM calcium,
2.5 mM potassium after the stabilisation period, vdiilst verapamil 
again had no significant effect (Figure 8lc).
Neither drug had a significant effect on heart rate prior to 
coronary artery ligation (Figure 8la).
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3» 35 p-adrenoceptor antagonists on ventricular arrhythmias during 
coronary artery ligation.
dl-Propranolol (l x 10 significantly (P<0.05) reduced the 
number of premature ventricular contractions following coronary 
artery ligation (386 ±  68 / 30 min). A higher concentration (l x lO”^  
M) further reduced the number of premature ventricular contractions 
(40 ±  12 / 30 min; PCO.Ol). Ventricular tachycardia and ventricular 
fibrillation were not observed in the 5 experiments performed in the 
presence of 1 x 10~^M dl-propranolol (Figure 82).
A concentration of 1 x 10~^M of the d-isomer of propranolol was 
used which would have had a similar local anaesthetic activity to the 
1 X 10”^ M concentration of the racemate, \diilst having a similar 
j3-adrenoceptor antagonist activity to that of the 1 x 10~^ concen­
tration. The d-isomer reduced the incidence of all arrhythmias to a 
level similar to that observed during perfusion with 1 x 10”^M dl-pro­
pranolol (premature ventricular contractions, 44 ±  14 / 30 min; 
ventricular tachycardia, 0%; ventricular fibrillation, 0%; n = 5).
A high concentration of atenolol (l x lO'^M), which has comp­
arable -adrenoceptor antagonist potency to dl-propranolol, did not 
confer any protective effect on the incidence of arrhytiimias during 
coronary artery ligation (premature ventricular contractions,
781 ±  141 / 30 min; ventricular tachycardia 63%; ventricular fibr­
illation, 43%; n = 7 - Figure 82).
3. 36 Catecholamine depletion on ventricular arrhythmias during 
coronary artery ligation.
As one approach to investigate the possible role of catechol­
amine release in the origin of arrhythmias, hearts from animals pre­
treated with reserpine (5 mg.kg  ^i.p. ) and 6-hydroxydopamine
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(50 mg.kg  ^i.v. ) were perfused with 2.46 mM calcium, 2.5 mM potass­
ium during coronary artery ligation.
Reserpine and 6-hydroxydopamine significantly (P<:0.01) reduced 
the number premature ventricular contractions following coronary 
artery ligation (268 ±  101 / 30 min and 254 ± 7 1 / 3 0  min, respect­
ively). The incidence of ventricular tachycardia was lower and 
ventricular fibrillation was not observed in any of the catecholamine 
depleted hearts (Figure 83).
3.37 /3-adrenoceptor antagonists and catecholamine depletion on devel­
oped tension, heart rate and perfusion pressure.
Heart rates immediately prior to coronary artery ligation were 
not significantly different from controls in hearts from reserpine 
and 6-hydroxydopamine treated animals, or during perfusion with 
either propranolol or atenolol (Figure 84). The different experi­
mental conditions also did not produce any significant alterations 
in the increase in perfusion pressure seen after the change-over 
from a perfusate containing 1.23 mM calcium, 5.9 mM potassium to one 
containing 2.46 mM calcium, 2.5 mM potassium (Figure 85).
Propranolol (dl- and d-) did not significantly alter developed 
tension prior to coronary artery ligation. Atenolol did produce a 
significant (P<0.05) increase in developed tension. Althou^ 
6-hydroxydopamine pretreatment did not elevate developed tension, 
reserpine pretreatment (as observed earlier in this study under 
different experimental conditions - Figure 42) produced hearts whose 
developed tension was significantly higher compared to controls 
(Figure 86).
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3.38 Catecholamine depletion on nyocardial ^ycogen levels.
Reserpine has been shown previously to increase nyocardial 
glycogen levels (Gaudel et al, 1979) and this increase may be bene­
ficial in maintaining ^ycolytic flux during ischaemia (see Section 
1. 12).
Hearts from reserpine or 6-hydroxydopamine treated animals were 
perfused for 15 min in a Krebs-Henseleit solution which contained
1.23 mM calcium, 5.9 mM potassium, prior to freeze-clamping. These 
tissue samples were then prepared for glycogen determinations.
The control glycogen level was 15.2 ±  0.8 yimoles glucose/g wet 
wt.. Reserpine and 6-hydroxydopamine pretreatment significantly 
(P--^ O.Ol) elevated cardiac glycogen levels (23.9 ±2.2 and 29.8 ±3.9 
pmoles glucose/g wet wt., respectively - Figure 87).
3.39 Coronary artery ligation on (3H)-noradrenaline overflow and
tissue tritium levels.
These experiments were designed in an attempt to show whether 
noradrenaline was released in ischaemia and whether the release of 
any noradrenaline could be temporally related to ventricular arrhy­
thmias.
In all three ionic permutations coronary artery ligation did not 
produce changes in (3H)-noradrenaline overflow which could be detected 
using the methods employed (Figure 88).
Also, no significant differences in (3H)-noradrenaline levels 
could be detected in normal and ischaemic tissue after 30 min of 











































FIGURE 71 An example of an experiment in which the criteria for a 
successful ligation were satisfied. Note the increase 
in perfusion pressure and the decrease in developed 




























FIGURE 72 Effects of potassium:calcium ratio of the perfusate 
during coronary artery ligation on:
(a) Premature ventricular contractions / 30 min,
(b) Percentage incidence of ventricular tachycardia,


















FIGURE 73 Time course of the occurrence of premature ventricular 
contractions during coronary artery ligation in the 
presence of 2.46 mM calcium, 2.5 mM potassium.



































5 m i n
FIGURE 74 An example of a heart in which coronary artery ligation 
was performed in the presence of 2.46 mM calcium, 2.5 mM 
potassium. Note the lag period between ligation and the 






























FIGURE 75 Potassium:calcium ratios on:
(a) Heart rate (beats.min
(b) Developed tension (g),
(c) Change in perfusion pressure (mmHg) 


















FIGURE 76 Effect of alteration of the potassium:calcium ratio 
used in the coronary artery ligation studies on the 
change in developed tension (g), when the ionic milieu 
was adjusted after the stabilisation period. During 
the stabilising period the perfusate contained












*  P <0.05




FIGURE 77 Effect of lignocaine (2 x 10 M^) on:
(a) Premature ventricular contractions / 30 min,
(b) Percentage incidence of ventricular tachycardia,
(c) Percentage incidence of ventricular fibrillation 
during coronary artery ligation in the presence of
2.46 mM calcium, 2.5 mM potassium. Significant diff- 




























FIGURE 78 Effects of lignocaine (2 x 10 M^) on:
(a) Heart rate (beats.min
(b) Developed tension (g),
(c) Change in perfusion pressure (mmHg)
during perfusion with 2.46 mM calcium, 2.5 mM potassium 




















FIGURE 79 Effect of nifedipine (l x 10 M) and nifedipine vehicle 
(ethanol, 0.0007% v/v) on:
(a) Premature ventricular contractions / 30 min,
(b) Percentage incidence of ventricular tachycardia,
(c) Percentage incidence of ventricular fibrillation 
during coronary artery ligation in the presence of
























FIGURE 80 Effect of verapamil (10 and 10 M) on:
(a) Premature ventricular contractions / 30 min,
(b) Percentage incidence of ventricular tachycardia,
(c) Percentage incidence of ventricular fibrillation 
during coronary artery ligation in the presence of
2.46 mM calcium, 2.5 mM potassium. Significant differ­
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FIGURE Si Effect of nifedipine (l x 10 M^) and verapamil (10  ^
and 10 ^M) on:
(a) Heart rate (beats.min
(b) Developed tension (g),
(c) Change in perfusion pressure (mmHg)
during perfusion with 2.46 mM calcium, 2.5 mM potassium 
prior to coronary artery ligation. Significant differ­
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FIGURE 82 Effect of the/3-adrenoceptor antagonists atenolol (10“^ M), 
dl-propranolol (lO”  ^and 10”^M) and the d-isomer of 
propranolol (10 ^M) on:
(a) Premature ventricular contractions / 30 min,
(b) Percentage incidence of ventricular tachycardia,
(c) Percentage incidence of ventricular fibrillation 
during coronary artery ligation in the presence of
2.46 mM calcium, 2.5 mM potassium. Significant differ­

























FIGURE 83 Effects of pretreatment with reserpine (5 mg.kg  ^i.p.) 
and 6-hydroxydopamine (50 mg.kg i.v.) on:
(a) Premature ventricular contractions / 30 min,
(b) Percentage incidence of ventricular tachycardia,
(c) Percentage incidence of ventricular fibrillation 
during coronary artery ligation in the presence of
2.46 mM calcium, 2.5 mM potassium. Significant differ­










































FIGURE 84 Effects of the ^ -adrenoceptor antagonists and catechol­








































FIGURE 85 Effects of ^ -adrenoceptor antagonists and catecholamine
depletion on the change in perfusion pressure (mmHg) when 
the perfusate was changed to one containing 2.46 mM 
calcium, 2. 5 niM potassium from one containing 1.23 mM 
calcium, 5*9 mM potassium.
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FIGURE 86 Effects of the^-adrenoceptor antagonists and catechol­
amine depletion on developed tension (g) immediately 
prior to coronary artery ligation. Significant differ­
ences are denoted (* P<0.05, ^  PcQ.Ol).
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FIGURE 87 Effects of reserpine (5 mg.kg  ^i.p.) and 6-hydroxydopa- 
mine (50 mg.kg  ^i.v.) pretreatment on myocardial 
glycogen levels (yxmoles glucose/g wet wt.). Significant 
differences are denoted (* P<0.01).
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FIGURE 88 Effect of coronary artery ligation on (3H)-noradrenaline 
overflow (cpm) in the presence of:
(a) 2.46 mM calcium, 5.9 mM potassium,
(b) 2.46 mM calcium, 2.5 mM potassium,
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-1FIGURE 89 Tissue levels of tritium (dpm.mg iu normal and
ischaemic areas after 30 min coronary artery ligation in:
(a) 2.46 mM calcium, 5.9 mM potassium,
(b) 2.46 mM calcium, 2.5 mM potassium,





4.1 Calcium in cardiac function.
The finding that calcium produced an increase in developed ten­
sion in the perfused rat heart which was maximal at 2,46 mM (Figure 15) 
is in agreement with the studies of Forester and Hainwood (1974-) and 
Quinn et al (198I) who both used rat left ventricular papillary muscle. 
The progressive increase in developed tension during perfusion of 
rabbit hearts with 0.6 - 3*6 mM calcium (Figure 29) is also in agree­
ment with Quinn et al (198I) who found the maximum inotropic concen­
tration of calcium on rabbit papillary muscle to be in excess of 8 mM.
This species variation in the effects of calcium on inotropy has 
been attributed to differences in calcium-triggered calcium release 
(Sutko and Wilierson, 198O). These workers used ryanodine, which 
inhibits sarcoplasmic calcium release, and concluded that rat myocard­
ium was largely dependent on the intracellular stores of calcium as a 
determinant of contractile force. These intracellular stores of 
calcium are fully saturated in the presence of 2.5 mM extracellular 
calcium, which could explain the lack of positive inotropic response 
at extracellular calcium concentrations above 2.5 mM. This dépendance 
on intracellular stores of calcium for inotropy in rat nyocardium, 
which are activated by relatively small transmembrane calcium fluxes, 
could also explain the greater depressant potency of verapamil on rat 
myocardium compared to other species (Quinn et al, I98I). The rank 
order of species dependence of sarcoplasmic reticulum calcium-triggered 
calcium release in skinned muscle preparations is similar to the rank 
order of the effects of extracellular calcium on contractile function 
(Fabiato and Fabiato, 1978).
However, it should be noted that these explanations of the 
maximum inotropic concentration of calcium in the rat being 2.5 mM
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are only applicable to steady-state contractile activity. Elevations 
of calcium to 4.96 mM did produce a large initial inotropic response 
but this only persisted for about 2 min before returning to a level 
similar to that at 2.46 mM calcium.
Rat ventricular muscle in the presence of 2.5 mM calcium responds 
differently to other species to increasing rates of stimulation, 
hyperosmolarity, post-stimulus potentiation and ouabain (Forester and 
Mainwood, 1974,i Sutko and Wilier son, I98O) in that all of these inter­
ventions produce negative inotropic responses (see also Figure 22). 
These may be converted to positive inotropic responses in the presence 
of lowered extracellular calcium or in the presence of ryanodine 
(Forester and Mainwood, 1975; Sutko and Wilierson, 198O).
Calcium did not affect heart rate in either the rabbit or rat 
heart except when it was omitted from the perfusate (Figures 15 and 29) 
This lack of effect occurred despite speculation that the slow depol­
arisation phase of the sinus node may partially be due to a slow
influx of calcium ions (Bonke, 1978; Bouman et al, 1978). Similarly,
the three calcium slow channel antagonists did not significantly
reduce heart rate with the exception of very h i ^  concentrations 
which, like zero calcium, produced asystole.
However, in this study heart rate was derived electronically 
from the contractile activity and, therefore, it is not possible to 
say whether asystole was due to an absence of spontaneous sinus node 
discharge or to uncoupling of the excitation-contraction process. 
Therefore, heart rate derived from the electrical characteristics of 
the heart would be required to investigate the effects of zero calcium 
on spontaneous frequency of discharge.
Millar and Vaugjhan Williams (198I) found that alteration of
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calcium concentration over a range similar to that used in the pres­
ent study, produced changes in spontaneous frequency of beating of 
isolated rabbit atria. However, in the present study no significant 
changes in heart rate were observed in perfused rabbit heart over the 
range 0.6 - 3.6 mM calcium, or in rat hearts over the range 0.3 - 
4.96 mM.
The direct effects of calcium on coronary vascular resistance 
are difficult to interpret because perfusion pressure changes are 
probably a result of direct and indirect influences resulting from 
changes in contractile activity. An increase in contractile activity 
could increase perfusion pressure due to impedance of coronary flow 
by extravascular compression. The coronary vasodilator activity of 
drugs may also not be apparent in the isolated perfused rat heart 
since the latter does not appear to possess much basal coronary 
resistance, as indicated by the frequent lack of effect of nifedipine, 
verapamil and sodium nitroprusside.
The manipulations of calcium and potassium under the conditions 
in which coronary artery ligation was performed (Section 3D) produced 
an interesting paradox. When calcium was elevated from 1.23 to 2.46 mM 
a positive inotropic response occurred which was significantly greater 
when the potassium concentration was concomitantly reduced from 5*9 to
2.5 mM. This observation is in agreement with that of Eisner and 
Lederer (1979). However, when potassium was reduced from 5*9 to
2.5 mM in the presence of 1.2 mM calcium, a highly reproducible 
decrease in developed tension was observed. The mechanism of this 
negative inotropic action of lowered extracellular potassium is not 
clear, although it may be due to the effect of lowered potassium in 
reducing action potential duration (Morad and Trautwein, I968).
196
A reduction of extracellular potassium has been shown to produce 
a positive inotropic effect (Eisner and Lederer, 1979). This positive 
inotropic response was secondary to inhibition of the sodium/potassium 
ATPase which would lead to an accumulation of intracellular sodium. 
This enhanced intracellular sodium would then be available for 
exchange via the calcium/sodium exchange mechanism. Hence, intra­
cellular calcium would increase and have subsequent positive inotropic 
effects. This is a mechanism analogous to that proposed for digitalis 
(Schwartz and Adams, I98O).
In contrast to the effects on developed tension, lowering the 
potassium concentration to 2.5 mM increased the perfusion pressure 
despite there being a negative inotropic effect. The effect of 
elevating the calcium concentration during perfusion with lowered 
potassium was additive and this may be explained by an effect on the 
sodium/potassium ATPase system.
As with earlier experiments, none of the ionic concentrations 
significantly changed heart rate.
4.2  Calcium on cyclic nucleotide levels.
Changes in extracellular calcium produced concentration-dependent 
changes in cyclic AMP levels over the range 0 - 4*96 mM (Figure 16).
It was postulated that the changes in cyclic AMP were due to an 
alteration in the extracellular calcium concentration and various 
procedures were used to investigate this possibility.
Three protocols were used to manipulate intracellular calcium 
concentration, but these did not produce consistent changes in cyclic 
AMP levels. The three methods of manipulating intracellular calcium 
were ;
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a) changes in extracellular calcium;
b) different rates of stimulation (a manoeuvre assumed to alter 
intracellular calcium by an effect on developed tension);
c) the use of the calcium slow channel antagonists verapamil, 
nifedipine and manganese.
The fact that different rates of stimulation produced changes in 
intracellular calcium with no change in cyclic AMP levels, whilst 
alteration of extracellular calcium did produce changes, suggests 
that the extracellular calcium, or at least that associated with the 
membrane, is the more important factor in determining cyclic AMP 
metabolism.
The three calcium slow channel antagonists all produced negative 
inotropic effects but failed to produce consistent changes in cyclic 
AMP levels, althou^ the changes in cyclic AMP produced by different 
concentrations of the individual drugs did show consistent trends 
(Figure 27). Nifedipine and manganese did not change cyclic AMP 
levels, while verapamil decreased cyclic AMP but not in a concentra­
tion-related manner. The reason for these different effects on 
cyclic AMP levels within this group of drugs is not known.
Differences between the effects of these drugs on cardiac function 
were also observed and are discussed in Section 4.4.
The omission of calcium produced a decrease in cyclic AMP levels 
at 5 min, vdiich returned to control levels after 30 min. This obser­
vation may explain the conflict between reports on the effects of 
calcium omission on myocardial cyclic AMP levels. In agreement with 
Hancock and Hess (1976), 5 min of zero calcium perfusion decreased 
cyclic AMP levels in the rat heart. Also, these results concur with 
Dhalla et al (1977) who found no effect on cyclic AMP levels after
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40 min of calcium-free perfusion in the rat.
However, Nannn et al (1968) found cyclic AMP levels were approx­
imately double the control value after 30 min calcium-free perfusion. 
This observation lies in contrast to the present study particularly 
since their control values were obtained in the presence of 2.5 mM 
calcium, compared to the 1.23 mM used in this investigation.
Endoh et al (1976) found that 30 min of calcium omission also
produced elevated levels of cyclic AMP in rabbit papillary muscle
compared to control values in the presence of 2.5 mM calcium. This
finding was related to their experiments on pacing frequency in which
they found an inverse relationship between developed tension and
cyclic AMP levels (see Section I.4). However, this finding has not
been reproduced by Roger and Shahid (198I) vdio used a shorter period
A
of pacing. Also, in the present study, decreasing calcium to 0.6 mM 
in perfused rabbit hearts produced decreased cyclic AMP levels after 
20 min compared to those in the presence of 1.2 mM calcium.
A more extensive study into the time course of cyclic AMP changes 
is required to clarify these conflicting results. The studies of 
Endoh et al (1976) and Rcjger and Shahid (198I) also suggest that this 
time course may be altered at different pacing frequencies.
It was noted that the 30 min period of calcium-free perfusion 
produced hearts vdiich had a patchy, discoloured appearance, suggesting 
that cellular damage had occurred during the prolonged exclusion of 
calcium. Therefore, it is considered that experiments involving such 
lengthy periods of calcium omission probably have limited value in 
extrapolation to the physiological situation.
Several possibilities for the mechanism of action of calcium 
on cyclic AMP levels were considered.
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As described in Section I.4, the effects of calcium on the 
enzymes responsible for the synthesis and degradation of cyclic AMP 
suggest very complicated control mechanisms and it is probable that 
the feedback mechanism described by Tada et al (1975) represents an 
oversimplification. Besides the problems of multi-enzymatic systems 
and compartmentalisation that were previously discussed, a more 
fundamental problem of enzyme kinetics does not appear to have been 
considered. Intracellular free calcium is thougjht to fluctuate 
between 10 at diastole and 10 at systole and it has been 
reported that enzymatic activity can be manipulated over this range 
of calcium concentration. However, the highest concentration of 
calcium will only be achieved for a transient period in the cardiac 
cycle (of the order of a few milliseconds) and it has not been shown 
that enzymatic activation (or inactivation) can occur with this 
rapidity.
In addition to the effects of calcium on the enzymes responsible 
for synthesis and degradation, a possible mechanism by which cyclic 
AMP levels could be manipulated is by an effect on efflux into the 
extracellular fluid. However, attempts in the present study to 
quantify this efflux have failed, possibly due to the lower limits of 
the sensitivity of the assay procedure. This lack of measurable 
cyclic AMP in the perfusate is in agreement with the report of O^Brien 
and Strange (1975) who also failed to detect basal release of cyclic 
AMP from rat hearts, even with the use of a small volume recirculating 
system. Although the present study failed to detect cyclic AMP efflux, the 
quantitative changes in ngrocardial levels of cyclic AMP which were 
observed could theoretically be explained by changes in efflux.
Therefore, this mechanism can not be completely discounted.
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The calcium-induced changes in cyclic AMP levels may have been 
secondary to catecholamine release and subsequent ^ -adrenoceptor 
stimulation. However, the potent ^ -adrenoceptor antagonist atenolol 
(lO ^M) failed to modulate cyclic AMP levels (Figure 23). Therefore, 
it is unlikely that the decrease in cyclic AMP levels produced by low 
extracellular calcium was a result of reduced catecholamine release. 
The similar levels of cyclic AMP at 1.23 and 4.96 mM calcium also do 
not suggest a mechanism via release of endogenous catecholamines. 
Finally, although cyclic AMP levels were elevated when the calcium 
concentration was increased from 1.23 to 2.46 mM, no increase in 
(3H)-noradrenaline was observed in later experiments (see Section 3D).
The changes in cyclic AMP in the presence of different calcium 
concentrations may have been a reflection of the altered contractile 
state. This is also considered unlikely from the present results 
and those of other authors. Increasing rates of stimulation produced 
a decrease in developed tension but cyclic AMP levels were similar at 
all frequencies (Figure 22). This is in agreement with Dobson et al 
(1976) \dio also observed no change in cyclic AMP levels on increasing 
pacing frequency in guinea-pig papillary muscle, vhich exhibits a 
positive force-frequency relationship. It would also be difficult to 
reconcile the effects of developed tension on cyclic AMP with the 
findings of Endoh et al (1976) who demonstrated a reciprocal change 
in developed tension and cyclic AMP in rabbit papillary muscle. 
Additional evidence against contractility being an important deter­
minant of cyclic AMP metabolism is that nifedipine depressed 
developed tension but had no significant effects on cyclic AMP levels.
It was noticed that cyclic AMP levels in electrically paced 
hearts in the presence of 1.23 mM calcium were higher than in unpaced
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controls. There is a number of possible explanations for this effect. 
Broadley (1976) demonstrated the release of catecholamines from guinea- 
pig hearts upon commencing electrical pacing. Catecholamine release 
would increase cyclic AMP levels through the well-defined mechanism 
of |3-adrenoceptor activation. The trauma of removal of the right 
atrium may in itself have been a cause of the elevated cyclic AMP 
levels in paced hearts. Finally, it is possible that electrical 
pulses per se elevated cyclic AMP due to excessive depolarisation 
(Wollenberger et al, 1973; Kalmchi et al, 1969; Osnes and Oye, 1975).
No consistent changes were observed for the effects of extra­
cellular calcium on cyclic GMP levels. The most salient fact derived 
from these studies was that high extracellular calcium produced high 
levels of cyclic GMP. This could explain why the levels of cyclic GMP 
in the rat heart observed by George *s group (who commonly used high 
calcium concentrations in their perfusates) were higher than those 
observed by other authors (Gardner and Allen, 1976; George et al,
1973).
4.3 Cyclic nucleotides as modulators of cardiac contractility.
The present study found a correlation between cyclic AMP levels 
and developed tension when both variables were manipulated by extra­
cellular calcium (Figure 17). However, despite this relationship, 
other experimental procedures dissociated cyclic AMP levels and 
contractile state. Verapamil, nifedipine and manganese all depressed 
developed tension but did not change cyclic AMP levels in a manner 
which would be consistent with it having a modulatory role in cardiac 
contractility.
However, it should be recognised that dissociations between 
total cardiac levels of cyclic AMP and contractile state do not
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necessarily show that the cyclic nucleotide is not the modulator of 
the response. It is now accepted that total levels of neurotrans­
mitters have little bearing on determining a physiological response, 
and instead a more pertinent index is that of transmitter turnover 
(Brodi^, 1966). Turnover studies of neurotransmitters are relatively 
simple due to the specific metabolites of each transmitter which are 
produced. However, cyclic AMP is metabolised via phosphodiesterase 
to AMP \diich is a metabolite common to other biochemical pathways 
and therefore turnover is not easily measurable. Despite these 
technical difficulties Osnes and Oye (1975) attempted to measure 
turnover by labelling cyclic AMP stores with (l40)-adenine and found 
a relationship between the positive inotropic response produced by 
phenylephrine and the production of (l40)-cyclic AMP.
Elevated levels of cyclic AMP in the ngrocardium which are assoc­
iated with positive inotropy also do not necessarily mean that it is 
not involved in modulating contractility. An example is that of 
papaverine which elevated cyclic AMP but did not influence the 
contractile state of guinea-pig hearts (Henry et al, 1975), although 
this may be due to papaverine directly inhibiting the slow inward 
calcium current (Schneider et al, 1975).
The dissociation between developed tension and cyclic AMP with 
the use of the calcium slow channel antagonists may be explained in 
a similar manner to papaverine, in that the direct effects of 
inhibiting transmembrane calcium flux makes the intracellular levels 
of cyclic AMP irrelevant to the inotropic response.
Compartment al i s ation probably represents the most difficult 
problem in the interpretation of cellular regulation (Denton and 
Pogson, 1975). Therefore, suggestions that the effects of cyclic
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nucleotides may occur due to shifts in functional pools within the 
cell (Brooker, 1977) can not be substantiated with present technology.
There is dispute as to whether cyclic AMP is involved in the 
whole cardiac response or just in one facet of contractility; 
i.e. does it influence the enhanced inotropic response and/or the 
decreased relaxation time? Two studies specifically designed to 
investigate this problem have produced conflicting conclusions.
Morad et al (198I) concluded that cyclic AMP was probably only involved 
in the enhanced inotropic response, vdiilst Laustiola et al (198I) 
considered that cyclic AMP was only important in modulating relaxation. 
It would have been of interest to investigate the effects of calcium 
on time to peak tension and relaxation time in view of the effects 
observed on cyclic AMP. Unfortunately, an appropriate method to 
measure the relaxation time using the rat heart could not be devised.
The role of cyclic GMP in the modulation of cardiac contractility 
is unclear (Drummond and Severson, 1979). Results from this study 
failed to substantiate a role for cyclic GMP in cardiac contractility 
in the majority of experimental designs, with the exception of the 
effects of sodium nitroprusside. Sodium nitroprusside produced a 
large increase in cyclic (MP associated with a depression of developed 
tension and no change in levels of cyclic AMP. This may appear to be 
in disagreement with the study of Diamond et al (1977) who found 
sodium nitroprusside produced a positive inotropic effect associated 
with elevated cyclic GMP levels. However, their measurements were 
recorded immediately after the sodium nitroprusside came into contact 
with the heart, whereas measurements in the present study were taken 
after 5 min. An initial positive inotropic response was noted in this 
study which preceded the depression of developed tension, giving a
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contractile profile similar to verapamil although not of comparable 
potency.
As discussed previously, no relationship between the ratio of 
cyclic AMP to cyclic GMP could be detected.
4.4  Calcium slow channel antagonists - similarities with reduction 
of calcium concentration.
Many drugs have been classified as calcium slow channel antag­
onists, although it is becoming apparent that the drugs which are 
commonly ascribed this terminology have differing mechanisms of 
action (Raschack, 1976; Spedding, 1981ol; Spedding, 1981b; Payet et al,
1980).
It has been previously described in Section 4.2 that differences 
were observed in the effects of calcium slow channel antagonists on 
cyclic nucleotide metabolism. Besides this disparity on biochemical 
mechanisms, functional differences were observed with the three 
calcium slow channel antagonists used (nifedipine, verapamil and 
mangane se).
Both manganese and nifedipine depressed developed tension to a 
similar extent to that produced by a reduction in the calcium 
concentration from 1.23 to 0.6 mM, although the effects of nifedipine 
were far slower than those of low calcium in attaining an equilibrium.
In marked contrast, the depression of developed tension seen in the 
presence of verapamil was preceded by a positive inotropic effect. 
Himori et al (1976) have described initial positive inotropic effects 
of verapamil, nifedipine and diltiazem in canine papillary muscle. 
However, significant effects were only observed with verapamil in the 
present study (Figure 24). The d-isomer of verapamil has been observed 
to increase dP/dt^^g^ in the anaesthetised dog (Raschack, 1976).
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The mechanism of this initial positive inotropic effect of verapamil 
may relate to its ability to displace surface-bound calcium (Nayler 
and Szeto, 1972).
The effects of nifedipine and verapamil on perfusion pressure 
were dependent on the initial control value. Only in the presence 
of a high resting perfusion pressure (>70 mmHg) did these drugs reduce 
perfusion pressure. In the presence of a low perfusion pressure 
neither drug produced a reduction. Therefore, these data suggest that 
both nifedipine and verapamil are vasodilators in the intact heart, 
but this action may not be apparent in an isolated perfused heart 
due to the lack of basal tone. The increase in perfusion pressure 
during the administration of manganese was unexpected and the mode of 
action producing this response is obscure.
4.5  Changes in levels of cyclic nucleotides during underperfusion.
There is a large body of literature to suggest that cyclic AMP 
is elevated at some time during ischaemia in many animal models 
(for references see Krause and Wollenberger, 198O). However, the 
origin of these elevated levels has not been established.
Extracellular calcium was found to modify the profile of changes 
in cyclic AMP levels during under per fusion, with a delayed peak 
occurring in the presence of a low calcium concentration (Figure 33). 
Since the release of noradrenaline from nerve endings is a calcium- 
dependent process (Kirpekar and Misu, 1967), this observation of the 
effects of extracellular calcium may suggest that the altered levels 
of cyclic AMP could be due to catecholamines. Alternatively, these 
changes may be due to a direct influence of calcium on cyclic AMP 
metabolism, although these effects are poorly defined (see Section 1.4).
Hearts from rats which had been pretreated with reserpine did not
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produce a measurable peak during underperfusion, %diile functional 
parameters were near control levels (Figure 42). This observation 
may indicate that elevated levels of cyclic AMP during underperfusion 
originate from adrenergic influences. However, the other effects of 
reserpine on cardiac muscle may require consideration (see Section 
1.12).
Nifedipine and verapamil both reduced cyclic AMP levels during 
underperfusion (Figure 39). Verapamil reduces the potassium-induced 
release of noradrenaline (Paton et al, 1977), although it has been 
stated that noradrenaline release is not influenced by this drug 
(Verrier and Lown, I98O). However, verapamil also has antagonist 
activity on adrenoceptors (Melville and Benfey, 1965) and, therefore, 
effects could have been due to the combined action at pre- and post- 
synaptic sites. Although nifedipine was effective in reducing 
cyclic AMP levels, it had been found to be ineffective at preventing 
the cardiac effects of adrenaline (Verrier and Lown, 198O).
Whether nifedipine affects the release of noradrenaline does not 
appear to have been documented. Therefore, the pharmacological 
profiles of verapamil and nifedipine require further elucidation so 
as to interpret fully these underperfusion studies.
In support of the hypothesis that adrenergic influences are 
responsible for elevated levels of cyclic AMP in ischaemia, Krause 
et al (1978) found that racemic propranolol reduced cyclic AMP levels 
during coronary artery ligation in anaesthetised dogs, whereas the 
d-isomer was ineffective. However, Lubbe et al (I98O) found the 
elevated levels of cyclic AMP in the ischaemic area of coronary 
artery ligated rat hearts to be reduced by both isomers of propranolol.
It should be recognised that cyclic AMP levels are not under the
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exclusive control of ^ -adrenoceptor stimulation. With regard to 
ischaemia, lysophospholipids and prostaglandins accumulate and are 
released during coronary artery ligation and these are known to 
influence cyclic AMP levels (Ahumada et al, 1979; Coker et al, I98I; 
Vapaatalo et al, 1978).
The levels of cyclic GMP during underperfusion were less consist­
ent and more variable than those of cyclic AMP. The results from the 
series of experiments involving different calcium concentrations 
suggest that elevation of cyclic (MP during underperfusion was 
calcium-dependent (Figure 34), although more data are required to 
support this speculation.
The possible mechanism by which cyclic GMP levels change during 
ischaemia has not been extensively investigated. Krause et al (1978) 
found elevated levels of cyclic GMP in the ischaemic nyocardium of 
coronary artery ligated anaesthetised dogs, an effect which was 
abolished by vagotomy. Therefore, present evidence suggests that 
elevated levels of cyclic CMP are due to muscarinic receptor 
stimulation.
4.6 Global underperfusion - anoxia or ischaemia?
Due to the oxygen handling characteristics of haemo^obin in 
blood, the total coronary flow in vivo is far lower than that required 
in vitro to provide adequate oxygenation during perfusion with a 
physiological solution. Total coronary blood flow in vivo in the rat 
heart is approximately 2 ml.min  ^ (Sapirstein, 1956) whereas coronary 
flow in isolated hearts perfused at constant pressure by the Langen- 
dorff technique is approximately 10 ml.min  ^ (Sen et al, 1975; Lubbe 
et al, 1978; Winslow et al, I98O). Therefore, the possibility exists 
that in the present study the reduction of coronary perfusion rate
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from 10 ml.min”  ^to 2 ml.min”  ^was not a true representation of 
ischaemia and was more strictly a decrease in oxygen availability 
(Carbonin et al, IÇSO). From the metabolic measurements which were 
recorded it was not possible to assess whether there was a decreased 
washout of noxious metabolites, a prerequisite for fulfilling the 
definition of ischaemia.
Bricknell and Opie (1979) considered that their globally under­
perfused rat heart model was ischaemic because of a) a reduced 
contractile activity, b) an impaired contractile activity, c) the 
occurrence of reactive hyperaemia on reperfusion, d) a decreased 
content of high energy phosphates and e) an increase in lactate 
output.
Conditions a, b and d were satisfied in the globally underperfused 
model used in the present study. However, these conditions may also 
occur in rat hearts perfused at a high flow rate with a perfusate 
which had been previously gassed with nitrogen (Gaudel et al, 1979; 
Nayler et al, 1979).
During underperfusion decreases in heart rate were observed 
vdiich would also have reduced oxygen demand, a response vdiich would 
have had beneficial effects. To avoid this problem pacing could be 
used, althou^ this procedure was not performed in the present study.
4.7 Ventricular fibrillation thresholds as an index of electrical
instability.
Wiggers and Wegria (1940) first established that a brief direct 
current could evoke ventricular fibrillation when placed during the 
appropriate period of the cardiac cycle. The factors which influence 
this electrically induced fibrillation have been extensively discussed 
by Surawicz (1971), althou^ the most obvious is the energy of the
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stimulus.
In the present study it was found (in paired experiments) that 
ventricular fibrillation thresholds determined by the single stimulus 
method were significantly lower than those determined by the two 
train methods (Figure 50). Two train parameters were used althou^ 
both produced similar fibrillation thresholds. One set of parameters 
placed a 2 msec pulse every 10 msec for 100 msec , similar to the 
parameters used by Lubbe et al (198O). The other set of parameters 
was devised so that pulses could be placed more rapidly over a 
shorter interval (i.e. a 2 msec pulse every 5 msec for 60 msec).
Using unpaired pooled data Opie and Lubbe (1979) found that the 
train method produced slightly higher fibrillation thresholds than 
those determined by the single stimulus method, although this 
difference did not achieve significance.
In contrast to the results presented in this thesis and those 
of Opie cind Lubbe (1979), Winkle et al (198O) noted in anaesthetised 
dogs that the sin^e stimulus method produced a fibrillation thresh­
old which was an order of two or more higher than that produced by 
the train method. The lower fibrillation threshold produced by trains 
of stimuli was attributed to catecholamine release from adrenergic 
neurones as a result of the stimulation (Winkle et al, 198O).
Indeed, it is interesting to note that in both the present study and 
that of Opie and Lubbe (1979) the fibrillation threshold in the 
isolated rat heart was approximately 10 mA, whereas an in vivo 
investigation has produced control values in the region of 0.5 mA 
(Marshall et al, I98I). Whether a neural influence could explain the 
difference between thresholds from jn vitro and in vivo models 
requires investigation.
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Winkle et al (198O) have raised important questions concerning 
the protocols used in experiments to determine ventricular fibrill­
ation thresholds by train methods. They found that different 
fibrillation thresholds could be obtained by varying the intervals 
between stimulation periods and by changing the increments in the 
current of successive trains. Short intervals between successive 
stimulus trains produced lower fibrillation thresholds. In the 
present study a comparatively long interval between stimulations 
(one every 20 sec) was used (which corresponds to a train approximately 
every hundredth beat) and therefore this would overcome this possible 
source of error. Also, increments in the current of the trains 
were comparatively small steps of 1 mA. With both methods of 
fibrillation threshold determination all timing was maintained as 
standard as possible, and this was found to give the most reproducible 
results. This fact was also observed by Winkle et al (198O).
It is considered that the major shortcoming of the ventricular 
fibrillation threshold determinations of the present study is that 
they were all performed on non-ischaemic tissues. The important 
implications of the presence of ischaemia to the investigations of 
anti-arrhythmic activity are discussed in Section 4.11.
Whether the fibrillation produced by electrical stimulation has 
any relevance to fibrillation produced by acute myocardial ischaemia 
in the clinical setting is obviously a matter of conjecture, although 
anti-arrhythmic agents are effective in this model (Lubbe et al, 1975).
4. 8 Calcium and calcium slow channel antagonists on ventricular
fibrillation thresholds.
Elevated extracellular calcium produced a concentration-dependent 
reduction in the ventricular fibrillation threshold, possibly due to
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the increase in resistance in cell-to-cell communication (De Mello, 
1975). Elevated calcium concentration of the perfusate also produced 
a concentration-dependent reduction of the time interval between the 
peak of the R wave and the nadir of the vulnerable period. This 
latter effect is probably due to the calcium reducing the effective 
refractory period.
Nifedipine and verapamil both significantly elevated ventricular 
fibrillation thresholds in the presence of 2.46 mM calcium, but only 
at concentrations which depressed developed tension. Even this 
elevation of fibrillation threshold .produced a value which was lower 
than that observed in the presence of 1.23 mM calcium, despite this 
concentration of ccilcium only producing a slight depression of 
developed tension compared to that in the presence of 2.46 mM calcium. 
Since good relationships have been observed between the calcium slow 
channel current and contractility (Vassort, 1973), it is tempting to 
suggest that the effects of extracellular calcium on fibrillation 
thresholds are not totally dependent on the slow channel. Therefore, 
calcium may be entering the myocardium via another mechanism or, 
alternatively, calcium may be exerting its effects directly on the 
membrane.
There is a close relationship between calcium and potassium 
on the electrophysiological characteristics of the action potential 
(S’Wgelbaum and Tsien, I98O). Therefore it is difficult to predict 
the effects that the calcium slow channel antagonists may exert on 
action potential duration. Verapamil does not influence the action 
potential duration in cat papillary muscle in concentrations higher 
than those used in this study. This lack of effect of verapamil on 
action potential duration may account for its lack of effect on the
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time between the peak of the R wave and the nadir of the vulnerable 
period. However, it should be noted that action potential duration 
and effective refractory period do not always undergo mutual changes 
(Sobel et al, 1978). This assumes that the index measured in this 
study reflects a change in effective refractory period.
4» 9 Cyclic AMP as a prime arrhythmogenic mediator.
In agreement with Lubbe et al (1978), a fairly hi^ concentration 
of adrenaline (l x 10 M) decreased fibrillation thresholds with a 
concomitant increase in tissue cyclic AMP levels (Figures 66 and 67). 
These workers have made a more thorough study of the dose-response 
relationships of adrenaline to fibrillation thresholds and to cyclic 
AMP levels and concluded that cyclic AMP was a major arrhythmo genic 
mediator.
Althou^ the results with the adrenaline infusions agree with 
the cyclic AMP hypothesis of Podzuweit et al (1976), the data from 
most of the other interventions used produced disparities between 
cyclic AMP levels and ventricular stability.
Elevated calcium reduced fibrillation thresholds in a 
concentration-dependent manner, whilst cyclic AMP levels did not 
change in accord with the changes in electrical stability (Figures 
l6 and 51). It may be argued that this observation on calcium 
concentration may have no relevance to the events occurring in 
ischaemia, since total calcium has been reported to be unchanged in 
blood from the ischaemic region of the pig heart (Downar et al, 1977). 
However, this was only a measure of the total calcium levels whereas 
the relevant feature is the level of ionised calcium. To date, no 
investigations appear to have determined whether calcium availability 
changes in ischaemia. This lack of information is no doubt due to
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the technical difficulties in performing such studies, although the 
recent development of electrodes which are relatively specific for 
calcium ions may aid resolution of this problem.
The calcium slow channel antagonists, nifedipine and verapamil, 
also produced a disparity between electrical instability and cyclic 
AMP levels (Figures 52, 54, 56 and 58). However, the postulated 
mechanism by which cyclic AMP produces arrhythmias involves calcium 
transfer across the sarcolemma (Opie et al, 1979). Therefore, the 
experiments involving verapamil and nifedipine may be similar to those 
discussed in Section 4» 3 in that these drugs have a primary action in 
preventing sarcolemma! calcium fluxes and hence the intracellular 
level of cyclic AMP is irrelevant.
The other disparities observed between cyclic AMP and electrical 
stability were those involving insulin and elevated potassium 
concentration, both of which Increased the fibrillation threshold 
but did not significantly affect cyclic AMP levels.
The present ventricular fibrillation threshold study may be 
criticised for the use of a non-ischaemic model, and hence changes 
in cyclic AMP levels were observed in a normal situation which may 
not necessarily reflect the adverse effect of elevated cyclic AMP 
levels in the pathophysiological situation of ischaemia.
An attempt was made to quantify changes in cyclic AMP levels in 
the ischaemic and normal areas from hearts in the coronary artery 
ligation study. IMfortunately, the technique used was not considered 
sufficiently reliable to resolve the two areas for the measurement of 
a labile metabolite such as cyclic AMP. However, Lubbe et al (198O) 
have shown that cyclic AMP is elevated in the ischaemic tissue from 
coronary artery ligated isolated rat hearts during perfusion with
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2.5 mM calcium and 5.9 mM potassium. However, in the present study 
the induction of ischaemia by coronary artery ligation using this 
perfusate produced a very low incidence of spontaneous arrhythmias 
(Figure 72).
Dissociations between cyclic AMP and ventricular arrhythmias 
in models of ischaemia-induced arrhythmias have also been shown by 
other workers. These dissociations are:
(a) Sotalol inhibited the elevation of cyclic AMP in the ischaemic 
region of the coronary artery ligated pig heart but did not 
reduce the occurrence of ventricular fibrillation (Muller and 
Opie, 1980).
(b) Lignocaine elevated the ventricular fibrillation threshold during 
ischaemia in coronary artery ligated isolated rat hearts but did 
not prevent the elevated levels of cyclic AMP (Lubbe et al, 198O).
(c) Verapamil, nifedipine and diltiazem all prevented the elevation of 
cyclic AMP in the ischaemic tissue of coronary artery ligated 
isolated rat hearts, but only verapamil and nifedipine were 
effective in elevating the fibrillation threshold (Thandroyen
et al, 1980).
A very important series of experiments has recently been 
reported by Krause (198I Bologna meeting of the International Society 
for Heart Research) who investigated the effects of isoprenaline on a 
^obally underperfused rat heart. Isoprenaline produced elevated 
levels of cyclic AMP during underperfusion, but protein phosphoryl­
ation did not occur. Therefore, any elevations of cyclic AMP observed 
in ischaemia may be unable to exert any cellular effect.
It has been speculated that cyclic GMP should increase electrical 
stability, since it may be a physiological antagonist of cyclic AMP
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(Opie et al, 1979). In the present study sodium nitroprusside was 
used to elevate cyclic GMP, However, despite sodium nitroprusside 
producing large increases in cyclic GMP levels, there was no signif­
icant effect on fibrillation thresholds (Figure 70). In fact, there 
was a trend for sodium nitroprusside to decrease fibrillation thresh­
old. Therefore, this very short series of experiments did not 
substantiate the speculation of Opie et al (1979) that cyclic GMP 
may have anti-arrhythmic actions.
4.10 Coronary artery ligation in the isolated rat heart as a model 
of arrhythmias.
The advantage of using an isolated rat heart preparation is that 
it is devoid of haemodynamic, neural or hormonal influences and hence 
interpretation of results is less complicated. Therefore, in contrast 
to in vivo models of arrhythmia, this preparation would be expected 
to show direct anti-arrhythmic activities of drugs.
Besides the desirable properties of in vitro perfusion, this 
model also induced heterogeneous ischaemia which more closely 
simulates the events occurring in acute myocardial infarction than 
would global underperfusion. For the investigation of anti-arrhythmic 
action the presence of ischaemia may be important since the conditions 
in ischaemia may modify the pharmacological profile of a drug. Two 
examples of this phenomenon are:
(a) The enhanced local anaesthetic potency of propranolol due to the 
high extracellular potassium, low oxygen tension and acidosis 
present in ischaemia (Vaughan Williams, 1978).
(b) The selectivity with which verapamil depresses contractility in 
ischaemic tissue which may be due to the presence of acidosis 
(Smith et al, 1976; Smith and Briscoe, 198I).
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The induction of heterogeneous ischaemia by coronary artery 
ligation is probably important for investigations on early ventricular 
arrhythmias since the mechanism of a re-entrant pathway may be 
important in the genesis of these arrhythmias (Corr and Sobel, 1977) 
and such a pathway cannot occur in models of global ischaemia.
Two models of heterogeneous ischaemia were used in this study.
The first model involved ligation of the left anterior descending 
coronary artery in the isolated perfused rabbit heart. Unfortunately, 
only one parameter was used as an index of ischaemia (lactate levels) 
and the results suggest a rather poorly defined ischaemic area after 
5 min occlusion.
In contrast, by the time the coronary artery ligated rat model 
was used, the criteria for a successful ligation were more developed 
and hearts were instrumented in order to verify these criteria.
Also, in contrast to the rabbit study, successful ligation in the 
rat produced a clearly visible discoloured area within a few 
minute s.
It is therefore considered that coronary artery ligation in the 
isolated rat heart may represent a good model for the initial 
evaluation of anti-arrhythmic activity, before a drug is examined 
in in vivo models to study the contribution of extra-cardiac events 
on its anti-arrhythmic efficacy.
4.11 Fibrillation in the rat heart.
Doubts have recently been raised as to whether true ventricular 
fibrillation can occur in the coronary artery ligated rat heart which 
reverts to normal sinus rhythm. Marshall et al (198I) considered 
that this •fibrillation’ could more correctly be diagnosed as multi­
focal ventricular extrasystole or ventricular flutter. With relevance
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to the present in vitro study, Marshall et al (I98I) have stated that 
hearts which ’fibrillate’ and then return to normal sinus rhythm are 
usually accompanied by an electrocardiogram during the instability 
whose amplitude is greater than the R wave amplitude during normal 
sinus rhythm.
An example of electrically-induced ventricular fibrillation 
which reverts to sinus rhythm is illustrated in Figure 47 and in this 
example the R wave amplitude is smaller than that observed during the 
irregular period. The consistency of this observation was not 
quantified although smaller amplitudes of the electrocardiogram 
compared to the R wave during electrically-induced instability were 
observed.
Permanent recordings were not taken during the study involving 
coronary artery ligation and, therefore, no retrospective study can 
be performed on the waveforms during persistent and non-persistent 
fibrillation.
4»12 Potassium:calcium ratio and calcium slow channel antagonists
on ventricular arrhythmias.
The changes of extracellular potassium and calcium concentration 
used in this study would have manipulated the intracellular calcium 
concentration. Arrhythmias occurred during ligation in the presence 
of 2.5 mM potassium, 2.46 mM calcium which would have been the ionic 
milieu in vdiich the intracellular calcium concentration would have 
been highest.
However, the changes of potassium and calcium used in this study 
did not in themselves produce ventricular arrhythmias as would more 
extreme changes (Woodward, I98I). Following ligation there was 
approximately a three minute delay before the onset of arrhythmias.
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which then increased in frequency reaching a peak of instability at 
10 min. Following this peak of instability hearts reverted to a more 
stable condition. Therefore, although the intracellular calcium 
concentration was raised at the time of the ligature being tightened, 
there must have been an associated ionic and/or metabolic event 
during the course of ischaemia which precipitated the arrhythmias 
and which was also responsible for the reversion to a more stable 
condition.
The finding of a disparity in the anti-arrhythmic efficacy of 
nifedipine and verapamil (Figures 79 and 80) is in agreement with 
reports in anaesthetised dogs of ischaemia-induced arrhythmias 
(Verrier and Lown, I980) and reperfusion arrhythmias (Riberio et al, 
1980). The anti-arrhythmic action of verapamil is probably not due 
to a vasodilator effect, since nifedipine is a far more potent 
coronary vasodilator (Fleckenstein-Grun and Fleckenstein, 198O) but 
was not found to possess any anti-arrhythmic activity.
An alternative hypothesis for the anti-arrhythmic action of 
verapamil in ischaemia is that the drug normalised conduction delay 
throughout the myocardium (see Section l.ll). This hypothesis may be 
supported by the finding that nifedipine did not decrease conduction 
delay in the ischaemic tissue of dog hearts (Nakaya et al, I98I) and 
this drug was not found to be effective in preventing post-ligation 
arrhythmias in the present study. Nakaya et al (I98I) did find that 
high doses of nifedipine did slightly decrease conduction delay, 
although this effect was considerably less than that produced by 
lower doses of verapamil.
Nifedipine is known to be sensitive to light in the ultra-violet 
region of the spectrum and it may be speculated that the lack of
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anti-arrhythmic activity was due to degradation of the drug in the 
perfusate. However, all experiments using nifedipine were performed 
in a laboratory in which most light of wavelength below 4OO nm was 
filtered out. Also, during the coronary artery ligation studies, 
nifedipine exerted more potent effects than verapamil in depressing 
developed tension and reducing the increase in perfusion pressure. 
Therefore, nifedipine was definitely exerting pharmacological effects 
despite the absence of anti-arrhythmic action.
The lack of anti-arrhythmic action of nifedipine in this study 
contrasts with reports on coronary artery ligation in the anaesthet­
ised rat \dien nifedipine was administered either orally (Fagbemi and 
Parratt, I98I&) or intravenously (Fagbemi and Parratt, 198li). This 
difference may be due to a beneficial effect of nifedipine on regional 
myocardial blood flow following coronary artery ligation in the 
anaesthetised rat. It may also indicate that the ventricular 
arrhythmias occurring in this model are due to extra-cardiac influences.
It has been speculated (Henry, 1979) that the anti-arrhythmic 
effects of verapamil are due to fast channel inhibition rather than 
inhibition of the calcium slow channel. The fast channel inhibitor 
lignocaine was effective in reducing the incidence of arrhythmias 
during ligation in the model used in the present study (Figure 79). 
Although verapamil reduced the incidence of ventricular arrhythmias, 
a racemic solution of the drug was used. A study using the isomers 
of verapamil would be required to evaluate the contribution of its 
local anaesthetic properties. However, it should be noted that 
Kaumann and Serur (1975) found the 1-isomer (which is specific for 
the slow channel) of verapamil to be anti-arrhythmic in coronary 
artery ligated anaesthetised dogs. Therefore, the contrasting effects
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of verapamil and nifedipine on post-ligation arrhythmias may be due 
to the known electrophysiological differences by which these drugs 
inhibit the calcium slow channel (see Section 1.5).
Another possible mechanism by which verapamil may prevent 
arrhythmias is by decreasing potassium efflux, \diich may be a 
secondary effect of the reduced intracellular calcium (Nawrath et al,
1980).
4.13 Adrenergic system in early post-ligation arrhythmias.
Adrenaline (l x 10 M) decreased the ventricular fibrillation 
threshold in the isolated rat heart, a finding in agreement with 
that of Lubbe et al (1978). The presence of adrenaline has also been 
shown to increase the incidence of arrhythmias in the coronary artery 
ligated isolated perfused rat heart (Opie et al, 1979).
However, adrenaline has also been reported to elevate 
ventricular fibrillation thresholds in isolated rat hearts (Opie and 
Lubbe, 1979) and in anaesthetised dogs (Wegria and Nickerson, 1942;
Han et al, 1964). Adrenaline and noradrenaline have been shown to 
exert anti-arrhythmic effects at pressor doses in the coronary artery 
ligated rat heart (Marshall et al, I981), whilst noradrenaline in 
non-pressor infusions reduced the incidence of arrhythmias in 
ischaemic dog hearts (Regan et al, 1970). Therefore, jn vivo, there 
is evidence that the circulating catecholamines may be anti-arrhythmic, 
possibly due to mechanisms not directly related to the n^ocardium 
(Han et al, 1964).
Despite the observation that adrenaline decreased ventricular 
fibrillation threshold, no release of its precursor, noradrenaline, 
from the ischaemic heart could be detected (Figure 88) and hence no 
temporal relationship was observed between noradrenaline release and
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arrhythmia production. Although measurements were taken as total 
radioactivity without separation of the labelled noradrenaline, the 
lack of increase in tritium overflow could not be interpreted in terms 
of enhanced noradrenaline output. Similarly, the tissue levels of 
tritium in ischaemic and non-ischaemic areas were also expressed as 
total radioactivity, and no differences were found. These findings 
are confirmed by Didier et al (198O) who measured noradrenaline 
spectrophotometrically in ischaemic and normal areas from coronary 
artery ligated rat hearts and also found no difference in tissue 
levels in these two areas.
The method used in the current study would have detected 
differences in (3H)-noradrenaline overflow if it had increased by as 
little as 1 i»nole over any of the one minute periods measured.
Also, it has been shown that in coronary artery ligated isolated rat 
hearts, flow in the ischaemic area is still at least 20^ of that in 
the non-ischaemic area (which is already very high in a perfused 
system using physiological solutions - see Section 4.6)(Kannengiesser 
et al, 1975; Rochette et al, I98O). Therefore, with the sensitivity 
of the assay procedure used and the flow characteristics described, 
it seems probable that noradrenaline is not released from the 
ischaemic area. Additional support for this lack of release is that 
these experiments have recently been repeated in the presence of the 
potent uptake 1 inhibitor desmethylimipramine and, similarly, no 
enhanced noradrenaline overflow was detectable on ligation which 
could be related to arrhythmia production (Fox and Woodward, personal 
communication). These observations are also similar to the recent 
findings of Riemersma and Forfar (198I) who also performed their 
experiments in the presence of an uptake 1 inhibitor. Despite 
enhanced noradrenaline not being detectable, other metabolic markers
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of ischaemia (e.g. lactate) can be measured in blood (or perfusate) 
draining from an ischaemic area (Smith et al, 1976; Apstein et al, 
1977). The possibility that noradrenaline is released in discrete 
severely ischaemic areas cannot be totally excluded, althou^ 
whether it would exert any pharmacological effects in conditions of 
severe anoxia and acidosis remains to be resolved.
The lack of any protective effect of atenolol on ischaemia- 
induced arrhythmias is in agreement with Lubbe et al (I98O) who 
investigated ventricular fibrillation thresholds in isolated rat 
hearts subjected to coronary artery ligation. Although atenolol was 
not effective in ischaemia-induced ventricular instability, it has 
been found to antagonise the adrenaline-induced lowering of 
ventricular fibrillation thresholds (Lubbe et al, 1978). This may 
be interpreted either that catecholamines are not released in 
ischaemia, or that released catecholamines do not act via p-adreno­
ceptor stimulation. Propranolol was very potent at reducing the 
incidence of post-ligation arrhythmias, althou^ the equipotency of 
the d-isomer (which is practically devoid of j3-adrenoceptor 
antagonist potency) suggests that the protection was not due to 
|3-adrenoceptor antagonism. The most probable beneficial ancillary 
property of propranolol lies in its inhibition of the fast channel. 
This local anaesthetic property is not stereo-specific and, therefore, 
both the d-isomer and the racemate would have had similar potencies.
It has previously been disputed whether propranolol possesses 
sufficient local anaesthetic potency to be anti-arrhythmic (Coltart 
and Meldrum, 1970). However, it has now been shown that in the 
conditions prevailing in ischaemic tissue propranolol is a potent 
local anaesthetic at concentrations below those used in the present 
study (Vaugihan Williams, 1978). The potent anti-arrhythmic effect
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of the local anaesthetic lignocaine was demonstrated in the model of 
arrhythmias used in this study (Figure 77), hence showing that this 
ancillary property of propranolol may confer protective effects.
Propranolol has also been shown to be an inhibitor of 
phospholipase (Huunan-Seppala, 1972) which may limit the accumul­
ation of lysophospholipids. Lysophospholipids have been implicated 
as mediators of arrhythmias (Sobel et al, 1978; Corr et al, 1979). 
Whether this inhibition of phospholipase A^ is a stereo-specific 
property of propranolol has not been determined and measurements of 
lysophospholipids are required to substantiate this speculation.
Therefore, it is concluded that |3-adrenoceptor antagonism does 
not prevent arrhythmias when they arise from mechanisms inherent in 
the myocardium. This conclusion complements the finding of a lack 
of demonstrable noradrenaline release during ischaemia.
Recently, Sheridan et al (I98O) have shown that the OC-adreno­
ceptor antagonists, phentolamine and prazosin, reduced ventricular 
arrhythmias in the ischaemic hearts of anaesthetised cats. Further 
experiments are required to show whether this is a direct anti- 
arrhythmic effect. For example,OC-adren^eptor antagonism is known 
to stimulate insulin secretion (Ceremuzynski, I98I), which has been 
shown to possess anti-arrhythmic properties (Obeid et al, 1978).
In vitro experiments have demonstrated an anti-arrhythmic action of 
phentolamine on reperfusion arrhythmias in rat heart (Thandroyen et 
al, 1981). However, this study only used one drug at a very high 
concentration (10~^) so it does not clearly define vdiether this 
effect is due toOC-adrenoceptor antagonism. More appropriate 
experiments would require the use of several drugs that are classified 
as OC-adrenoceptor antagonists with assessment as to whether their
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relative anti-arrhythmic effects parallelled their oC-adrenoceptor 
antagonist potency.
The previously discussed lack of effects of adrenergic mechanisms 
in ventricular arrhythmias may appear paradoxical to the protective 
effects of reserpine and 6-hydroxydopamine (Figure 83). Experiments 
in anaesthetised animals have failed to show reserpine to be effective 
in preventing early post-ligation arrhythmias, althou^ 6-hydroxy­
dopamine has been shown to be effective (see Section 1.9).
The influence of the sympathetic nervous system on ventricular 
arrhythmias has produced conflicting reports (Corr and Gillis, 1978). 
Sympathetic outflow has been observed to increase during coronary 
artery ligation and has been implicated in arrhythmia production 
(Malliani et al, I969). However, it is difficult to show that the 
enhanced sympathetic outflow, which is usually only observed in 
some fibres, is distributed to the myocardium in the ischaemic area.
The role of increased sympathetic outflow in arrhythmia production 
is also difficult to reconcile with the finding that acute sympathetic 
denervation has no protective effect (Ebert et al, 1970). In contrast, 
chronic surgical sympathetic denervation has been shown to be effect­
ive in reducing ischaemia-induced ventricular arrhythmias (Ebert et 
al, 1970).
In the experiments described in this thesis rats were chemically 
denervated with 6-hydroxydopamine and catecholamine-depleted with 
reserpine. The hearts from these animals are probably more analogous 
to hearts from animals which had been chronically (rather than acutely) 
denervated. In these hearts there were large increases in glycogen 
content, which suggests that the ngrocardium had produced an adaptative 
response rather than just catecholamine depletion. Selective cardiac
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denervation by surgical means has also been shown to produce 
abnormalities in carbohydrate metabolism (Drake et al, I98O).
Enhanced glycogen content has been shown to be related to 
ischaemic protection of the myocardium in a number of studies 
(Gaudel et al, 1979). Althougih it is conceded that the evidence 
directly linking glycogen to production of arrhythmias is scant, 
the recent work (described in Section 1.13) showing that glycolytic 
flux may be important in determining ventricular arrhythmias suggests 
that the effects of glycogen levels on ventricular arrhythmias are 
worth considering.
4.14 Release of arrhythmogenic mediators.
Besides noradrenaline, the only other potential arrhythmogenic 
mediator studied was histamine. Histamine has been shown to be 
released in ischaemia (Anrep et al, 1936) and has been implicated in 
the production of ventricular arrhythmias (Trzeciakowski and Levi, 
1981). The present information to implicate histamine in the 
production of ventricular arrhythmias is sparse, although two reports 
have not substantiated a role for histamine in the production of 
early post-ligation arrhythmias (Hano and Harris, 1963; Harris, 1954).
The present study investigated the action of histamine on 
vulnerability to fibrillation in the non-ischaemic rat heart. Rat 
hearts contain large quantities of histamine althou^ they appear to 
be pharmacologically insensitive to the effects of this amine. Under 
normal conditions, even with the high concentration used (1 x 10"^M), 
no effect on ventricular fibrillation threshold (or any other monitored 
parameter) could be shown (Figures 67 and 68). This finding is in 
agreement with earlier work in the dog heart.
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However, a possible arrhythmogenic role for histamine cannot be 
totally excluded. The effects of this amine show a h i ^  species 
variation and hence other animals should be investigated as well as 
rat and dog. Also the conditions prevailing in ischaemia may modify 
the tissue response to a drug, and a pharmacological study is required 
to clarify whether histamine antagonists are anti-arrhythmic in 
ischaemic models even in species such as the rat. Assessment of the 
anti-arrhythmic actions of histamine antagonists will have to consider 
that many of these drugs have appreciable local anaesthetic activity.
The prostaglandins and thromboxanes may also be mediators of 
arrhythmias during ischaemia (see Section 1.12), but these were not 
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The effect of calcium on cyclic nucleotide levels 
in the rat isolated heart
A . D A U G H E R T Y  &  B. W O O D W A R D
Pharmacology Group, University o f  Bath, Claverton Down, 
Bath B A2 7A Y
Changes in m yocard ial c A M P  and c G M P  are in ti­
m ately linked to  the regulation o f in tracellu lar cal­
cium  av a ilab ility  and cardiac co ntrac tility  (D ru m ­
m ond &  Severson, 1979). Conversely, biochem ical 
studies have shown that calcium  can affect the 
enzym e systems responsible for the synthesis and 
degradation o f these nucleotides (Rasmussen &  
G o o d m an , 1977). Th e present study investigates the 
effects o f extracellular calcium  on cyclic nucleotide  
levels in an intact cardiac muscle preparation.
H earts  from  m ale W istar rats (2(X)-280 g) were per­
fused at a constant coronary flow  using a m odified  
Langendorff technique. C on tractility , at a resting ten­
sion o f 2 g, was measured using a Devices U F l  trans­
ducer attached to the apex o f the heart. A fter a 15 m in  
stabilisation period the calcium  content o f the K reb's- 
Henscleit solution was changed; 5 m in  later when the 
hearts had reached a new steady state they were freeze 
clam ped at the tem perature o f liqu id  nitrogen. 
Samples o f ventricle were then assayed for c A M P  and 
c G M P .
C alc ium  over the range 0 to 2.43 mw produced an 
increase in contractility which was associated w ith a 
rise in ventricular c A M P  and a variable effect on 
c G M P , this trend did not continue when the calcium  
level was raised to 4.92 mw (Table 1). V erapam il 
(1 0 " ’  m ) m im icked the effect o f low extracellular cal-
Tabk I The effect of extracellular calcium on cyclic nucleotides, contractility and heart rate in the isolated rat 
heart, means ± s e mean figures in parenthesis = number of hearts
C a^" cone cA M P cG M P cA M P C ontrac tility Heart rate
mM (pmoles/g wet wt) (pmoles/y wet wt) cG M P (9) (heats; min)
0.00 233 ± 14(5) 17.4 ± 1.3(5) 13.4 0.0(5)
0.30 277 ± 26(5) 16.0 ± 2.8(5) 17.2 1.1 ± 0.1 (5) 246 ± 10(5)
0.61 337 ± 23(51 37.1 ± 2.3(5) 9.9 4.6 ± 0.3(15) 234 ± 5(15)
1.23 422 ± 40(7) 19.6 ± 2.5(10) 21.5 9.1 ±0.1 (20) 239 ± 5 (20)
2.46 620 ± 43(10) 15.8 ± 1.9(15) 39.2 10.7 ± 0.6 (20) 232 ± 5(20)
4.92 461 ± 55(5) 51.1 ± 6.4(5) 90 10.8 ± 1.3(5) 254 ± 14(5)
pamil (1 X 10"’ m ) 320 ±22(4) 35.5 ± 13.0(4) 9.0 3.4 ± 0.1 (4) 248 ± 6(4)
plus Ca^ (1.23 mM)
cium  on the cyclic nucleotides, however, there was a 
difference in the profile o f contractile activity when 
verapam il and low  calcium  were compared.
These results show that extracellu lar calcium  is an 
im po rtan t determ inant o f the cyclic nucleotide levels 
w ith in  rat cardiac muscle over the concentration  
range in which contractility  is altered.
A. Daugherty is a University of Bath Research Fund 
student.
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The calcium dependence of venlricular 
fibnllation thesholds in the rat isolated heart 
and the effects of verapamil
A . D A U G H E R T Y  &  B. W O O D W A R D
Departm ent o f  Pharmacology, School o f  Pharmacy and  
Pharmacology, U niversity o f  Bath, C laverton Down, Bath 
BA2 7A Y
W e have previously reported that extracellular ca l­
cium has concentration dependent effects on cyclic 
nucleotide levels in isolated perfused rat heart 
(D au g h erty  &  W o o d w a rd , 1980). The present study 
investigated w hether vu lnerab ility  to ventricular
fib rilla tio n  could be related to extracellu lar calcium  or 
its m etabolic consequences.
The m ethod o f  producing vetricular fib rilla tio n  was 
sim ilar to  that described by Lubbe et al. (1975), using 
a com parable crite rio n  fo r q u an tific a tio n  o f  a rrh y th ­
mias. B rie fly , the m ethod involves pacing Langen­
d o r f f  perfused rat hearts at 3(X) b eats /m in  w ith one 
channel o f  a Grass S88 stim u lator whilst recording  
developed tens io n , le ft ve n tricu la r pressure, 
perfusion pressure and epicardial E C G . The second 
channel o f  the stim u lator was used to  deliver extra  
pulses, via a Grass C C U l constant current u n it, at a 
preset current and delay. Scanning o f  the vulnerable  
period was carried out in order to  ob tain  the 
ventricular fib rilla tio n  threshold (V F T )  at the nadir
o f  the vu lnerab le perio d . A fte r  in itia l instrum entation  
had been com pleted a s tabilization period o f 15 m in  
was a llo w ed . T h e re a fte r , 5 m in equilib ra tion  tim e  
was allow ed on changing perfusates before recom ­
m encem ent o f  V F T  determ inations.
T h e  co ntro l V F T  at a Ca^* concentration o f
1.23 m vi was 20 .7  ±  1.5 m A . Th is was significantly  
( P <  0 .0 0 1 ) reduced in the presence o f 2 .46  mM Ca^*, 
and fu rth er reduced in the presence o f  4 .96  m.M Ca^* 
( P < 0 .0 1 ) .  Associated w ith  the reduction in V F T , the 
nadir o f  the vu lnerab le period was displaced nearer to 
the peak o f  the R wave w ith increasing calcium  
concentration  (see T a b le  1). V erapam il failed to  
reverse fu lly  the ca lcium -induced low ering o f  V F T ,  or 
to increase significantly  the interval between the R 
wave and the nad ir o f  the vulnerable period, although  
the highest concentration used (1 x  10"  ^ m in the 
presence o f  2 .46  m M  Ca^*) produced a greater depres­
sion o f  developed tension than perfusion w ith
1.23 m M  Ca^* alone.
T h e  present da ta , and that o f  the previous report 
w ould  seem to suggest that in our model the extracel­
lu lar calcium  concentration affects vu lnerab ility  
independently o f  c A M P  levels. Th is dissociation
between c A M P  and ventricu lar fib rilla tio n  is in agree­
m ent w ith  a recent com m unication  (T h an d ro y en  et 
al., 1980) which has shown a d isparity between c A M P  
levels and arrh y th m ia  protection a ffo rd e d  by calcium  
slow channel antagonist.
A. Daugherty is supported by the Bath University Research 
Fund. This work is aided by a grant from the British Heart 
Foundation. Gifts of verapamil (Abbott) are gratefully 
acknowledged.
References
D a u g h e r ty , A & W o o d w a r d , B. (1980). The effect of 
calcium on cyclic nucleotide levels in the isolated rat 
heart. Br. J. Pharm ac., 70. 69P-7QP.
L ubbe, W .F ., Br ic k n e ll , O L , M a r z a c a o , C. (1975). 
Ventricular fibrillation threshold and vulnerable period 
in the isolated perfused rat heart. Cardiovas. Res., 9, 
613-620.
T h a n d r o y e n , F T ., H ic g in so n , L ..M ., O p ie , L .H . (1980). 
The effects of calcium antagonists on the ventricular 
fibrillation threshold in the isolated perfused rat heart. J. 
M ol. Cell. C ard io l., 12, Suppl 1, 166.
Table 1 Effects of calcium and verapamil on:
a) VFT at the nadir of the vulnerable period;
b) Interval between the peak of the R wave and the nadir of the vulnerable period.
a) V FT (m A )
A Ca^ * (1.23 m.M) 20.7 ± 1.5 (21) AvB P<0.001
B Ca^‘ (2.46 m M ) 7.8 ± 0.7 (19) AvC P<0.001
C Ca^‘ (4.96 m.M) 3.4 ± 0.9 (7) BvC P<0.01
AvD P<0.001
D Verapamil (1 x 10-' M), Ca^ * (2.46 mM) 9.1 ± 0.9 (9) AvE P<0.01
E Verapamil (1 x 10-' M), Ca'* (2.46 m M ) 13.2 ± 1.3 (9) DvE P<0.02
b) N a d ir o f  vulnerable pe riod  (ms)
A Ca%' (1.23 m M ) 42.4 ± 1.1 (21) AvB P<0.001
B Ca^ * (2.46 m M ) 32.4 ± 1.4 (19) AvC P<0.001
C Ca'- (4.96 mM) 18.9 ± 1.8 (7) BvC P<0.001
AvD P<0.01
D Verapamil 1( x 10-' M), Ca'* (2.46 m M ) 32.1 ± 1.4 (9) AvE P<0.01
E Verapamil (1 x 10-' M), Ca'- (2.46 m M ) 34.9 ± 1.8 (9) DvE NS
Values expressed as mean ± s.e. mean. Numbers in parentheses represent the number of experiments.
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The K* /Ca^* ratio and calcium slow channel 
antagonists on arrhythmias in the isolated 
perfused coronary ligated rat heart
A . D A U G H E R T Y *  &  B W O O D W A R D
Department o f  Pharmacology, School o f Pharmacy and 
Pharmacology, University o f Bath, Claverton Down. Bath  
B A 2  7A Y
L ig atio n  o f the m ain left coronary  artery  o f the  
iso lated rat heart perfused w ith  K re h s -H en s e le it sol­
ution ( K " ,  5 .9  m M ; C a^", 2 .5  m w ) produced a low 
incidence o f ve n tricu la r a rrh yth m ias, despite the ap­
pearance o f p ro fo u n d  ischaemic dam age (K a n n e n -  
giesser, L u b b e  &  O p ie , 1 9 7 5 ). H o w e v e r, occluîflpn of 
this co ro nary  arte ry  during  perfusion w ith a low ered  
K "  co ncentration  (K ^ , 2 .5  m M ; C a*"', 2 .5  m M ) p ro ­
duced v e n tricu la r arrh yth m ias w hich had a distinctive  
tim e course. T h e  first 3 m in p o st-liga tion  had a very 
low incidence o f p rem atu re  ve n tricu la r contractions  
(P V C 's ) . Pvc's then increased in incidence w ith  a 
peak of in s tab ility  occurring at 10 m in. H earts  then  
reverted  to  a m ore stable state fo r the rem aind er of 
the 30  m in o f record ing .
Th e  incidence o f e lectrica l instab ility  produced by 
ligation du rin g  perfusion w ith  a lo w ered  potassium  
co ncentration  was significantly reduced by the con­
com itant redu ctio n  o f the calcium  concentration (K ^ , 
2.5  m M ; Ca*'*’ , 1.2 m M ) (See T a b le  la ) .  T w o  calcium  
slow channel antagonists, ve rap am il and n ifed ip in e, 
w ere used to  d e term in e  w h eth er the protectiv e effect 
o f low calcium  perfusion could be m im icked  b j these 
drugs (See T a b le  lb ) .
T h e  highest concentration  o f verap am il used 
(1 X 1 0 " ’  M ) produced a significant ( P ‘ 0 .0 1 ) redu c­
tion  in th e  P V C ’s du ring  lig atio n . V e ra p a m il also 
reduced the incidence o f v e n tricu la r tachycardia and 
v e n tricu la r f ib rilla tio n  although these reductions did 
not a tta in  statistical significance using chi-squared  
analysis. N ife d ip in e  ( 1 x 1 0 " ’ m ) d id  not effect any 
index o f e lectrica l in stab ility  d u ring  ligation. T h e  
solvent fo r  n ifed ip in e , e than o l (0 .0 0 0 7 %  v /v ), s im i­
la rly  d id not in fluence a rrh y th m ia  p roduction .
In  sum m ary , the e lectrica l in stab ility  produced by 
ligation  du ring  perfusion w ith  a lo w  potassium  con-
Table la The effect of the K'^ /Ca’'^ ratio on the 
incidence of premature ventricular contractions 
(PVC’s, mean ± s.e.mean), ventricular tachycardia 
(VT; percentage incidence) and ventricular fibril­
lation (VF; percentage incidence) during 30 min of 
ligation
Ion ic m ilieu (m M )  
(K")(Ca’^)


















centration  m ay be reduced by a low ered  calcium  
concentration , as has been shown in non-ischaem ic  
tissues (E isn er &  L e d ere r, 1 9 7 9 ). A lth o u g h  v e r­
apam il exerted a protective effect, this m ay be due to  
its local anaesthetic properties (B a y e r , Kalusche, 
K au fm ann  &  M a n n h o ld , 1 9 7 5 ), since n ifed ip in e  did  
not in fluence the incidence o f arrhythm ias.
This work is supported by the British Heart Foundation and 
Bath University Research Fund. Gifts of nifedipine (Bayer) 
and verapamil (Abbott) are gratefully acknowledged.
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TaMe lb The effect of verapamil, nifedipine and nifedipine solvent (ethanol) on ventricular arrhythmias produced
by ligation during perfusion with 2.5 rtiM K 
using Wilkcoxon Rank Sum test.
2.5 m M  Ca . Statistical difference from control denoted* (6^ 0.01 )
D rug Treatment n PVC'S % VT % V F
Verapamil 1 x  1 0 " *  M 5 559± 151 60 0
Verapamil 1 x  10"’ m 8 297 ±74* 13 0
Nifedipine 1 x  10 ’ m 7 791 ± 1 6 4 4 3 14
N ife d ip in e  solvent 
(E th a n o l 0 .0 0 0 7 %  v /v )
8 6 0 0 ± 130 3 8 13
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ARRHYTHMIA PRODUCTION IN THE CORONARY LIGATED RAT HEART. THE LACK OF 
EFFECT OF ADRENERGIC INFLUENCES.
B. Woodward, A. Daugherty. Pharmacology Group, University of Bath,
Bath. BA2 7AY. U.K.
Occlusion of the main left coronary artery of the Langendorff perfused rat 
heart perfused with Krebs-Henseleit containing 2.5mM K+ (cf normal 5.9mM) 
produced a distinctive time course of electrical instability. Hearts were 
stable for the first 3 min, the incidence of premature ventricular con­
tractions (pvc's) then increased with a peak of instability after 10 min. 
Hearts then reverted to a more stable condition. Total PVC's were 797± 
101/30 min, n=15, with 46% VT and 26% VF. Release of noradrenaline (NA) 
was measured by the NA overflow technique to establish whether a tem­
poral relationship existed between arrhythmia production and NA release. 
However, no NA release could be detected during occulusion, and determin­
ation of tissue NA in ischaemic and non-ischaemic areas showed sim­
ilar levels. Infusion of dl propranolol (10~^M) reduced the incidence of 
P V C ’s (40113/30 min, n=6) and prevented VF and V T . Atenolol (10~^M) a 
antagonist without local anaesthetic properties failed to influence the 
incidence of arrhythmias (PVC's 7801147/30 min, 42% VF, 71% VT, n=7).
These results suggest that factors other than adrenergic influences are 
responsible for arrhythmia production in this model.
Supported by Bath University Research Fund and British Heart Foundation.
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C a lc iu m  and C alciu m  Slow  C hannel A n tagon ists  on  
C yclic N u c leo tid e  L evels in  the Iso la ted  R at H eart
A lan  D a u g h er ty  an d  B rian  W ood w ard*
Department o f  Pharmacology, School o f  Pharmacy and Pharmacology,
University o f  Bath, Claverton Down, Bath, Avon, England
{Received 11 November 1980, accepted in revised fo rm  2 August 1981)
A. D A U G H tR T Y  AN D  B. W o O D W A K D . Cakiuiii and Calcium Slow Cliannel Antagonists on 
Cyclic Nucleotide Levels in the Isolated Rat Heart. Journal o f Molecular and Cellular Cardiology 
(1981) 13, 843-854. .An investigation has been carried out into the effects of extracellular 
calcium on cyclic nucleotide levels in rat ventricle. Increasing extracellular calcium, over the 
range which directly affected contractility, produced a concentration related increase in the 
level of cyclic .AMP. Positive correlations were found between extracellular calcium and 
cyclic .AMP; and between cyclic .AMP and isometrically developed tension. No reciprocal 
relationships were found for cyclic G M P  over the same calcium concentration range. 
Increasing extracellular calcium above the maximal inotropic concentration did not produce 
a further increase in cyclic AMP, although increases in cyclic G MP were noted. Calcium slow 
channel antagonists, nifedipine and manganese both depressed developed tension at the 
concentrations used, but this effect was not associated with any significant change in cyclic 
nucleotide levels. A'erapamil depressed developed tension and cyclic AMP levels but the effect 
on cyclic .AMP was not concentration related. No calcium slow channel antagonist signifi­
cantly affected cyclic G M P  levels. In electrically paced hearts, increasing rate of stimulation 
depressed developed tension but had no significant effect on cyclic AMP.
Key Words: Rat ventricle; Cyclic .AMP; Cyclic GMP; Ca’^^ ; Ca'^  slow channel antagonists; 
Developed tension; Heart rate.
In tro d u ctio n
There is good evidence that cyclic A IMP is involved in the regulation of myocardial 
contractility via its effects on calcium fluxes within the cell {2, 7, 3 2 ]. In addition, 
biochemical studies on subcellular fractions have implicated that calcium can in turn 
regulate the levels of cyclic AMP via its actions on adenyl cyclase and phosphodiester­
ase. Adenyl cyclase preparations from cardiac tissue are inhibited by calcium [d ], 
while phosphodiesterase is stimulated {3 1 ]. These findings have led to the suggestion 
that there is a negative feedback system existing between calcium and cyclic AM P 
in the regulation of cardiac contractility [3 0 ].
The involvement of cyclic GMP in the modulation of cardiac contractility is still 
unclear [7]. However, as with cyclic AMP, it has been shown that the enzymes 
responsible for the synthesis and degradation of cyclic GMP are also affected by 
calcium [29].
The presence of different forms of phosphodiesterase [1 4 ],  guanyl cyclase [2 2 ],  
and different subcellular locations of adenyl cyclase [9] and the involvement of 
calcium in the regulation of some of these enzymes make it difficult to predict how 
changes in extracellular calcium w ill affect the levels of these nucleotides in intact 
muscle preparations. We have therefore examined the effects of calcium over the 
range 0 to 4.92 m M  on the levels of cyclic AMP and cyclic GMP in perfused rat
* Correspondence to B. Woodward.
0022-2828/81/090843+12 S02.00/0 ©  1981 Academic Press Inc. (London) Limited
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hearts. In  addition, the effects of the calcium slow channel antagonists verapamil, 
nifedipine and manganese and electrical pacing on developed tension and cyclic 
nucleotides have been studied. A preliminary report of this work has been presented 
previously [4 ] .
M a te r ia ls  and M eth o d s
Experimental protocols and materials
Hearts from Wistar rats (180 to 300 g, University of Bath strain) were perfused by 
the non-recirculatory Langendorff technique with Krebs-Henseleit solution (in 
m M :  NaCl, 118.4; KCl, 4.7; MgSO^, 1.2; KH^PO^, 1.2; NaHCOg, 25.0; CaClg, 
1.23; glucose, 11.5) gassed with 95% Og and 5% COg at a constant flow of 10 ml min~^ 
and maintained at 37'^C.
Isometric contractions, at a diastolic tension of 2 g, were recorded via a small 
hook placed in the apex of the left ventricle and attached to a Devices U F l trans­
ducer. The resultant signal was also used to trigger a Devices instantaneous ratemeter 
(4521). Perfusion pressure was monitored with a Bell and Howell pressure transducer 
(4-422). A ll recordings were displayed on a Devices M19 recorder.
From the start of the perfusion a stabilization period of 15 min was allowed. The 
perfusate was then changed for one containing the calcium concentration or drug 
under investigation. After a further 5 min, when hearts had achieved a new steady 
contractile state, they were freeze clamped with a pair of Wollenberger tongs cooled 
to the temperature of liquid nitrogen. In some experiments hearts were perfused 
with zero calcium for 30 min before freeze clamping. Samples of perfusate were 
collected just prior to freeze clamping and assayed for the presence of cyclic AMP. 
In  the electrically paced experiments, right atria were removed and hearts were 
paced with bipolar electrodes placed on the metal aortic cannula and the atrio­
ventricular groove. Stimulation parameters were square wave pulses of 1 ms duration, 
4V amplitude delivered by a Grass S44 stimulator. Frequency of stimulation was 
varied between 200 and 500 beats min~^. Hearts were paced for 5 min before freeze 
clamping as described above.
Due to the light sensitive nature of nifedipine (Bayer) all experiments using this 
drug were carried out in a room in which light below 400 nm had been filtered out. 
Stock solutions of nifedipine were made up in 90% v/v ethanol, while verapamil 
(Abbott) and manganese chloride were made up in physiological saline.
Extraction and cyclic nucleotide assays
Frozen ventricular tissue was pulverized in a stainless steel pestle and mortar at the 
temperature of liquid nitrogen. The finely powdered tissue was extracted in 6% w/v 
perchloric acid and neutralized with 2 m KHgCOg/O.l m Tris solution.
Cyclic AM P was assayed in the neutralized supernatant using a modification of 
the Gilman protein binding technique [75], using binding protein isolated froni dog 
heart. Cyclic GMP was assayed using a radioimmune assay kit (Amer&ham 
T R K  500). Tissue levels of the cyclic nucleotides are expressed as pmol g“ '  wet 
weight. The different ionic milieu and calcium antagonists used were not found to 
interfere with the assay.
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Statistical analysis
Results are expressed as means standard error of the mean (s .e .m .) ,  P  values 
were obtained by a paired or unpaired Student’s t test (two tailed) as appropriate 
and values <0.05 were considered to be significantly different. Regression lines were 
fitted by least squares analysis.
R e su lts
Extracellular calcium concentration on developed tension and cyclic nucleotide levels 
Increasing extracellular calcium over the range 0 to 2.46 m M  produced a progressive 
increase in developed tension [Figure 1 (c)], tension did not increase further when the
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FIGURE 1. The effect of extracellular calcium concentration on; (a) Cyclic A MP levels (pmol/g 
wet weight) ; (b) Cyclic G M P  levels (pmol/g wet weight) ; (c) Steady state developed tension (g) ; 
(d) Heart rate (beats min~‘). Significant differences from controls (Ca*+, 1.23 mM) are denoted 
{ *  P <  0.05; * *  P  <  0.01). Numbers in parentheses represent the number of experiments.
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calcium concentration of the perfusate was raised to 4.92 m M . Heart rate was not 
significantly altered at the different calcium concentrations, except when calcium 
was omitted; zero calcium caused asystole w ithin 60s [Figure 1(d)].
Over the calcium concentration which caused an increase in developed tension 
(0 to 2.46 m M ) ,  ventricular cyclic AM P increased from 223 ±  14pmolg~* wet 
weight at zero calcium to 620 i  43 pmol g“  ^ wet weight at 2.46 mM calcium 
[Figure 1(a)]. A significant correlation was found between extracellular calcium 
and cyclic AMP over this range (r =  0.80, P  <  0.001, n =  37 ; Figure 2). As with 
developed tension increasing the calcium concentration from 2.46 to 4.96 mM did 
not result in a further rise in cyclic AMP. At this high calcium concentration cyclic 
AM P levels fell to 461 i  56 pmol wet weight. From Figure 3 it can be seen that 
there is also a positive correlation between cyclic AMP and developed tension over 












FIGURE 2. The relationship between ventricular cyclic AMP content and extracellular calcium 
concentration (0 to 2.46 mw). r = 0.80; n = 37; P < 0.001. — 232.7 + 33.2%.
Unlike cyclic AMP, no correlation was found between extracellular calcium and 
ventricular cyclic GMP, or between cyclic GMP and developed tension. The level 
of cyclic GMP (19.6 i  2.5 pmol g'^ wet weight at 1.23 m M  calcium) was signifi­
cantly increased at calcium concentrations of 0.61 and 4.92 m M  [Figure 1(b)]. 
However, there was no consistent trend in cyclic GMP levels when extracellular 
calcium was altered.
I t  has been suggested that when cyclic nucleotides are involved in the modulation 
o f cellular activity, the ratio of cyclic AMP to cyclic GMP is more important than 
the absolute level of the individual nucleotides [72]. However, no relationship was 
found between the cyclic AMP/cyclic GMP ratio and developed tension (r — 0.75, 
P  >  0.05, n — 5).
Under no condition could cyclic AM P be detected in the perfusate leaving the 
heart.
In one series of experiments cyclic AM P levels were determined following 30-min 
perfusion with zero calcium. I t  can be seen from Table 1 that cyclic AM P levels are 
higher following 30-min perfusion with zero calcium than after 5 min.
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FIGURE 3. The relationship between ventricular cyclic A M P  content and developed tension when 
both variables were manipulated by extracellular calcium concentration (0 to 2.46 mw). r = 0.93; 
n = 5; P < 0.02; j = 224.2 -f- 33%. Ca*+ concentrations in mw: (#) 0; (O) 0.3; (gi 0.61; 
(□) 1.23; (A) 2.46.
TABLE 1. The change in cyclic A M P  levels with time after removal of calcium from the 
perfusate
n Cyclic A M P  
(pmol/g wet weight)
(a) Control 10 420 ±  14
(b) 5 min Ca^ +-free perfusion 5 223 ±  14
(c) 30 min Ca^ +-free perfusion 5 433 i 13
(a) k (b), P < 0.001; (a) v ( c ) ,  n .s . ;  (b) y (c), P < 0.01.
C a lc ium  s low  channel an tagon is ts  on developed tension a n d  cyc lic  nucleotides
After a transient increase (P <  0.01) in developed tension [Figure 4(c)], verapamil 
(3  X  10“ ® M to i X  1 0 “ ® m ) produced a concentration related depression of developed 
tension [Figure 5(c)]. Heart rate was not significantly affected by lower concentra­
tions of verapamil (3  X  10“ ® m and 1 X  10“ ’ m ) but asystole occurred with a  
concentration of 1 X  10“ ® m. A ll concentrations of verapamil reduced cyclic AMP 
levels {P  <  0.05) when compared with control values [Figure 5(a)]. However, 
there was no significant difference between the decrease in cyclic AM P level 
produced by the different concentrations of verapamil.
Cyclic GMP was increased by all concentrations of verapamil, but in no instance 
did the increase achieve statistical significance [Figure 5(b)].
Nifedipine, like verapamil, produced a concentration related depression of de­
veloped tension [Figure 5(c)], but, in contrast to verapamil, the depression was not 
preceded by a transient increase [Figure 4(b)]. At the concentrations of nifedipine 
used (1 X 10“ ’ M and 1 x 10“ ® m ), no significant changes were seen in the levels of 
cyclic AMP or cyclic GMP [Figure 5(a) and (b)].
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FIGURE 4. The effects on developed tension with respect to: (a) altering the calcium concentration 
from 1.23 m M  to 0.61 m M  (n = 20); (b) administration of nifedipine (1 X  10*’m, n — 6); 
(c) administration of verapamil (1 X  10*’ m , n — 6). All interventions occur at time 0 and the lag 
in response is due to the dead space of the system. Note the initial increase (P <  0.01) in developed 
tension during perfusion with verapamil (1 x 10*’m). Signicant differences from initial developed 
tension are denoted {*  P <  0.01).
Manganese (1 X  10*^ m) producetd a significant decrease in developed tension 
{P  <  0.01) whilst having no effect on cyclic nucleotides [Figure 5(a) and (b)]. 
Higher concentrations of manganese were not used in this study due to the coronary 
constriction which developed. Verapamil and nifedipine produced either a reduction 
or no effect on perfusion pressure. A reduction in perfusion pressure was produced i f  
the in itia l control value was high.
During perfusion with the calcium slow channel antagonists cyclic AM P could not 
be detected in the perfusate.
Effect o f  rate o f  stimulation on developed tension and cyclic A M P  levels
I t  is well documented that the rat heart exhibits a negative force-frequency 
relationship [1 3 ].  We have used this phenomenon to manipulate developed tension 
whilst concomitantly determining tissue cyclic AMP levels. Cyclic GMP was not 
measured in this series of experiments.
Pacing hearts over the range 200 to 500 beats min*^ produced the expected decrease 
in developed tension [Figure 6(b)]. This was not associated with any significant change
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FIGURE 5. The effects of verapamil (3 x 10** m , 1 x 10“’ m , 1 x 10"* m ), nifedipine
(1 X 10"’M, 1 X 10"* m ) and manganese (1 X lO"* m ) on: (a) cyclic A M P  levels (pmol/g wet weight) ;
(b) cyclic G M P  levels (pmol/g wet weight); (c) developed tension (g). Significant differences from 
controls are denoted {*  P  <  0.05, * *  P  <  0.01). Number of hearts are shown in parentheses.
in tissue cyclic AM P levels [Figure 6(a)]. However, it can be seen that the tissue levels 
of cyclic AM P in these paced experiments were higher than the unpaced control
value [Figures 1(a) and 6(a)].
D isc u ss io n
Cyclic nucleotides y calcium and developed tension
We have shown that in the isolated perfused rat heart, calcium produces concentra­
tion dependent changes in cyclic nucleotide levels and developed tension. A 
significant relationship was found between extracellular calcium and cyclic AMP 
levels over the calcium concentration range which directly affected steady state 
developed tension. The finding that steady state developed tension was maximal
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FIGURE 6. The effect of rate of stimulation on : (a) cyclic A M P  levels (pmol/g wet wt) ; (b) developed 
tension (g). Both were measured after 5 min of pacing. For stimulation parameters see Materials and 
Methods.
at a calcium concentration of 2.46 mM is in agreement with the results of other 
workers
Changes in extracellular calcium and frequency of electrical stimulation would 
both be expected to manipulate intracellular calcium levels as indicated by changes 
in developed tension. The fact that cyclic AM P was increased only when extracellular 
calcium was elevated suggests that i f  calcium regulates cyclic AMP levels, then the 
extracellular rather than the intracellular calcium concentration may be the more 
important factor. Other authors have investigated the effects of omitting calcium 
from the perfusate on cardiac cyclic AMP. Hancock and Hess [77] found that 
removal of calcium for 5 min produced a decrease in cyclic AM P in rat hearts. 
However, Namm et al. [2 3 ] and Dobson et al. [5 ] found that omission of calcium 
for 30 min produced increases in cyclic AMP in rat ventricle and guinea-pig papillary 
muscle respectively. These findings and our experiments using 30-min zero calcium 
perfusion suggest that cyclic AMP levels vary both with calcium concentration and 
time. Harary et al. [1 8 ] have shown that cyclic AM P levels in cultured rat heart cells 
bear a reciprocal relationship to the calcium concentration of the culture medium. 
In these cells, calcium also exerted chronotropic effects, while in our intact heart 
preparation, calcium had no effect on heart rate, except when it was omitted.
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Endoh et al. [5 ] have also shown an inverse relationship between calcium and 
cyclic AM P in electrically paced rabbit papillary muscle. Other than species 
variation and the time for which the muscle is perfused with different calcium 
concentrations there is no obvious reasons why these results differ from ours.
The absence of any relationship between calcium, cyclic GMP and developed 
tension does not give support to the concept that cyclic GMP may act as an 
intracellular antagonist of cyclic AMP in the control of cardiac contractility [1 6 ].  
In  addition there was no correlation between developed tension and the cyclic 
AMP/cyclic GMP ratio. This is in contrast to the recent observations of Flitney 
et al. [11 , 12, 2 8 ] who have shown good correlations between the cyclic AMP/cyclic 
GMP ratio and contractility under a number of diverse situations. However, all of 
their results have come from studies on amphibian myocardium.
The higher levels of cyclic AM P observed in the electrically paced preparations 
compared to unpaced controls may be attributable to the experimental design. 
Broadley et al. [7] demonstrated the release of catecholamines from electrically paced 
guinea-pig hearts. Catecholamine release would be expected to increase cyclic AM P 
levels via ^ adenoreceptor stimulation. The trauma due to removal of the right atria 
may in itself be the cause of the elevated cyclic AM P level in the paced hearts. I t  is 
also possible that electrical pulses per se raised cyclic AMP levels as has been shown 
in other tissues [21 , 3 3 ].
Cyclic nucleotides, calcium slow channel antagonists and developed tension
Nifedipine, verapamil and manganese have been classified as calcium slow channel 
antagonists [1 0 ] ,  but they appear to have different mechanisms of action [26 , 2 7 ].  
We have used these drugs to reduce developed tension, thereby mimicking the effects 
of low calcium. However, these drugs did not have the same effect as lowered 
extracellular calcium on cyclic nucleotide levels; the drugs themselves also produced 
different effects on the heart. O f the three calcium slow channel antagonists used, 
only verapamil produced a significant reduction in cyclic AMP, but this reduction 
was similar for all concentrations used. Nifedipine and manganese both failed to 
alter cyclic AM P levels at concentrations which reduced developed tension. None of 
these three drugs affected cyclic GMP significantly. In addition to their effects on 
cyclic AM P other differences were also observed between these drugs. Unlike vera­
pamil and nifedipine, manganese produced a marked coronary vasoconstriction 
suggesting that the calcium slow channel in coronary smooth muscle is different to 
that of myocardium. We also observed a significant increase in developed tension 
prior to the negative inotropic action of verapamil. Calcium slow channel antago­
nists have previously been shown to have positive inotropic actions by H imori et al. 
[79]. In their study, verapamil, nifedipine and diltiazem increased developed tension 
in a blood perfused dog papillary muscle preparation. In the present study only 
verapamil produced a positive inotropic effect. The mechanism of this is not clear, 
but verapamil has been shown to displace calcium from the cell surface of dog 
trabecular muscle [2 4 ], this could account for the in itia l inotropic action.
Possible mechanisms by which calcium may influence cyclic nucleotide levels
Our finding that increased extracellular calcium over the range which directly 
affects developed tension produces an increase in cyclic AMP is difficult to explain. 
I t  is possible that cyclic AM P changes simply as a consequence of the contractile
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state. This is unlikely as cyclic AM P was not reduced in a concentration-dependent 
manner by the calcium slow channel antagonists or by electrical pacing, both of 
which reduced developed tension. Also 30-min exposure to zero calcium caused 
asystole but did not reduce cyclic AM P levels. In  guinea-pig papillary muscle, 
unlike rat heart, increased frequency of electrical pacing results in a positive inotropic 
effect which is not associated with an increase in cyclic AM P [5]. Also, Endoh et a l. 
[5 ] have shown that in rabbit papillary muscle increased developed tension produced 
by increased frequency of stimulation is associated with a fall in cyclic AM P levels.
Calcium could increase tissue cyclic AM P levels by affecting the synthesis and/or 
degradation of cyclic AM P; by reducing the efflux of cyclic AMP, or by enhancing 
catecholamine release. I t  is unlikely that calcium is mediating its effects via 
catecholamines as these amines would be expected to have chronotropic actions 
which were not seen. Using a small volume recirculating system O ’Brien and 
Strange [2 3 ] have been able to demonstrate cyclic AMP efflux from isolated rat 
hearts. The lim itation of our assay procedure prevented us measuring cyclic AM P 
in the perfusate, we are therefore unable to say whether calcium affects AMP 
efflux.
Calcium is known to modulate the activity of the enzymes responsible for the 
synthesis and degradation of cyclic nucleotides [20 , 22, 29, 30] .  However, these 
observations on isolated enzyme systems present a very complex picture of calcium 
and cyclic nucleotide metabolism and any explanation of our results using informa­
tion from these studies would be very speculative.
In  summary, we have shown that extracellular calcium affects cyclic nucleotide 
levels in the isolated rat heart, and this appears to be a time dependant process. 
There was a good correlation between cyclic AM P and developed tension over the 
calcium range 0 to 2.46 m M .  The calcium slow channel antagonists did not affect 
cyclic nucleotide levels in a consistent pattern, they also had different effects on 
developed tension and coronary resistance. The study failed to provide evidence for a 
modulatory role for cyclic GMP in the regulation of cardiac contractility.
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